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Since the decoding of the first RNA virus in 1976, the field of viral genomics has 
exploded, first through the use of Sanger sequencing technologies and later with the 
use next-generation sequencing approaches.  With the development of these 
sequencing technologies, viral genomics has entered an era of big data.  New 
challenges for analyzing these data are now apparent.  Here, we describe novel 
methods to extend the current capabilities of viral comparative genomics.  Through 
the use of antigenic distancing techniques, we have examined the relationship 
between the antigenic phenotype and the genetic content of influenza virus to 
establish a more systematic approach to viral surveillance and vaccine selection.  
Distancing of Antigenicity by Sequence-based Hierarchical Clustering (DASH) was 
developed and used to perform a retrospective analysis of 22 influenza seasons.  Our 
methods produced vaccine candidates identical to or with a high concordance of 
antigenic similarity with those selected by the WHO.  In a second effort, we have 
  
developed VirComp and OrionPlot: two independent yet related tools.  These tools 
first generate gene-based genome constellations, or genotypes, of viral genomes, and 
second create visualizations of the resultant genome constellations.  VirComp utilizes 
sequence-clustering techniques to infer genome constellations and prepares genome 
constellation data matrices for visualization with OrionPlot.  OrionPlot is a java 
application for tailoring genome constellation figures for publication.  OrionPlot 
allows for color selection of gene cluster assignments, customized box sizes to enable 
the visualization of gene comparisons based on sequence length, and label coloring.  
We have provided five analyses designed as vignettes to illustrate the utility of our 
tools for performing viral comparative genomic analyses.  Study three focused on the 
analysis of respiratory syncytial virus (RSV) genomes circulating during the 2012-
2013 RSV season.  We discovered a correlation between a recent tandem duplication 
within the G gene of RSV-A and a decrease in severity of infection.  Our data 
suggests that this duplication is associated with a higher infection rate in female 
infants than is generally observed.  Through these studies, we have extended the state 
of the art of genotype analysis, phenotype/genotype studies and established 
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Chapter 1: Introduction to Viral Genomics and Comparative 
Genomics 
Viral genomics began with the sequencing of the first RNA virus in 1976 (6) soon 
followed by the sequencing of the first DNA virus using the Sanger method of 
sequencing in 1977 (7).  Both of these viruses were relatively small bacteriophages, 
MS2 and Φ X174 respectively (6, 7).  Due to its amenability for use as a high-
throughput technique, Sanger’s method of DNA sequencing (8), using dideoxy chain-
terminating nucleotide analogues, was responsible for the great genomics revolution 
of the 1990’s and 2000’s.  Starting with radiolabeling and later with florescent 











sequencing techniques (NGS) that use massively parallel sequencing approaches to 
greatly accelerate the speed at which DNA sequences can be produced (Figure 1).  




Viral genomics has benefited significantly from these technological advances, 
enabling sophisticated epidemiological and evolutionary analyses and providing 
novel insights into the pathogenicity, ecology, and epidemiologic nature of countless 
human and animal pathogens. 
Viral Genomics 
Background  
 Early viral surveillance, evolution, epidemiology, and molecular pathogenesis 
studies typically did not rely on whole genome sequencing.  Rather, small portions of 
viral genomes were sequenced to answer specific questions regarding the viruses in 
question.  For example, influenza virus surveillance largely relied on the sequencing 
of the hemagglutinin and neuraminidase genes due to fact that these genes could be 
used to genotype the virus.  Knowing these genetic types allowed researches to track 
the evolution of the virus and predict when the virus had drifted sufficiently to require 
a new vaccine.  Similarly, respiratory syncytial virus (RSV) researchers focused their 
sequencing efforts on the G and F proteins, as these genes could be used to 
discriminate between the circulating lineages of RSV.   
Whole genome approaches, as enabled by high-throughput sequencing 
technologies, allow a deeper understanding of viral evolutionary and epidemiological 
dynamics.  For instance, whole genome studies provide researchers with the ability to 
identify reassortment in segmented or recombination events in non-segmented 
viruses.  These types of genomic rearrangements give viruses a mechanism to 
increase their genetic diversity and hence increase their chances of acquiring a 




into the epistatic interactions between mutations.  These epistatic interactions could 
have implications for the molecular pathogenesis and epidemiology of the virus.  An 
example of this was published by Das et al showing that through monoclonal 
antibody challenge epistatic mutations could be elicited in influenza virus proteins to 
provide both an immune escape at one site and compensatory protein stabilization at a 
second and even third site (9).  The stabilization described could be structural or 
functional in nature (9).  This type of research is especially important to uncover 
possible mutational paths available at any given point in the evolution of human 
pathogens. 
Whole genome sequencing also enables a wide range of methods for 
performing viral research.  These methods include generating virus stocks from 




viruses.  These systems 
are used to generate 
viruses in cell culture 
without the need for 
access to natural isolates 
(Figure 2).  Combined 
with synthetic 




be generated simply from the digitally stored whole genome sequence of a virus, 
without the need for any of the starting DNA used with traditional molecular cloning 
techniques.  The ease of generation of viral stocks has accelerated a wide range of 
molecular studies, such as the antigenic testing of viruses, replacing the previous use 
of the hemagglutination inhibition assay to assess antigenic similarity of influenza 
viruses.  This has the potential to positively influence the process by which influenza 
virus vaccine candidates are selected.  Similarly, specific mutations of interest can be 
identified using whole genome sequencing, those mutations quickly synthesized into 
virus rescue systems and the viruses tested either in in vitro or in vivo testing models. 
Traditional Viral Sequencing Using the Sanger Method 
 Until the advent of next-generation sequencing technologies in the mid to late 
2000’s, viral genome sequencing was performed using traditional Sanger sequencing 
methodologies.  To prepare viral genomic materials, the viral class must first be 
determined.  The genetic material of DNA viruses can be sequenced directly, 
however RNA viruses must first undergo a reverse transcription (RT) step to convert 
the genomic material from RNA to DNA.  Sanger and next-generation sequencing 
can only be done on DNA.  Once the source material is prepared, Sanger sequencing 
using specific primers can be used.  Primers will differ depending on whether a 





Viral Sequencing Using Next-Generation Technology 
 Viral genomic sequencing using next-generation technology has enabled a 
rapid acceleration of the completion of the sequencing of viral genomes in recent 
years.  Platforms such as Roche 454, Illumina MiSeq and HiSeq, and Life 
Technologies Ion Torrent are a few used to generate genome sequences in a 
massively parallel fashion.  These technologies all produce huge amounts of sequence 
by sequencing in parallel small fragments of the source material.  Typically, the 
source material is first prepared for sequencing by constructing libraries with 
technology-specific adaptor sequences.  In the case of viral genomes, whole runs on 
next-generation devices for individual viruses are not necessary.  Multiplexing 
techniques are used to combine multiple viral genomes onto a single next-generation 
runs.  Multiplexing is also accomplished by attaching unique DNA barcode sequences 
(typically six to eight nucleotides in length) to the genome fragments.  This allows for 
the genomes from single runs to be de-multiplexed and binned per genome or 
genomic library after sequencing is complete.   
Sequence-Independent Methods 
 Sequence-independent viral sequencing methods are typically used for viral 
discovery or for when no close relatives of the target virus are available.  Sequence-
independent methods do not rely on the use of specific primers for the target genome.  
Instead, these methods use random priming, usually with tagged primers to amplify 
the source material prior to sequencing (10).  Random priming techniques will 
amplify both the target genome and any other genetic contamination present in the 




material and excluding host sequences are recommended (11).  Using Sanger 
methodology, sequencing is conducted with primers specific to the tag sequences on 
the random primers (10).  Using next-generation approaches, technology specific 
libraries are constructed with the enriched and amplified products (11). 
Sequence-Dependent Methods 
 Sequence-dependent viral genomic approaches require that close references of 
the target genomes are available in the public sequence repositories.  Target genomes 
are amplified prior to sequencing using primers specific to the genus or species of 
virus of interest.  Typically, genomes must contain 90% sequence identity for PCR 
primers to be designed and used to amplify target genomes (12).  Given adequate 
reference sequences, primers can be designed with automated computational pipelines 
and such computer generated primers have exceptionally high reaction success rates 
(12).  Once genomes are amplified, usually using several PCR reactions (one or more 
reaction per genomic segment for segmented viruses, or several for non-segmented 
genomes), sequencing can be performed.  For Sanger technologies, PCR products are 
sequenced directly, whereas with next-generation approaches the PCR products are 
fragmented and technology-specific sequencing libraries are produced prior to 
sequencing. 
DNA Versus RNA Viruses 
 Viruses come in a variety of classes according to the Baltimore classification 
system.  The most notable difference between the classes, as it applies to sequencing, 




sequenced using the same basic methods as any higher order organism; however, 
RNA viruses must first undergo a RT step to convert the RNA into DNA prior to 
sequencing.  Several RT methods exist, most notably multiplexed reverse 
transcription polymerase chain reaction or mRT-PCR (13, 14).  In an mRT-PCR 
reaction on an influenza A virus genome, all eight genomic segments can 
simultaneously be reverse transcribed and amplified in a single reaction tube (13).  
This greatly accelerates the speed at which influenza viruses can be prepared for 
sequencing.  Not all viruses have an efficient mRT-PCR method developed for them.  
Rotavirus, for example, currently requires separate RT-PCR reactions for each 







next step in data 
preparation for viral 
genomic sequences is 
assembly.  Initially, the NIAID Influenza Genome Sequencing Project (NIGSP) relied 
on a custom assembler called Minimus that was capable of assembling Sanger 
sequences with minimal overlaps (15).  This was possible due to the fairly constant 
genomic structures in closely related influenza virus genomes.  More variable 




genomes require different methods for assembly.  Currently, the J. Craig Venter 
Institute (JCVI) employs a de novo-mapping-mapping assembly approach to genome 
assembly using next-generation sequences (Figure 3) (1).  In this method, genomic 
sequences are first assembled using CLCBio’s de novo assembler (16).  The resultant 
contigs are put into NCBI’s Basic Local Alignment Search Tool (BLAST) (17) 
against a reference database of genomes presumed to be similar to the subject.  The 
closest reference for each genomic structure is selected for a CLC mapping assembly 
(18).  The consensus of this first round of mapping assembly is then used as a 
reference for a second round of CLC mapping assembly.  This second mapping 
assembly pulls in sequences that are more distant from the original reference.  This de 
novo-mapping-mapping approach has been successfully used for a variety of viral 
genome species (1).  Drawbacks of this approach come up when dealing with 
genomes where no close reference sequence is available for mapping, or when the 
subject genome is recombined with respect to two or more reference genomes (1).  
Both of these scenarios require manual intervention in the assembly process, which in 
turn slows the pace of the assembly process (1). 
Annotation 
 Genome annotation is the process by which genes are located and protein 
sequences are assigned annotation data types (such as gene symbols, protein names, 
go terms, or enzyme commission numbers).  In higher order organisms, the discovery 
of open reading frames (ORFs) in nucleotide sequences is accomplished by 
statistically assessing each base pair in the genome in its context to determine if it is 




string together many so-called coding bases to form ORFs.  In a second stage of 
annotation, the ORFs or resultant translated amino acid sequences can be used as a 
query in a database search with BLAST or run through hidden Markov model 
(HMM) search programs to assess similarity to proteins with a known function.  If 
adequate similarity is determined, functional assignments of the aforementioned 
annotation data types can be made.  Viral annotation requires a different approach 
compared to that used for other genomes due to the typically small genome sizes of 
many viral species.  Viruses rely on densely coded genomes to transmit their genetic 
material and carry out the functions of viral cellular infections.  Statistical approaches 
to ORF calling are not applicable, since very little non-coding sequence is available to 
build appropriate ORF calling models (21, 22).  Instead, successful viral genome 
annotation requires a homology-based approach to ORF calling and functional 
annotation.  Homology-based approaches require highly curated reference databases 
containing all the target proteins of interest needed to adequately annotate a viral 
species (21, 22).  Annotation programs, such as the Viral Genome ORF Reader 
(VIGOR), utilize the homology-based approach (21, 22).  VIGOR first performs a 
BLASTX (nucleotide query against a protein subject database) against the reference 
database.  High-scoring hits are clustered and merged according to genome location 
and the best hit(s) are selected.  For each hit, the start and stop codons are located.  If 
the complete coding sequence (CDS) for a given protein is identified, it can be 
assigned the full annotation from the reference database for the gene that the CDS 
represents.  If the start or stop codons are missing or are in less than ideal locations, 




confidence for the structural annotation.  VIGOR can identify polyproteins and 
mature peptides in viral genomes that then translate all or several viral proteins in a 
pre-processed state; these proteins are later cleaved into smaller functional viral 
proteins (21, 22).  Approaches like VIGOR also allow for novel viral features, such as 
RNA editing or ribosomal slippage, to be identified and adjustments to the CDS and 
amino acid translations can be made accordingly (21, 22).  Despite the fact that 
homology-based methods are powerful tools for viral genome annotation, they do 
require the expert curation of an appropriate reference database, a potentially time-
consuming process that can necessitate consultation with experts on specific virus 
families. 
Viral Genomic Standards 
 The viral genomics revolution has brought together data from various smaller 
communities of researchers.  For this reason, special attention to viral genomic 
standards should be made as we expand our knowledge of the vast varieties of viral 
species that exist in our world.  Where once community or even researcher driven 
standards of annotation where sufficient to understand a particular virus, now 
common data types across viral species can be made abstract and applicable to all 
viral genomic studies.  A few features common to viral genomics projects amenable 
to standardization include viral strain names, protein names, and metadata types: such 
as passage medium and number for cultured viruses, host species designations, and 
collection methods or even collection locations.  Use of common data types across 
viral genome projects will serve to enable access to viral genomic research across 




throughput computational analysis could also benefit from such standardization.  This 
need is apparent, for example, in the use of standardized strain names.  Influenza 
virus strain A/California/07/2009 could be written any number of ways (such as 
A/CA/07/09, or A/California/7/09).  To the human eye these names appear to 
describe the same virus; however, computers require explicit rules to be established in 
code to make the same associations.  Similarly, passage metadata for an influenza 
virus may be listed as “Siat2” or “E3”.  A human knowledgeable of influenza 
passaging techniques would know “Siat2” means passaged in siat cells (a cell line 
derived from canine kidney cells) twice, or that “E3” means passaged in embryonated 
eggs three times.  Again, such nomenclature requires computer code to enable 
automated use of such fields.  This is especially true of passaging information that is 
not standardized, such as when researches code information using synonymous texts 
like “S2”, “SIAT2”, “Siat 2”, “Siat-2” or other variants.  Similarly, standards for 
protein naming are essential.  NES and NS1 both refer to the same influenza virus 
protein.  If one is used, the synonym should also always be listed.  In short, some 
thought on genome standards should be given, and standards should be developed and 
enforced across all viral species for naming, annotation data types, and metadata in 
order to enable computer analysis of these data, and for the sake of accurate analysis. 
Viral Comparative Genomics 
Background 
 Preparation of viral genomic sequences is merely the first step in 
understanding the intricacies of viral ecology, evolution, molecular pathogenicity and 




then need to be placed in context of other viruses in order to glean insights about the 
virus of interest.  This can be done using a number of techniques and together these 
techniques form the basis for modern viral comparative genomics. 
Public Resource Databases 
 Public repositories of viral sequence, phenotype and related metadata are 
essential resources for any comparative viral genomics study.  Public databases can 
be categorized into two basic forms: those that simply enable data archiving and those 
that also allow for bioinformatics analysis.  Some public repositories of note are listed 
in Table 1.  Beyond the sequences generated from a study, the addition of context 
sequences is essential to perform useful analyses.   
Table 1 Select Web-Accessible Public Repositories of Viral Genomic Data. 
Resource Short Name Viral Taxa URL 
Viral Pathogen Resource (23) ViPR All http://www.viprbrc.org 
Viral Zone (24, 25) ViralZone All http://viralzone.expasy.org 
International Repository for Hepatitis B 




Heptatitis C Virus Database (26) HCV Database HCV http://hcv.lanl.gov 
HIV Sequence Database (26) HIV Database HIV http://www.hiv.lanl.gov 
Influenza Research Database (27) IRD Influenza http://www.fludb.org 
Influenza Virus Resource (28) IVR Influenza 
http://www.ncbi.nlm.nih.gov/genomes/
FLU/FLU.html 
Global Initiative on Sharing Avian 
Influenza Data (29) GISAID EpiFlu Influenza http://platform.gisaid.org 
Network of Expertise on Animal Influenza OFFLU Influenza http://www.offlu.net 
 
In recent years, database resources that go beyond simple data archiving 
functionality have been engineered.  Viral comparative resources, such as the 
Influenza Research Database (IRD) and Viral Pathogen Resource (ViPR), aim to be 




genomic studies (23, 27).  These resources have had some notable successes and 
some drawbacks have been found.  Successes include the implementation of 
standards for viral genome annotation and metadata types (30, 31), metadata-driven 
sequence analysis (32), and implementation of maximum likelihood phylogenetic 
analysis (23).  Drawbacks include a limited set of analysis applications.  For instance, 
ViPR does not instantiate Bayesian phylogenetic tools for use with database-derived 
or user-supplied data sets; although, Bayesian tools have been implemented on other 
web-based resources, such as Cyberinfrastructure of Phylogenetic Research 
(CIPRES) (33).  Another limitation to a web-based approach to bioinformatics is that 
it limits the ability of advanced users to perform high-throughput or custom analyses. 
Phylogenetics and Related Methods 
 Phylogenetic analysis techniques are among the most important set of 
methods for performing viral comparative genomics.  Phylogenetics is the study of 
the evolutionary relatedness between species or other entities most often based on 
data for morphological characters or biological sequences (nucleotides or amino 
acid).  Early algorithms for performing phylogenetic analyses were extensions of 
hierarchical clustering algorithms; however, with the advent of more complex 
evolutionary models and modern computing technologies, the collection of 
phylogenetic methods available today extends the capabilities of performing 
evolutionary studies significantly.   
Due to the computational demands and availability of advanced phylogenetic 
methodologies, older viral comparative studies relied on methods such as neighbor 




operates on distance data to perform a heuristic search of tree topologies (34).  Many 
have speculated on the precise nature of the NJ algorithm and the optimality criterion 
it aims to solve (34, 35).  Given the same input data and evolutionary assumptions it 
will give the same resultant tree each time the program is run, although this tree may 
not be the most optimal solution. 
With the development of more advanced algorithms and modern computer 
processing technology, phylogenetic methods such as maximum likelihood (ML) and 
Bayesian techniques have been applied to phylogenetics.  ML can be coupled with 
advanced substitution models, such as the general time reversible model, to infer 
evolutionary change between sequences. NJ is a deterministic algorithm, that given 
the same input and evolutionary model, will arrive at the same output tree (34, 36). In 
contrast ML searches for the tree that best fits a particular evolutionary model that 
satisfies the maximum likelihood criterion via a stochastic search of tree space (37) 
utilizing strict or non-strict hill climbing algorithms.  
ML algorithms aim to find the most likely phylogeny from a given a set of 
input characters.  ML methods are thought to be robust to violations in the 
substitution model because they are able to account for hidden evolutionary changes 
that were likely to occur over time, at some probability as determined by the model 
used to make the phylogenetic inferences.  Even with relatively few taxa, the space of 
all available tree topologies vastly dwarfs the number of trees the ML algorithms are 
capable of examining under reasonable time scales.  Tree space is also non-uniform.  
Strict hill climbing algorithms are more likely to get stuck in local maxima without 




but to a lesser degree.  Ultimately the ML tree is just a point estimate, with a rational 
statistical methodology to support the evolutionary relationships it describes.  For 
these reasons, methods for assessing the quality of the ML tree are required.  Most 
notably, bootstrapping is typically performed to assess the reliability of specific node 
branching topologies found within the tree (36).  Similarly, multiple ML analyses can 
be run to increase confidence that the ML phylogeny has been well sampled.  
Together, these methods form the basis for best practices in ML phylogenetics.  It 
should be noted that bootstrapping is also routinely performed on NJ inferred 
phylogenies. 
Bayesian phylogenetic techniques are now frequently performed in viral 
phylogenetics and offer a framework for performing state-of-the-art spatiotemporal 
analyses of sequence data.  Bayesian statistics has the advantage of using prior 
knowledge of a problem of interest to help inform the analysis of the problem (36).  It 
is different from ML methods in that Bayesian methods aim to sample multiple 
possible phylogenetic hypotheses and use all of them to generate distributions of the 
various parameter statistics related to the inferred phylogenies (38).  These statistics 
range from probabilities for specific branch length and node topologies, to mutation 
rates or times to most recent common ancestors.  The distributions of these statistics 
can be used to infer credible intervals around various aspects of the phylogeny in 
question and thus provide confidence in the phylogenetic hypothesis.  These intervals 
are calculated on distributions collected primarily as part of the Markov chain Monte 
Carlo (MCMC) algorithm (36), as opposed to after-the-fact using bootstrapping in an 




complexity of the analyses and the selection of the priors.  Computation for a 
Bayesian analysis can take days to months on modern computers, although some 
analyses can be completed in much less time (minutes to hours).  It should be noted 
that the time to complete any particular analysis is largely dependent on the size of 
the data set and the complexity of the model being examined.  Additionally, the 
selection of priors can sometimes be difficult, necessitating the rerunning of analyses 
to find the right parameters to use for a given data set. 
Methods related to phylogentics allow researchers to measure the variability 
and the selective pressures seen in viral data sets.  These methods include entropy 
analysis, which simply calculates the variability seen at specific sites within the viral 
genome or within the viral gene of interest (39), and dN/dS analysis, which quantifies 
the proportion of non-synonymous substitutions at non-synonymous sites to 
synonymous substitutions at synonymous sites within the coding genes of a genome 
(40, 41).  The latter example is used to assess whether specific sites within a genome 
are undergoing positive, neutral (diversifying), or purifying selection.  Each type of 
selection has a specific, measurable signature that can be use to inform downstream 
analysis and future research activities.  For example, high numbers of positive 
selected sites in a protein tells us that the protein is likely to be experiencing some 
sort of selective pressure in its environment.  This pressure could be exerted by the 
immune response of the host or be seen as the mutations required for a pathogen to 
adapt to the biological environment of a new host species, in the case of an emerging 
pathogen.  Both examples can help direct future research, inform us about a vaccine’s 




Regardless of the methodology used, phylogenetics is an essential tool for 
making important inferences about viral epidemiological and pathogenic features. 
Examining an influenza virus hemagglutinin gene tree, for instance, can suggest to 
researchers that the gene is under selective pressures, presumably host immune 
system pressures (42).  Close examination of a viral phylogeny with geographical 
data can reveal if local or global circulation is seen during an epidemic (43). Trees 
can put viral studies into an ecological context, such as identifying which bird species 
are involved in the spread of avian influenza virus across the North American flyways 
(44).  This information can give researchers insights into how highly pathogenic 
outbreaks of influenza virus originate.  These are just a few examples of the power of 
phylogenetics to draw important conclusions about viruses.   
Phylodynamics 
 Phylodynamics is a relatively new concept in phylogenetics.  It encompasses a 
set of methods related to Bayesian phylogenetics that enable researchers to look at the 
epidemiologic, immunologic and ecological factors that lead to specific viral 
phylogenies (45).  The most notable of these techniques is phylogeography.  
Phylogeography enables researchers to examine how viruses spread across 
geographic spaces (46).  This is especially useful in tracking emerging infections as 
they traverse geographic space from one host to the next, and enables researchers to 
make important inferences about the epidemiological characteristics of these 
pathogens.  Phylodynamics is, in essence, a merging of important viral metadata or 




inferences about viral evolution and the notable characteristics of viral pathogens (45, 
47).   
Genome Constellation Analysis and Recombination Analysis 
 Although phylogenetics tells us a great deal about the nature of viral ecology, 
the complexity of phylogenies makes interpretation of the results challenging.  
Categorical assignments of specific viral strains or viral genes can simplify these 
complex relationships for ease of interpretation.  One such methodology of 
categorical assignment of viral genes is known as genome constellation analysis, 
sometimes referred to as genotype analysis.  Constellation analysis is simply a way of 
grouping specific genes between viral genomes together based on some sort of 
objective criterion.  These methods utilize simple percent identity or phylogenetic 
distances to establish categorical membership (48-52).  Once categories are assigned, 
constellations between viral strains can be compared to determine a number of 
characteristics.  These include: evidence of reassortment events in segmented viruses, 
recombination in non-segmented viruses, and overall genetic diversity.  Combined 
with other viral data types, this information can reveal relationships between the 





Figure 4 Example Genome Constellation Figure Depicting Avian Influenza H7 Genomes.  The genome 
constellation analysis performs independent categorization of each gene per column.  Colors for individual genes 
are not related to identical colors in other columns and are assigned arbitrarily by gene cluster number. Viral 
strains are listed per row.  In this case highly pathogenic influenza strains are indicated with red dots by the name 
of the strain in a post analysis annotation step (4). 
 Although constellation analysis can reveal recombination events, other tools 
exist to identify probable recombination within viral data sets.  These tools include 
the Recombination Detection Program (RDP), Single Breakpoint Recombination 
(SBP), and the Genetic Algorithm for Recombination Detection (GARD).  RDP 
implements several recombination detection algorithms and provides a graphic that 
denotes the probable locations of the recombination events, as well as the probable 
donor of the recombinant subsequences (53).  Similarly, SBP and GARD (both 
methods implemented on the datamonkey.org website), are capable of detecting the 




events, respectively (54).  These algorithms are more statistically grounded than the 
detection through constellation analysis, and should be considered higher order 
evidence.  It is important to note, however, that recombination event detection should 
always be confirmed, as methodological errors in sequencing can lead to the artificial 
detection of recombination events.   
3-D Structural Analysis 
 Structural analysis of viral proteins is a key component of research aimed at 
determining the effects of mutation on viral phenotypes.  3-D structures of proteins 
can be compared between viruses to determine the structural changes with the 
potential to alter antigenic phenotype, viral attachment efficiency, or any number of 
other phenotypes associated with molecular pathogenicity and epidemiology.  For 
example, the hemagglutinin protein of influenza has been reported to alter its 
glycosylation pattern as part of its strategy to evade host immunity.  These types of 
changes can be modeled as 3-D structures for ease of visualization.  One drawback to 
3-D structural analysis is that it is relatively low-throughput compared to may of the 
other comparative techniques discussed here.  Additionally, solved 3-D structures of 
the exact subject protein or a close relative to the subject protein are typically 
required.   
Intrahost Variation Analysis 
 Next-generation sequencing technology has allowed for inexpensive deep 
sequencing analysis of individual viral infections.  Due to high mutation rates, 




swarm of evolutionarily related viruses (55).  The differences between intrahost 
variants are typically small, but with deep sequencing approaches they are identifiable 
(55, 56).  This type of analysis can give researchers insights into the mutations related 
to host adaptation and immune evasion, among others.  In one study of an RSV-
infected child with combined severe immune deficiency syndrome, samples were 
taken before and after a bone marrow transplant to establish adaptive immunity (57).  
It was demonstrated through deep sequencing analysis that post-transplantation 
immune pressures began acting on the intrahost viral populations, revealing mutations 
within the immune-facing surface glycoprotein (the G protein) (57).  This is just one 
example of the power of this type of analysis. 
Phenotype and Metadata Analysis 
 As large-scale viral genomic sequencing efforts have become commonplace, 
the potential for detailed metadata and phenotype analysis has become possible.  The 
practice of integrating detailed phenotype data with the genotype analyses is in its 
infancy.  Although antigenic phenotyping of influenza virus is performed on a regular 
basis, this data is not routinely integrated into phylogenetic or cluster-based 
comparisons of viral data sets.  Integration of metadata analysis into phylogenetic 
analysis is perhaps a bit more advanced.  These types of analyses would be best used 
to determine if metadata could be associated with genotypes in any way, and perhaps 
to establish new phenotypes for viral species.  Tools such as the Bayesian Tip-
association Significance Testing (BaTS) exist to determine if specific metadata values 
have relationships to parts of or entire phylogenetic reconstructions (58).  Similarly, 




website, is another tool that is capable of examining the degree to which certain 
labeled metadata values group together within a specific set of phylogenies (59). 
Outside of a phylogenetic context, the Metadata-driven comparative analysis tool for 
sequences (MetaCATS) (32), as implemented on the IRD and ViPR bioinformatics 
resource websites, is capable of analyzing multiple sequence alignments to determine 
if specific amino acid or nucleotide variants can be statistically associated with 
particular metadata values.  In addition to these tools, custom analysis is always 
possible with the use of statistical packages such as R or Matlab.  As mentioned 
above, viral data standards are of the upmost importance.  A cross-study analysis of 
metadata sets is only possible if metadata standards are adhered to when designing 
and implementing viral cohort studies (30, 31). 
Study One: DASH: A Novel Method for Influenza Virus Surveillance and 
Vaccine Candidate Evaluation 
Overview 
 This study aims to provide a computational framework for evaluating 
influenza vaccine candidates and demonstrates a model for a sequence-first approach 
to influenza virus surveillance (Figure 5).  The data workflow described in this study 
provides a methodology for determining the specific viruses, based on virus 
sequence, which would provide the most information via hemagglutination inhibition 
(HI) assay experimentation in a hierarchical fashion.  Additionally, the vaccine 
candidate evaluation methodology provided in this study extends the abilities of 
conventional antigenic distancing (AD) by providing a statistically robust approach to 




State of the Art 
 Viral surveillance and vaccine candidate selection for influenza A and B 
viruses is a complex internationally coordinated process.  Networks of clinical 
collection centers around the world take samples from patients presenting in their 
facilities with influenza-like illness (ILI).  These samples are tested using the HI 
assays to assess their similarity to viruses known to have circulated in the recent past.  
This HI assay testing process is quite time consuming.  Some of the viruses are fully 
sequences, but a subset of the viruses have only their HA and NA genes sequenced.  
The viruses selected for complete genome sequencing either demonstrate an 
irregularity with respect to the HI testing or are randomly selected from the cohort of 
HI tested viruses to provide genetic information for further characterization.  In 
addition to the sequencing and HI testing, the HI assay data is used in a computational 
process known as antigenic cartography or distancing (AD).  With AD, antigenic 
maps of viruses can be used to visualize and rudimentarily quantify the differences 




between viruses.  Direct associations between the antigenic phenotypes and other 
genetic information have, up to this point, been somewhat sparse. 
 This study hopes to extend the current state of influenza virus surveillance and 
vaccine selection by providing a framework for performing surveillance using a 
sequence-based approach first, followed by an HI assay approach.  With this 
paradigm shift in surveillance methodologies we hope to extend the capabilities of 
current antigenic distancing technologies and reduce the latency between vaccine 
strain selection and the delivery of fully licensed vaccine products.  Since the advent 
of NGS technologies, sequencing has become fast and cheap.  All the genetic 
information from surveyed viruses can easily be captured using current approaches.  
From the genetic information, targeted HI testing plans can be developed using our 
methodology and can be used to enhance the antigenic information on currently 
circulating viruses.  This study also aims to extend the capabilities of AD by 
providing a rigorous statistical assessment of the antigenic phenotype of all potential 
vaccine candidates.  This statistical approach provides a more informed assessment of 
the antigenic relatedness of the viruses through a bootstrapping technique that 
accounts for the error in the AD methodologies. 
Status of Work 
 The scope of work within this study has been incorporated into a manuscript 
that is currently in the revision stages.  The findings of this study have been combined 
with the results from a novel complementary computational pipeline, known as 
proportion tracking.  All analysis related to this study and proportion tracking have 





I developed the DASH pipeline, the grid-computing capabilities, early 
versions of uncovered cluster analysis R scripts and the antigenic coverage 
bootstrapping analysis.  I also performed all of the initial protein clustering analysis; 
evaluation of the agglomerative hierarchical clustering techniques; designed, ran, and 
performed the retrospective analysis; and designed, ran and performed the 
computational component of the JCVI HI data analysis.  I made minor suggestions for 
the improvement of the PTP pipeline, including use of the knee of the graph an 
appropriate height for cutting protein clusters.  I developed the production pipeline 
wrapper around the preexisting PTP pipeline for expedited automated computation.  I 
developed the name standardization methodology and the early database loading 
routines.  I, along with other team members, manually curated the HI assay data.  I, 
along with other team members, wrote and edited the relevant sections of the 
manuscript for publication. 
Study Two: VirComp: A Novel Method for Viral Comparative Analysis Using 





 This study aims to enhance the offerings of the constellation or genotype 
analysis packages available for viral researchers (Figure 6).  Viral genotype or 
constellation analysis is the systematic categorization of the entire genome content of 
one or more viruses based on 
predefined clustering criterion.  
The approach described here 
utilizes the farthest-neighbor 
clustering algorithm to build 
sequence dendrograms and clusters 
based on several predetermined 
percent identity cutoffs.  This 
study also describes a novel near-
publication ready figure generation 
application.  Even though it has 
been designed for the visualization 
of viral genome constellations, this 
application could also be used for 
the visualization of metadata, 
phenotypes or other data types 
associated with viral or other 
biological projects.   




State of the Art 
 Virus specific packages and websites exist for performing constellation 
analysis, as well as the methodologies describing the process.  Many of these 
applications rely on phylogenies to infer category membership and utilize 
phylogenetically derived criterion to cluster genes.  Some of the available tools 
provide categorization within the context of a specific set of well-curated viral 
constellation typing databases. 
 It is the aim of this study to extend the available constellation analysis toolsets 
with a virus-agnostic methodology and a set of associated tools for clustering and 
visualizing constellations.  This includes VirComp, a pipeline written in PERL that 
performs alignments, hierarchal clustering and cluster categorization of a set of viral 
genes, of a set of viral proteins, or of arbitrary subsequences within a genome of 
interest.  These constellations are generated systematically in a virus-agnostic, 
context-specific manner using a sequence-identity based criterion.  In addition to this 
novel methodology for identifying genome constellations, this study presents a novel 
tool for generating near-publication ready graphic visualizations of the constellation 
data using OrionPlot.  In many cases the images could be used directly in a 
publication; although, the examples presented herein have been enhanced with 
relatively minor annotations to maximize impact and information gain.  
Status of Work 
 The manuscript for this study has been completed and awaits final revisions 




analyses using VirComp and OrionPlot have been published in two separate papers 
(4, 5).  All code for VirComp and OrionPlot has been completed.  The code has been 
deposited on GitHub and has been tested on a number of Mac OSX and Linux 
devices to ensure compatibility, to derive system requirements and to derive software 
requirements.  All benchmark analyses have been completed. 
Author Contributions 
I, along with others, conceived of the VirComp constellation methodology.  I 
wrote and refined the VirComp pipeline.  I conceived of the OrionPlot program.  I, 
along with others, performed the analysis of the swine, human, and avian influenza 
data sets.  I performed the analysis of the RSV and Ebola data sets.  I performed the 
comparative analysis with phylogentic techniques.  I, along with others, wrote the 
manuscript. 
Study Three: Large-Scale Respiratory Syncytial Virus Whole-Genome 






 Study three aims to examine genetic determinants for the pathogenicity and 
epidemiology of respiratory syncytial virus (RSV) (Figure 7).  Through an integration 
of phylogenetic methods and statistics, this study uncovers potential determinants for 
disease severity and transmission based on associations with clinical metadata.  These 
determinants range from the discovery of positive selected sites within several RSV 
genes, to glycosylation patterns on the G protein and examinations of large inserted 
repeat sequences. 
State of the Art 
 RSV epidemiological surveillance is currently in its infancy.  No globally-
coordinated whole-genome surveillance efforts are currently being implemented.  In 
the past few years, large numbers complete RSV genomes have become available.  
As of 2015, more than 600 genomes have been released to public data repositories.  
The deposition of large amounts of complete genomic information enables 
researchers, for the first time, to examine these data for molecular signatures of 
epidemiology and pathogenicity. 
 In an exploratory context, this study extends the current knowledge of RSV by 
integrating clinical metadata with phylogenetic analyses of whole RSV genomes, as 




well as individual RSV genes.  This study also aims to enrich the RSV research by 
making associations between the signatures of molecular evolution and the 
epidemiological or pathogenic phenotypes. 
Status of Work 
 The work from this study will be broken into two publications.  The first 
paper focuses on large-scale phylogenetic trends in RSV and the inferences that can 
be made between the genetic data and the clinical metadata.  The second paper will 
focus on the specific selective and mutational patterns in the various RSV genes, as 
well as an analysis of the glycosylation patterns in seen in the study data set.  The first 
paper has been drafted and is in the revision stage.  The second paper has been 
conceived of and exists in text only as Chapter 4 of this dissertation.  All analyses for 
these two papers have been completed. 
Author Contributions 
I, along with others, conceived of this study.  I, along with others, designed 
the phylogenetic experiments.  I performed neighbor joining, maximum likelihood 
and Bayesian analyses.  I performed selection and variation analysis.  I performed the 
glycosylation analysis.  I performed the clinical data statistical analysis and BaTS 




Chapter 2: DASH: A Novel Method for Influenza Virus 
Surveillance and Vaccine Candidate Evaluation 
Abstract 
The influenza virus poses a significant risk to human health.  Up to 500,000 
people are estimated to die annually during the influenza epidemics of the Northern 
and Southern Hemispheres.  The World Health Organization (WHO), and its related 
network of surveillance facilities, seasonally monitor the evolutionary and antigenic 
signatures of the viruses circulating in human populations around the globe.  This 
viral surveillance informs the semi-annual recommendations that are made to the 
public and pharmaceutical industry on the formulation of the seasonal influenza 
vaccine.  The data for this process takes months to collect, and it can take up to nine 
months for the pharmaceutical industry to turn the recommendations into a vaccine 
product ready for dissemination to the world population.  Here we have described a 
method, Distancing of Antigenicity by Sequence-based Hierarchical Clustering 
(DASH), which may alleviate some of the data analysis burden on those involved in 
viral surveillance.  DASH is capable of making statistically grounded choices for 
vaccine candidates based on a phenotype mapping algorithm and protein clustering.  
Each vaccine candidate can be evaluated for its suitability as a component of the 
influenza vaccine and compared against other antigens.  Similarly, through a close 
monitoring of available antigenic data derived from the hemagglutination inhibition 
(HI) assay, DASH can produce lists of viruses that would either enhance our 




context for the pharmaceutical industry.  Coupled with reverse genetics, cell grown 
vaccine components, and synthetic biology, it is our belief that the DASH 
methodology will enhance preparedness for seasonal influenza epidemics and shorten 
the manufacturing latency between strain selection and vaccine administration.  
Introduction 
Influenza is a significant risk to human health.  It is estimated that hundreds of 
millions of people are infected annually, causing between 250,000 and 500,000 
deaths (60).  The virus is a negative-sense single-stranded RNA virus with eight 
genomic segments that code for 10-12 known proteins (61).  Of these proteins, the 
hemagglutinin (HA) and neuraminidase (NA) proteins are of most interest 
immunologically, as these proteins are on the surface of the virus and are directly 
accessible to the host immune system (61, 62).  Influenza A viruses (IAV) are 
currently categorized into 17 HA types and 9 NA types (61).  Combinations of the 
two proteins result in the virus subtypes that are commonly known, such as H3N2, 
H1N1 and H5N1.  Influenza in humans is primarily caused by two types of influenza 
viruses – influenza A virus (H3N2 and H1N1 subtypes) and the influenza B virus 
(IBV) (60).  In the case of IAV there is the potential for zoonotic transfer from an 
avian host reservoir to humans (63), as illustrated by H5N1 (64).  All human 
influenza viruses (H3N2, H1N1 and influenza B) are under constant selective 
pressure to evade the host immune response and therefore undergo constant antigenic 
(and genetic) drift (65) to form new variants – some with epidemic, and occasionally 
pandemic potential (60).  At the present time, the best way to combat influenza 




64).  For these reasons, influenza surveillance must be two pronged (64).  First, to 
track the continual drift in the currently circulating strains, robust genome sequencing 
and antigenic tracking surveillance must be performed (64).  Secondly, to properly 
prepare for a pandemic of a previously zoonotic origin virus, such as H5N1, sequence 
and antigenic surveillance must also be performed in animal species known to carry 
and transmit influenza (66).   
With these surveillance data, it is possible to extensively analyze and, in some 
cases, build predictive models that aid in the production of multivalent influenza 
vaccines (42, 67-69).  Current methods for selecting vaccine candidate viruses have 
focused on a combination of techniques.  Phylogenetic analysis and tracking of co-
circulating viruses of different genetic lineages using the sequence surveillance data 
for the HA gene (and sometimes the NA gene) is part of the process (60).  
Additionally, antigenic distance (AD) mapping (42) (sometimes referred to as 
antigenic cartography) of select strains using the hemagglutination inhibition (HI) 
assay is also a major component of the selection process.  The latter does not rely on 
sequence data; however, for proper correlation of genetic lineages, or clades, to a 
particular antigenic group, some overlap in sequence and HI data sets is required (42).  
Once it is determined which virus clade is dominant and the antigenic characteristics 
of that clade during any given season, a recommendation to change or maintain the 
current viral components of the multivalent vaccine can be made.  This decision is 
further informed by the phenotypes of the virus related to growth and suitability for 
production in eggs (60, 70).  Although the general framework for this semi-annual 




this method, it can often take months to properly calibrate the reagents being used in 
the production process.  This method can prove to be too ineffectual during the course 
of a pandemic to prevent the spread of infection, as was seen in the H1N1 pandemic 
of 2009 (64). 
Bioinformatic techniques have previously have been used to study the 
evolution and antigenic traits of influenza.  These techniques have begun to make the 
selection of vaccine candidates easier; however, the current speed at which vaccine 
candidate reagents can be manufactured and calibrated is a limiting step in both 
pandemic responses and seasonal vaccine production (64).  Here we demonstrate 
modifications to the current methods that aim to speed the vaccine production process 
and allow better understanding of the nature of antigenic drift.  By tuning 
bioinformatic approaches to look for potential candidate viruses for manufacturing at-
risk (viruses that show some evidence for utility as a vaccine candidate, but not fully 
validated yet) and by further qualifying those candidates using computational 
inferences, we can greatly speed the selection of vaccine candidates for production.  
Coupled with synthetic biology and reverse genetics technologies (not discussed 






Data Collection and 
Database 
We have created a 
database of all publically 
available human IAV 
H3N2, H1N1 HA 
sequences (seasonal and 
pandemic), and IBV HA 
sequences found at both 
the GenBank and EpiFlu 
(Figure 8).  The database 
is a relational database 
implemented using 





(RDBMS).  The HA 
sequences have been 
processed such that Figure 8 Schema of Custom Influenza Sequence and HI Data Database.  
The central entity in this schema is the strain table representing a viral strain.  
Each strain is linked to its associated sequence and HI data via foreign key 
relationships.  It is essential to properly recognize synonymous strain names to 




protein and nucleotide sequences from these databases have been paired together.  
We further categorized these sequences according to their completeness, full-length 
coding DNA sequence (CDS), full-length HA1 domain, or partial sequence.  
Metadata was collected on all sequences, as well as the passage number, passage type 
(cell or egg), and collection date.  Strain information and passage information were 
standardized to allow for more accurate matching of strain sequence and HI data.  
Standardization was performed on geographic locations, lab identifiers and collection 
years.  For example, A/CA/07/09 would be standardized to A/CALIFORNIA/7/2009.  
It was our practice to use full geographic locations wherever possible, to remove 
leading zeros from lab identifiers, and to expand two digit years to full four digit 
years.  This ensures that a sequence labeled A/California/7/09 would accurately be 
associated with HI data labeled A/CA/07/2009, since both standardized names would 
resolve to A/CALIFORNIA/7/2009.  Geographic standardizations were done using 
the Google Maps application program interface (API).  Ambiguous results were 
curated manually.  The database stored both the standardized and the original names 
to allow us to track possible errors in associations, if discovered.  Similarly, passage 
metadata was mapped to egg or cell passage type via a mapping file that was 
manually curated.  For example, SIAT1 was mapped to cell passage type, since SIAT 
is a cell culture line.  Conversely, E1E5 was mapped to egg passage type, since E 
represents an egg passage.  If a passage was ambiguous, such as SIAT1E5 (SIAT1 for 
cell and E5 for egg passages), we mapped it to egg – as even a single egg passage has 
been shown to be enough to shift a human virus toward avian adaptation, potentially 




In addition to the sequence data we populated our database with an extensive 
set of HI assays.  HI data was collected from both the CDC via annual Vaccines and 
Related Biological Products Advisory Committee (VRBPAC) reports to the Food and 
Drug Administration (FDA), and semi annual National Institute for Medical Research 
(NIMR) (in the UK) surveillance reports to the WHO.  These HI data tended to be 
highly variable in format, with numerous errors due to the likely manual method by 
which they were created for their respective reports.  We therefore manually reviewed 
these tables for consistency of format and content to minimize the errors loading into 
our database.  Once loaded, we stored the metadata on the HI run (such as the source 
and test date), as well as the metadata on the strains (such as passage and collection 
date information).  A combination of passage information, collection date, and strain 
names were used to associate specific HI assay distances with specific sequences 
obtained from GenBank and EpiFlu.  This step was critical, as passage differences 
often alter sequences and affect the HI assay distances for a particular virus. 
The final component of the database was the storage of AD data results from 
our antigenic distancing pipeline.  The AD pipeline will be described later; however, 
the results included the AD distance matrix data for 15 separate AD runs in various 
dimensional spaces, using various distance calculation methods. 
Access to the database was provided via a PERL API and command line 
scripts, and later incorporated directly into the DASH pipeline to ensure seamless 
automated computation.  PERL scripts were also used for the database loading 
process.  The current database includes 62790 strains, 57609 complete HA sequences, 




subtype, there are 36778 H3N2 viruses, 8657 H1N1 viruses, 29484 H1N1pdm 
viruses, 7764 IBV Yamagata, and 8352 IBV Victoria sequences in the database 
collected between 1918 and January 12, 2015. Additionally, there are 670 HI assays 
for a total of 140262 pairwise antigenic distances. 
Antigenic Distancing 
We used a technique known as antigenic cartography, herein described as 
antigenic distancing (AD).  
Hemagglutination Inhibition Assay – Antigenic distance is measured using the HI 
assay.  In this assay, a solution containing red blood cells is combined with an 
influenza viral isolate and antiserum made in a mammal using a different virus.  First, 
the antisera are serially diluted and then a fixed amount of virus and blood cells are 
added to each sample (42).  If the antibodies in the sera do not bind the virus, the 
blood cells will bind the influenza virions and form a lattice, i.e. hemagglutinate.  
However, if the antibodies in the serum bind the virus, no hemagglutination takes 
place.  This inhibition of hemagglutination is dependent on both the intensity of the 
virus-antibody binding and the antibody concentration.  This test is repeated with the 
opposite combination of virus and antiserum.  These data are compared to determine 
the viral titer required to prevent red blood cell agglutination in the presence of 
antiserum.  Antigenically similar viruses will fail to agglutinate red blood cells at a 
similar titer (within 4-fold) (71) when in the presence of their inhibition partners’ 
antisera.  In addition to two-way titer assays, one-way assays are also performed to 
survey circulating strains to identify low antibody-antigen viral reactors that may 




Homo and Heterologous Distance Calculation – Titer data from the above-described 
HI assay were converted into antigenic units using the following two formulas.  
(1) Two-way d2 = √( H11 H22/H21 H12) 
(2) One-way d1 = log2(H11/H21) (71)   
Antigenic Distancing via Multidimensional Scaling – Through antigenic 
cartography HI data can be plotted in 2-dimensional space to show the relative 
antigenic distances between multiple influenza strains.  Once the above distances 
were calculated from HI assays, the antigens were plotted in a multi-dimensional 
space and the two-way pairwise distances between all members were calculated using 
a process known as multi-dimensional scaling (MDS) (42).  We believe that 2-
dimensional distancing is an oversimplification of the data for the sake of 
visualization, and thus have used a modified version of antigenic cartography to 
calculate antigenic distance.  We have utilized several different distance methods to 
calculate pairwise distance in multi-dimensional space rather than the simple 2-
dimensional calculation used in traditional antigenic cartography (42).  We have 
chosen to employ multi-dimensional antigenic distancing because 2-dimensional 
calculations do not take into account the multi-dimensionality of the HI data.  With 
each new distinct antiserum that is introduced into an HI assay an additional 
dimension is added to the data.  There are several methods for calculating the distance 
between two points in a multi-dimensional space.  We utilized three methods: 
Euclidean, Manhattan, and Minkowski, and evaluated each for its overall 




measured by root-mean squared deviation (RMSD), for a particular set of HI data was 
selected by DASH for the next step in our analysis procedure (Figure 9). 
Figure 9 Comparison of RMSD Values for Various Antigenic Distancing Experiment Using Mixed Metric 
Space and Dimensionalities and Frequency of Use.  (A) Box and whiskers plot showing the 25-75% 
interquartile range (box) and 2.5-97.5% range (whiskers) of the 580 AD runs of ferret antisera and 164 AD runs of 
sheep antisera HI assay data.  Statistically significant differences between the ferret 2-D to Best RMSD and 3-D to 
Best RMSD exist (p-values = 1.99e-09 and 4.761e-05 respectively) indicate our method of selecting the best of 15 
different distance metrics and dimensionalities produces better results than traditional 2-D or 3-D Euclidean 
methods.  (B) Histogram plot of ferret sera Best RMSD metric and dimensionality over 580 HI assay data sets.  
This result indicates higher dimensionality and often the Minkoswki metric space as a more accurate measure of 





Distancing of Antigenicity by Sequence-based Hierarchical Clustering 
(DASH) 
Pipeline architecture overview – The DASH computational pipeline consists of a 
series of PERL and R scripts (Figure 10).  Data is prepared and permuted using the 
various scripts. Then, together with the results of various analyses, the data is 
compiled for inspection by analysts familiar with the methodology.  The following 
will describe the pipeline architecture, based on three phases of computation. 
Figure 10 Workflow of the DASH Pipeline.  Scripts responsible for various aspects of the computational 
pipeline are indicated next to category boxes in the diagram. 
Data extraction and sanitation – The first step of the run_DASH.pl script is to 
extract all the relevant information needed to perform the DASH analysis.  The user 
provides the date ranges for which they wish to analyze data and run_DASH.pl will 
in turn run getHI.pl and getSequence.pl to extract the relevant sequence and AD data 
from the MySQL database.  Data sanitation is required to ensure AD data and 
sequence data is in a format necessary to link the data types together.  Specifically, 
egg and cell passage labeled sequence and AD data are properly tagged with this 




analysis steps.  If the passage data is ambiguous for either the AD or the sequence 
information, the passage information is stripped from the record.  The run_DASH.pl 
script also automatically creates lists of antigens to run vaccine coverage predictions 
on.  The criteria for inclusion in this analysis set is that there exist at least 40 pairwise 
AD across the subset of HI data included in the analysis, thus providing a  ≥ 95% 
prediction interval for 
its antigenic distances 
with respect to other 
strains in the same 
season.  We have 
specified 40 distances, 
as our cutoff, since 
smaller subsets of AD 
data tends to not give 
accurate estimations of 
predicted coverage because there are not enough viruses with both sequence and HI 
data available to anchor the phenotypic coverage predictions (Figure 11).  This cutoff 
requirement has not been rigorously evaluated; however, larger protein cluster 
dendrograms tend to require more HI AD data to make plausible inferences across the 
entirety of the clusters.  Similarly, unevenly tested antigens (antigens that have been 
tested heavily against viruses from one cluster, but with little or no testing against 
viruses from a different cluster) show more variability in the coverage prediction 
results. 
Figure 11 Antigenic Distance Plot of Three HI Assays Performed for 
The 2012-2013 Vaccine Strain Selection.  It should be noted that to 
generate representative distances during a given season, multiple HI 
assays should be performed.  The data points in green, for instance, do not 





ANDES scripts – After data extraction and sanitation is complete, run_DASH.pl 
invokes the main DASH script (run_sequence_mask_analysis.pl).  This script is 
responsible for running the majority of the preliminary analysis R and PERL scripts.  
The run_sequence_mask_analysis.pl script also runs the 
run_estimate_vaccine_coverage.pl script.  The run_estimate_vaccine_coverage.pl is 
responsible for running the individual coverage predictions for the set of antigens 
with sufficient pairwise HI AD data, as established by run_DASH.pl.  Each 
prediction takes several minutes and often there are tens to several hundred antigens 
to analyze; therefore, to speed up computation we have enhanced DASH with grid 
computation capabilities. 
GRID computing enhancements – The run_estimate_vaccine_coverage.pl is grid 
enabled and launches individual vaccine candidate coverage predictions, as well as 
the bootstrap analysis on the JCVI grid, supported by the SunGrid Engine.  The 
summarization of antigenic coverage predictions is dependent on all the grid 
computations being complete, thus run_estimate_vaccine_coverage.pl has grid-
monitoring capabilities built in.  Once summarization of all predictions is complete, 
DASH analysis has finished. 
Pipeline Details 
Alignment – An important step in the DASH computational pipeline is to create 
protein clusters.  To do this, proteins are aligned and the pairwise distances are 
calculated for them using the program MAFFT (set with default options) to create the 




sequence alignment.  With such highly similar sequences, as are seen in the various 
influenza types we have analyzed, the probability of misalignments is low.   
Modified BLOSUM62 – DASH uses BLOSUM62 to calculate distance between the 
subject protein sequences.  Although, technically not a distance matrix, we have 
derived a distance matrix from the 
BLOSUM62 scoring-matrix.  To 
make this derivation, similarity scores 
were rescaled between 0 and 1 and 
inverted to represent distances. 
Protein Masking – For the same 
reason as the choice to examine 
antigencity on protein clusters, as 
opposed to phylogenetic clades, it 
may be possible to find portions of the 
HA protein that are critical in 
determining the antigenic phenotype 
of the virus (62, 65, 67, 69).  DASH 
uses the concept of protein masking to 
eliminate from consideration certain 
non-relevant areas of the HA protein 
when calculating distance.  DASH 
implements protein masking in the 
following ways to ensure just the 
Figure 12 Influenza H3N2 3-D Protein Structure With 
Five Known Immunodominant B-Cell Epitopes 
Highlighted.  The known epitopes are colored according to 





relevant specified sequence is considered for the distance calculation: all HA, HA1 
domain, all known antibody epitopes, and specific known antibody epitopes (H3N2 
AB epitopes and H1N1 SaSb epitopes) (Figure 12).  The masks were developed 
through the curation of HA protein data using the literature citations that documented 
the antibody binding sites of the various influenza types. 
Hierarchical Protein 
Clustering – Clustering 
HA protein sequences is an 
essential part of the 
methods described here.  
DASH uses an 
agglomerative hierarchical 
clustering method that is 
deterministic.  This allowed 
for repeated clustering experiments on the same data with the same resulting 
dendrograms.  Specifically, DASH utilizes the Ward’s minimum variance method 
(74) as implemented in the R package of statistical software to cluster the protein 
sequence data.  
 





Phenotype Mapping – To predict the effectiveness of particular vaccine seed 
Figure 14 Inference Algorithm Utilized by DASH.  Each node in the dendrogram is assigned a state (In, Out, 
or Conflicted) based on whether or not its decedents contain leaves with HI data points and whether those 
leaves conflict.  If no conflicts exist all decedents from that node will inherit the parent nodes state.  If conflicts 





candidates, DASH uses a novel technique of mapping antigenic phenotype traits onto 
the protein clusters generated using the methods described above.  The mapping 
process focuses on one single viral antigen at a time and multiple candidates are 
evaluated in parallel using grid-computing technology.  Distances generating by the 
AD process are used as well as the protein cluster data.  If the reference antigen is 
determined to be antigenically similar to the candidate antigen it will be assigned to 
an “in” group.  If the reference antigen is determined to be antigenically variant it will 
be assigned to an “out” group.  Antigenic similarity, or “likeness”, is most commonly 
estimated to be ≤ 2 AD units.  DASH projects this “in”/“out” grouping onto the 
protein cluster dendrogram, and the leaf nodes will be colored according to a 
prediction associated with the “in” or “out” group (Figures 13 and 14).  For a leaf 




sequence, meaning we have both sequence data and HI data for the leaf sequence, it 
will be colored according to the group to which it belongs.  Next, if a leaf node is 
between two accomplice leaves of the same group and there are no leaves of a 
conflicting group at the same level in the hierarchical cluster, it will be colored with 
the same group as the two accomplice nodes.  Lastly, if a terminal cluster (a cluster 
extended far off the trunk of the dendrogram with no additional branches) contains 
one accomplice and there are no conflicting nodes at the same level outside the 
terminal group, all nodes in 
the cluster will be colored 
with the group of the single 
accomplice in the cluster.  
These colored predicted 
antigenic coverage protein 
clusters form the basis of 
DASHs vaccine candidate 
selection algorithm 
described below.  
Bootstrap analysis – It is 
important to establish the 
statistical accuracy of the 
predicted vaccine seed 
candidate.  To do this, the 
phenotype-mapping 
Figure 15 Bootstrap Analysis Methodology Used to Assess Reliability 
of Antigenic Coverage Predictions.  (A) Bootstrap analysis uses random 
resampling with replacement from a sample population.  In the case of 
DASH the resampling is done on the set of Antigenic Distances (AD) 
available for a particular influenza season.  (B) Once the HI data point is 
sampled it is modified by the DASH algorithm.  DASH selects a new 
value for this data point randomly from a distribution with a mean equal 
to the original AD value and the standard deviation equal to the RMSD of 
the MDS computation where it was generated.  This RMSD approximates 




algorithm includes a bootstrap analysis to measure the variance of the predictions.  
Bootstrapping is a process by which a population sample is resampled with 
replacement repeatedly (Figure 15A).  With each resampling, statistical measures are 
made (such as median or mean).  After several iterations confidence intervals around 
the original statistic can be generated from the bootstrap replicates.  DASH employs a 
modification of this technique.  After an initial phenotype mapping step, the 
population of pairwise antigenic distances is resampled with replacement.  Instead of 
taking the original distance value; however, DASH resamples the distance over a 
normal distribution where the mean is defined as the original distance and the 
standard deviation is the RMSD value of the AD computation used to generate that 
distance originally (Figure 15B).  It is this modified resampling that allows DASH to 
take into account the error associated with both the HI assay and the AD computation 
when making coverage predictions. 
Identification of Clusters without AD data – During the initial phase of DASH 
analysis, identify_clusters_without_accomplices.r identifies 10 clusters without 
protein sequence data but with AD data.  These clusters are of the utmost importance 
to surveillance because they represent newly emerging genetic variants.  Antigenic 
testing on these newly emerging clusters is key to maintaining high levels of 
phenotypic measurements across the entire diversity of circulating viruses.  These 
new uncovered protein clusters are then analyzed using the R script 
(Analyze_Variances_in_DistanceMatrix.r) to established the HA sequences at the 
center of the cluster (the centroid virus), or those viruses closest to the center of mass 




centroid viruses DASH surveillance candidates, as further antigenic testing should be 
performed on these viruses for maximum gain of phenotypic information.  In a later 
experiment, DASH surveillance candidate viruses were constructed at JCVI with 
synthetic genomics technology and tested in HI assays, as a proof-of-concept that this 
methodology could be used to drive influenza virus surveillance in real time and 
positively influence and refine DASH predictions.  In certain instances, these centroid 
viruses show the antigenic characteristics of good vaccine candidates.  Retrospective 
analysis suggests that without running HI analysis on the centroid viruses, selecting 
these DASH surveillance candidates from several uncovered clusters often leads to 
the prediction of WHO vaccine or manufacturing candidates prior to the release 
vaccine recommendations. 
Identification of Vaccine Candidates – DASH uses grid-computing technology to 
generate candidate antigen centered phenotype maps.  Each antigen that has 
undergone antigenic distancing analysis and meets the DASH minimum distance 
requirement is evaluated as a potential vaccine seed in the phenotype mapping 
analysis.  A bootstrap analysis is also performed for each mapping run to further 
establish the predicted antigenic coverage of that antigen against similar, 
contemporary viruses.  An effective vaccine prediction maximizes the predicted 
antigenic coverage while simultaneously minimizing the variance in the prediction.  
During the retrospective and JCVI HI analysis experiments statistical analysis of all 
qualifying antigens and their bootstrap analyses were performed to establish the 




Proportion Tracking Pipeline 
 In parallel to the development of DASH we developed a methodology to track 
the proportions of the subpopulations of influenza viruses circulating concurrently 
during any arbitrary time period.  We call this method the Proportion Tracking 
Pipeline (PTP).  These subpopulations are not inferred using phylogenetic methods 
and do not necessarily follow the standard clade designations provided by the CDC 
and the WHO.  Instead the subpopulation designations are generated using the 
Ward’s clustering method, as it is used in DASH.  This allows us a common 
clustering methodology between DASH and PTP that provides consistency when 
comparing PTP results to DASH predictions.  Knowing which groups of viruses are 
expanding or contracting allows us to put the DASH analysis into context and to 
determine which DASH predictions should be emphasized.  To perform the PTP 
analysis, first all HA1 domain sequences from a particular subtype or lineage of 
influenza viruses are partitioned into 18-month subsets of viral sequences.  Each 
partition overlaps by 12 months in a windowed fashion based on the collection date 
for the virus.  This results in 12 months of viruses seen in other partitions and 6 
months of novel viruses.  Next, we apply weighting to the viruses in each 18-month 
partition.  Viruses isolated in the oldest 6-month period are given a weight of 0.16, 
viruses from the middle 6-month period are given a weight of 0.33, and viruses from 
the most recent 6-month period are given a weight of 0.50.  Clustering is performed 
and a cutoff for the partition is calculated.  This cutoff is derived by calculating the 
sum of squares for the intra-cluster group distances at each possible height (k) and 




value is plotted; and the k value nearest the knee (or inflection point) of the resultant 
graph is selected and used to generate clusters for the partition of interest.  This 
process is repeated for all partitions over the time period being examined.  Once 
clustering is competed, the proportions for each cluster are calculated using the 
weighting scheme described above.  Clusters between partition periods are linked 
based on similarity, to show forward associations of past partitions’ clusters.  Both 
the weighting scheme and the linkages between partitions provide continuity in the 
analysis, showing clusters that continue to expand over successive partition periods 
versus those that shrink or die out altogether.  Clusters with the most of expansion 
during a given period are weighted accordingly, allowing for visualization of the 
importance of a particular viral subpopulation. 
Retrospective Analysis 
We performed a retrospective analysis over 11 years and 22 influenza seasons 
for IAV H3N2, IBV Yamagata, and IBV Victoria.  For the IAVs H1N1 and 
H1N1pdm, we analyzed seven years (15 seasons) and four years (seven seasons), 
respectively.  The retrospective analysis involved pulling sequence and precomputed 
AD data from a 12-month period for each influenza season examined.  For the 
Northern Hemisphere seasons, the dates ran roughly from March to March.  For the 
Southern Hemisphere seasons, the dates ran from September to September.  The 
month cutoffs for analysis corresponded with the WHO’s Northern and Southern 
Hemisphere vaccine selection meetings.  We are assuming the data we used for each 
season’s prediction we are assuming closely matches what the WHO had available at 




 Once the data ranges for the individual seasons were established, DASH was 
launched using the run_DASH.pl script.  Analysis of the results focused on the HA1 
region of HA, as this was the most commonly used subsequence for influenza 
surveillance used by the WHO.  DASH Surveillance candidates from the uncovered 
clusters were selected if at least three candidates existed in the cluster and the strains 
were different (often resequenced strains or egg/cell passage variants showed up in 
the same uncovered clusters).  The centroid virus from these clusters was always 
selected.  DASH vaccine candidates were selected from the summarized antigenic 
coverage prediction results at an antigenic distance cutoff of two (Demonstrated via 
an AD plot, Figure 16).  Antigenic coverage data were sorted by the “in” median 
results from bootstrapping, followed by the observed “in” from the initial phenotype 
mapping, then the number of available AD values, and finally by the lower bound of 
the “in” bootstrap confidence interval.  All values were sorted from largest to 
smallest.  Once the data were sorted, the top-scoring candidate was selected as the 
DASH candidate for each IAV subtype and IBV lineage examined during the season 




Once DASH surveillance candidates and vaccine candidates were predicted 
we compared these results to the manufacturing and vaccine seeds recommended by 
the WHO for the subject season.  To determine concordance between prediction and 
recommendation, 
two antigens were 
considered 
antigenically like, if 
the antigenic 
distance between 
them is within two 
AD units.  To make 
this analysis more 
stringent, a more 
conservative cutoff 
using an antigenic 
distance of one was 
utilized to 
determine 
concordance.  If the 
DASH candidate 
and the WHO 
candidate were the 
same, the prediction 
Figure 16 Antigenic Distance Plot HI Data Collected for the 2012-2013 Vaccine 
Candidate Selection. (A) AD plot is centered on A/Perth/16/2009, all green points 
(within the circle) are viruses considered to be within an antigenic distance of two 
of this virus.  (B) Same AD plot except now we have centered the plot on A/S. 
Australia/3/2011.  Comparing these two graphs, A/S. Australia/3/2011 is within an 




was labeled as exact.  If the DASH candidate and the WHO candidate were ≤	 1 AD 
unit of each other, then they were labeled as concordant.  Finally, if the DASH and 
WHO candidate were > 1 AD unit of each other, then they were labeled as discordant.  
DASH surveillance candidates were examined to see if any of the candidates matched 
the manufacturing or vaccine seeds later recommended by the WHO.  If a WHO 
candidate appeared in an uncovered cluster, but not as the centroid, we evaluated how 
close said candidate was to our surveillance candidate by estimating the quartile rank 
of the pairwise sequence distance between the two candidates and the remaining 
distances available for the subject sequence.  This resulted in an estimate of how 
close our predictions were to the WHO candidate viruses.  These comparisons were 
repeated for all the seasons of interest and summary statistics were generated to 
indicate how successful DASH was at predicting the same or, in our estimation, better 
vaccine candidates. 
Analysis of Effect of JCVI HI Data 
For the 2013 Southern Hemisphere predictions we generated our own HI 
assay data with synthetically constructed viruses rescued using a reverse genetics 
system.  The synthetic viruses were compared using HI assays and AD data generated 
using our antigenic distancing pipeline.  DASH analyses (with and without additional 
in-house HI assay data) were performed for IAV H3N2 and H1N1pdm subtypes and 
for IBV Victoria and Yamagata lineages.  All sequences were kept identical, only the 
addition of JCVI HI data was changed between the DASH runs.  DASH dendrograms 
were cut to generate 10 uncovered protein clusters – that is protein clusters containing 




differences between the DASH runs with and without JCVI HI assay data, three 
measures were used.  The height in k of the dendrogram at which 10 uncovered 
clusters were identified was recorded.  The median and range of the uncovered cluster 
sizes were also recorded and compared. 
Results 
Preliminary Data Analyses 
Several preliminary experiments were conducted to establish the feasibility of 
later work.  These experiments included a reanalysis of the 2004 Smith et al. data set 









could potentially exploit, for example, the discovery of a close relationship between 
Ward’s protein clusters and the Smith et al. antigenic groups. 
Analysis of the Smith et al. 2004 Data set – Early trials with mapping antigenic traits 
onto dendrograms generated through protein clustering were conducted using a data 
set first described by Smith et al. in 2004 (42) when demonstrating antigenic 
Figure 17 Protein Clusters of HA Sequences From Smith et. al. 2004. (A) With no protein 
masking some sequences interdigitate into neighboring antigenic groups.  (B) Clustering on 




cartography was possible.  This data set includes antigenic groups from H3N2 viruses 
from 1968 until 2003.  The antigenic assignments from this paper were mapped onto 
dendrograms generated using the Ward’s algorithm (74), among others, although the 
coloring of the leaves of the dendrograms was done according to the antigenic group 
assignments laid out in the data set (Figure 17).  These analyses showed that it should 
be possible to cluster proteins and have fairly consistent clustering according to 
antigenic group.  The protein masking described above was also applied to these data 
to see if different treatments would increase the efficiency of clustering.  In most 
cases, clustering was improved using known epitope mask data; however, not all 
individual known epitopes cleaned up the cluster antigenic group assignments with 
the equal accuracy.  Two problems arose from these analyses.  First, some cluster 
assignments were confused by single amino acid changes in specific viruses across 
clusters.  A sequence could maintain the overall profile of its cluster, but could be 
colored with a neighboring antigenic group.  In nine cases where this was observed, 
the mis-grouping was the result of one amino acid change (Figure 17).  This problem 
was noted in the Smith et al. 2004 paper (42).  Our methods may be susceptible to 
clustering problems if single amino acid changes can alter the antigenicity of a 
protein and we are using a mask that does not heavily weight those positions.  The 
second issue we discovered was that it may be difficult to find a height cutoff that 
properly cuts all clusters accurately with respect to antigenicity.  This may be due to 
uneven rates of evolution in various protein clusters that lead to higher amounts of 




documented the tendency for antigenic drift to follow a punctuated pattern and 
sequence evolution to have a more uniform rate (42, 65).  
Development of Distancing of Antigenicity by Sequence-based Hierarchical Clustering 
(DASH) – As a natural extension of the work performed above, we developed a suite 
of software called Distancing of Antigenicity by Sequence-based Hierarchical 
Clustering (DASH).  Our early work with DASH was focused on contemporary 
sequence data from 2012, with one notable exception.  For the vaccine candidate 
virus selection for the 2012-2013 Northern Hemisphere (NH) influenza season, we 
have accurately predicted the need for, changes in the IAV H3N2 and the IBV virus 
vaccine seeds.  The H3N2 vaccine seed that we predicted is very close in sequence 
space to the actual candidate, and we were able to identify the protein cluster from 
which the H3N2 vaccine was selected.  Our centroid virus from that cluster was not 
the candidate selected, but it did match the vaccine seed we predicted as the best for 
covering the antigen using the phenotype mapping analysis of DASH.  It should be 
noted that the actual vaccine seed selected for the 2012-2013 vaccine was not 
Figure 18 Preliminary Analysis with DASH's Antigenic Coverage Prediction. A comparison of the top and 
bottom plots indicate that the H3N2 A/S. Australia/3/2011 virus is predicted to cover (green leaves in tree) a 




analyzed in any HI experiment publically available; however, the antigen our 
algorithm predicted was the closest to the actual recommended virus of any for which 
HI data was available (Figure 18).  
 In addition to the analysis for 2012-2013 season, the first phase analysis 
(focusing on DASH surveillance candidates) was performed on H3N2 viruses 
circulating one year prior to the vaccine candidate selection of 2003 for the NH 
season 2003-
2004.  It should 
be noted that the 
2003-2004 





system did not 
accurately select the correct vaccine seed (70).  In this analysis we were able to 
identify MAR candidates from seven clusters, including one cluster which contained 
the antigen selection A/Fujian/411/2002.  This virus was not easily manufactured.  A 
centroid virus from another cluster, A/Wyoming/3/2003, was eventually used as the 
vaccine seed as a result of a subsequent selection meeting (Figure 19).  It is unclear at 
this time if the success in predicting this is due to having a more complete picture of 
the sequences circulating at the time, or if the success is based on the robustness of 
Figure 19 Analysis of the 2003-2004 Vaccine Strain Selection. This uncovered clusters 
plot suggests that DASH would have identified several MAR candidates similar to 
A/Fujian/411/2002, including A/Wyoming/3/2003, which was selected for the H3N2 





the analyses presented here.  It is clear, however, that all viruses isolated from 
humans should be rapidly sequenced and those data released to the public (75), as the 
methods described here may be able to identify important variations in influenza far 
faster than current methods. 
Retrospective Analyses Compared DASH Predictions with WHO 
Influenza Vaccine Strain Recommendations.  
To evaluate the ability of DASH to predict vaccine strains, a retrospective 
analysis was performed for each human seasonal IAV subtype and IBV lineage 
beginning in 2002, except for pandemic H1N1 (H1N1pdm), which was analyzed 
since its introduction into humans in 2009.  For each NH and Southern Hemisphere 
(SH) influenza season, DASH was used to predict the vaccine strains that provided 
the greatest predicted percent antigenic coverage against circulating viruses.  If the 
DASH-predicted strain matched either the WHO-recommended vaccine strain or an 
antigenically similar strain (defined as ≤ 1 antigenic distance from the WHO-
recommended vaccine strain), then the concordance was considered exact.  For 
seasons where the vaccine strains were generally well-matched against circulating 
viruses based on post-season vaccine effectiveness data, we expected a high 
concordance between the DASH predictions and the WHO recommendations.  In 
seasons with a poorly matched vaccine strain, we evaluated whether our DASH-
predicted strain may have provided a better-matched vaccine than the WHO-
recommended strain.  Overall, the results of this retrospective comparison indicated a 
high level of concordance between the vaccine strain identified by DASH analysis 




and IBV Victoria, the overall concordance rates were 77.3% (17/22), 100% (15/15), 
100% (7/7), 100% (5/5) and 85.7% (12/14), respectively (Table 2).  However, using 
an antigenic distance of < 2 (the accepted upper bound for antigenic similarity) 
yielded a concordance of 95% (21/22) for H3N2.  
For the NH season of 2003-2004, the H3N2 DASH analysis selected 
A/Fujian/411/2002 as the vaccine candidate, which was in disagreement with the 
WHO recommendation of A/Moscow/10/1999 (Table 2).  During the 2003-2004 
season, H3N2 viruses predominated and caused a relatively severe influenza 
epidemic (76).  The WHO-recommended vaccine A/Moscow/10/1999 had only 
modest vaccine effectiveness, estimated to be 47% (77), and it was subsequently 
replaced with A/Fujian/411/2002 in the next season (Table 2).  This demonstrates that 
our DASH analysis was able to identify the need to change to A/Fujian/411/2002 one 
season in advance of the updated WHO recommendation.  The DASH analysis 
predicted A/Fujian/411/2002 because of its higher predicted coverage against 
circulating strains (“in” = 26.1%) compared with A/Moscow/1999 (estimated 
coverage of only 3.1%).  Because there were limited HI assay data available for that 
year’s circulating viruses, the majority of virus coverage (96.9%) was found to be 




Table 2 Results of a Retrospective Analysis of DASH Candidate Predictions Compared to WHO Vaccine 
Selections for 22 Influenza Seasons Between 2002 and 2013. 
Hemisphere In Unknown In Unknown Concordance
2013 Southern A/Victoria/361/2011 47.4% 49.1% A/Brisbane/299/2011 84.4% 14.8% 0.40 Like
2012-2013 Northern A/Victoria/361/2011 59.5% 35.9% A/South_Australia/3/2011† -- -- -- Exact
2012 Southern A/Perth/16/2009 24.7% 53.4% A/Rhode_Island/1/2010 67.8% 30.7% 1.09 Discordant
2011-2012 Northern A/Perth/16/2009 30.9% 50.9% A/Perth/10/2010 73.4% 23.4% 1.18 Discordant
2011 Southern A/Perth/16/2009 45.3% 40.6% A/Hong_Kong/34430/2009 54.4% 36.2% 0.97 Like
2010-2011 Northern A/Perth/16/2009 55.4% 17.2% A/Hong_Kong/1985/2009 62.4% 11.9% 0.37 Like
2010 Southern A/Perth/16/2009 44.8% 11.3% A/Perth/16/2009 -- -- -- Exact
2009-2010 Northern A/Brisbane/10/2007 27.5% 62.8% A/Sweden/3/2008 82.9% 16.7% 0.39 Like
2009 Southern A/Brisbane/10/2007 32.2% 66.9% A/Texas/37/2007 53.5% 45.4% 0.21 Like
2008-2009 Northern A/Brisbane/10/2007 43.1% 55.0% A/Brisbane/10/2007 -- -- -- Exact
2008 Southern A/Brisbane/10/2007 37.0% 62.8% A/Wisconsin/3/2007‡ 34.6% 62.8% 1.38 Discordant
2007-2008 Northern A/Wisconsin/67/2005 3.9% 68.4% A/Hong_Kong/4443/2005 9.2% 84.6% 1.74 Discordant
2007 Southern A/Wisconsin/67/2005 4.8% 88.4% A/Wisconsin/67/2005 -- -- -- Exact
2006-2007 Northern A/Wisconsin/67/2005 98.5% 1.5% A/Wisconsin/67/2005 -- -- -- Exact
2006 Southern A/California/7/2004 51.6% 46.9% A/California/7/2004 -- -- -- Exact
2005-2006 Northern A/California/7/2004 81.2% 16.8% A/California/7/2004 -- -- -- Exact
2005 Southern A/Wellington/1/2004 14.8% 84.2% A/Wellington/1/2004 -- -- -- Exact
2004-2005 Northern A/Fujian/411/2002 96.5% 3.5% A/Fujian/411/2002 -- -- -- Exact
2004 Southern A/Fujian/411/2002 25.0% 73.1% A/Fujian/411/2002 -- -- -- Exact
2003-2004 Northern A/Moscow/10/1999 3.1% 96.9% A/Fujian/411/2002 26.1% 72.0% 3.34 Discordant
2003 Southern A/Moscow/10/1999 92.3% 7.7% A/Moscow/10/1999 -- -- -- Exact
2002-2003 Northern A/Moscow/10/1999 100.0% 0.0% A/Moscow/10/1999 -- -- -- Exact
Overall Concordance: 77.3%
‡ A/Brisbane/10/2007 was the DASH recommendation when the requirement for ≥ 40 antigenic distance measurements was relaxed.
WHO Recommendation DASH Recommendation
Influenza 
Season
Predicted Coverage Predicted Coverage Antigenic Distance from 
WHO Recommendation
† The sequence and HI assay data for A/Victoria/361/2011 was not publically released until after the vaccine recommendation was made. The  HA segment for 
A/South_Australia/3/2011 only differed from A/Victoria/361/2011 in the signal peptide.
Strain Name Strain Name
 
Due to the limited activity in past few years of the seasonal H1N1 to a large 
naïve population of hosts to H1N1pdm, these viruses have been found to have lower 
diversity compared with H3N2 and IBV.  This was reflected in our analyses.  DASH 
results had maximal concordances with WHO-selected vaccine strains for seasonal 
H1N1 (100%, 15/15) and H1N1pdm (100%, 7/7).  For H1N1pdm, the DASH-
selected strains were essentially antigenically identical to the WHO 
recommendations, with computed antigenic distances of < 0.1.  Differences in the 
predicted coverage of circulating strains between the WHO recommendations and the 
DASH predictions are likely due to the conservative inference rules of DASH.  The 
predicted coverage of DASH-recommended H1N1pdm strains against circulating 
viral strains was supported by more HI assay evidence than for the WHO 
recommendations; therefore, a larger proportion of circulating viral sequences were 




DASH predictions had 100% (5/5) and 85.7% (12/14) concordances with 
WHO vaccine strains for the IBV Yamagata and Victoria lineages, respectively.  
Since the 2002-2003 Northern Hemisphere season, the WHO recommendation has 
essentially alternated lineages from Victoria to Yamagata and back twice, and 
recommendations have only changed when the lineage has changed.  That means that, 
within each lineage's succession, the WHO's recommendation has remained constant.  
This suggests the anticipation of lineage swapping and the aim to not burden the 
manufacturers with a new strain that would only be utilized for one season.  This may 
explain the discordant prediction in the 2007-2008 Northern Hemisphere season, 
where the predicted coverage by the WHO-recommended Victoria strain 
(B/Malaysia/2506/2004) was only 27.5%, whereas the predicted coverage by the 
DASH-recommended Victoria strain (B/Victoria/304/2006) was 100%.  The 
relatively low prevalence of waning IBV lineages (29% on average for all IBV (78)) 
in human population is likely a mitigating factor for not matching the most dominant 
genotypes. 
For the cases where the predicted coverage for DASH-recommended strains 
exceeded that for WHO-recommended strains, it is difficult to evaluate whether the 
DASH candidate would have had a better vaccine efficacy without controlled 
experiments.  Even correlating the predicted coverage of the WHO recommendations 
with vaccine effectiveness data is difficult despite a number of reports on vaccine 
effectiveness (77, 79-81).  These reports have largely been inconsistent in their goals 
and methodologies, leading to variations in their criteria for determining vaccine 




buttressed with wide and overlapping confidence intervals and may be estimated 
based on models with inconsistent covariates controlled between analyses.  
DASH Identified Drift Variants for Additional Testing and Ranked 
Potential Vaccine Candidates  
In addition to predicting coverage and selecting a vaccine strain, DASH 
identifies circulating drift variants for which there is no, minimal, or conflicting 
antigenic data.  DASH chooses candidates from among these variants with the aim of 
increasing coverage knowledge.  These DASH surveillance candidates can then be 
rescued using synthetic genomics and reverse genetics, used to generate ferret anti-
sera, and analyzed further using the HI assay and the newly generated anti-sera.  This 
data can be fed back into DASH to refine its vaccine prediction.  In many cases, 
DASH-selected candidates, or very closely related strains, have become the WHO-
recommended vaccine strains or vaccine seed stocks in upcoming seasons (as 




Table 3 WHO Influenza Vaccine Recommendations and Accepted Seeds Viruses Compared to Time 
Similar or Identical Viruses Were Identified as DASH Surveillance Candidates.  
DASH
Hemisphere Vaccine Strains Accepted Seed Stocks STICK Candidates
2013-2014 Northern A/Victoria/361/2011 (cell propagated) A/Texas/50/2012





2012-2013 Northern A/Victoria/361/2011 A/Almaty/3277/2012 α
2012 Southern A/Perth/16/2009
2011-2012 Northern A/Perth/16/2009
2011 Southern A/Perth/16/2009 A/Wisconsin/15/2009 
A/Victoria/210/2009 
2010-2011 Northern A/Perth/16/2009 A/Wisconsin/15/2009 
2010 Southern A/Perth/16/2009
2009-2010 Northern A/Brisbane/10/2007 A/Uruguay/716/2007 A/Victoria/210/2009 
A/New_York/3148/2009 β
2009 Southern A/Brisbane/10/2007 A/Uruguay/716/2007
2008-2009 Northern A/Brisbane/10/2007
2008 Southern A/Brisbane/10/2007
2007-2008 Northern A/Wisconsin/67/2005 A/Hiroshima/52/2005 A/Brisbane/10/2007 
A/Uruguay/716/2007
2007 Southern A/Wisconsin/67/2005 A/Hiroshima/52/2005
2006-2007 Northern A/Wisconsin/67/2005 A/Hiroshima/52/2005
2006 Southern A/California/7/2004 A/New_York/55/2004 A/Wisconsin/67/2005
2005-2006 Northern A/California/7/2004 A/New_York/55/2004 A/Wisconsin/67/2005
2005 Southern A/Wellington/1/2004 A/New_York/55/2004 
A/Waikato/1/2004 
γ
2004-2005 Northern A/Fujian/411/2002 A/Wyoming/3/2003 
A/Kumamoto/102/2002
2004 Southern A/Fujian/411/2002 A/Wyoming/3/2003 
A/Kumamoto/102/2002
2003-2004 Northern A/Moscow/10/1999 A/Panama/2007/1999
2003 Southern A/Moscow/10/1999 A/Panama/2007/1999
2002-2003 Northern A/Moscow/10/1999 A/Panama/2007/1999 A/Fujian/411/2002
WHO Recommendations
α Shared cluster with A/Texas/50/2012 (0.10 percentile) and A/Brisbane/1/2012 (13.30 percentile)
β Shared cluster with A/Wisconsin/15/2009 (0.62 percentile)
γ




DASH-selected candidates for additional testing and analysis are identified for 
each IAV subtype and IBV lineage by first deciding the maximum number of viral 
strains to select (nVS) and then iteratively cutting the tree towards the leaves until the 
number of clusters without any antigenic information equals nVS.  Clusters with only 1 
member are not selected because they are considered spurious.  A strain closest to the 
centroid of each identified cluster is selected based on an analysis of molecular 
variance (AMOVA) (82).  In the H3N2 analysis presented here, nVS was set a priori 




A DASH analysis of H3N2 viruses identified A/Fujian/411/2002 as a DASH-
selected candidate during the 2002-2003 NH season, three seasons before it became 
the WHO-recommended vaccine strain in the 2004 SH season (Table 3).  During the 
2005-2006 NH season, A/Wisconsin/67/2005 was identified two seasons before the 
WHO recommended it as a vaccine strain.  Importantly, by the second time 
A/Wisconsin/67/2005 was chosen as a DASH-selected candidate for the 2006 SH 
season, HI assay data for this strain and its anti-sera were still not available in the 
public databases, despite its significant difference from the majority of the sampled 
strains.  Three DASH-selected candidates (A/Almaty/3277/2012, A/New 
York/3148/2009, and A/Waikato/1/2004) shared the same cluster with a WHO-
recommended vaccine strain or accepted vaccine seed stock.  Although these isolates 
were different than the WHO-recommended strains, their sequence similarity was 
high enough to consider them as antigenically similar strains.  
However, in hierarchical clustering, the number of members sharing the same 
cluster depends on the height at which the tree is cut.  Thus, it is misleading to simply 
claim that a DASH vaccine candidate is in the same cluster as a WHO-recommended 
strain.  In order to evaluate the probability of randomly choosing a strain by chance 
that was more similar to the targeted strain, we sorted all the strains available in the 
season of interest by decreasing sequence similarity relative to the target strain and 
then computed the percentile of the strains that had been chosen based on that 
ordering.  For example, A/Almaty/3277/2012 shared a cluster with A/Texas/50/2012 
and was in the top 0.1 percentile of all strains in the 2012-2013 season.  In other 




were less similar and therefore were less preferred proxies for A/Texas/50/2012 than 
was A/Almaty/3277/2012.  Equally, highly similar DASH-selected candidates (in the 
top 1 percentile) were also identified for A/Wisconsin/15/2009 (in the top 0.62 
percentile) and A/California/7/2004 (in the top 0.51 percentile). 
Additional HI Assay Data from DASH-Selected Synthetically Generated 
Viruses Improved DASH Vaccine Strain Prediction 
The evaluation of the impact of DASH-directed surveillance showed that ,in 
all cases, JCVI HI assay data increased the proportion of circulating viruses with 
antigenic coverage (Table 4). 
Table 4 Evaluation of The Impact of DASH Directed Antigenic Surveillance During the 2013 Southern 
Hemisphere Vaccine Selection. 







0.93% with the 
inclusion of JCVI HI assay data.  The tree height required to identify 10 uncovered 
clusters increased by one (meaning a deeper cut into the tree), and the median 
uncovered cluster size decreased by two.  The predicted antigenic coverage for 
H1N1pdm improved by 10.00% with the inclusion of JCVI HI assay data.  The tree 
height required to identify 10 uncovered clusters increased by six, and the median 
Type Data set Tree Height 
Median 
(Range) % Uncovered 
H3N2 
w/JCVI 36 7.5 (2,17) 9.44% (81/858) 
w/out 35 9.5 (2,17) 10.37% (89/858) 
Difference -1 2 0.93% 
H1N1pd
m 
w/JCVI 25 7.5 (4,29) 21.60% (108/500) 
w/out 19 12.5 (1,50) 31.60% (158/500) 
Difference -6 5 10.00% 
IBV Vic 
w/JCVI 23 4.5 (1,18) 23.83% (66/277) 
w/out 17 5 (1,18) 28.52% (79/277) 
Difference -6 0.5 4.69% 
IBV Yam 
w/JCVI 24 2.5 (1,6) 17.71% (31/175) 
w/out 18 2.5 (1,11) 23.43% (41/175) 




uncovered cluster size decreased by five.  The predicted antigenic coverage by the 
Victoria and Yamagata lineages of IBV improved 4.69% and 5.71%, respectively, 
with the inclusion of JCVI HI assay data.  The tree height required to identify 10 
uncovered clusters increased by six in both cases, and the median uncovered cluster 
size decreased by 0.5 for the Victoria lineage.  The median uncovered cluster size for 
the Yamagata lineage did not change, although the range noticeably shifted toward 
smaller cluster sizes. 
The overall impact of these analyses on potential vaccine candidate viruses 
depends in part on how many antigens overlap between HI assays and how many new 
DASH-selected candidate viruses are tested, as well as on the overall distribution of 
tested viruses across the protein cluster dendrogram.  This analysis is best viewed as a 
method for increasing the overall knowledge about a particular antigen and about 
circulating viruses in general.  A candidate may look more or less desirable as a 
vaccine strain, but the net gain is an improved resolution of the antigenic phenotype 
across all circulating viruses.  The results described below demonstrate that targeted 
antigenic analysis through HI assay testing of DASH-selected candidates can have a 
significant impact on the resolution of the antigenic phenotype.  This information is 
highly relevant for vaccine production. 
A total of 81 viruses were tested in the two CDC H3N2 HI assays.  JCVI HI 
assay testing of DASH-selected candidates provided data for an additional 10 viruses, 
as well as providing additional HI assay data for nine CDC-tested viruses.  Changes 
in the percentage of “in” predictions after including the additional JCVI HI assay data 




predictions ranged from -46.12% to 2.64%, and the percentage of “unknown” 
predictions ranged from -10.90% to 30.86% (Table 5 and Figures 20 and 21).  
Table 5 Relative Shift in Observed Predicted Antigenic Coverage for Nine H3N2 Viruses With and Without 
JCVI HI Data. 
 
 
Figure 20 DASH Diagrams Comparing Antigenic Coverage Prediction for A/S. Australia/3/2011 Without 
(A) and With (B) JCVI HI Data.  The relationship between circulating viruses over the collected between 
August 2011 and August 2012 is depicted in the dendrogram at the top of each panel.  The green bars in the center 
of each plot indicate the ratio of “in” (green), “out” (red), and “unknown” (grey) predictions for each virus in the 
dendrogram over 80 bootstrap replicates.  The green and red bars in the bottom row of each plot indicate which 
viruses in the dedrogram also had HI assay data.  Overall these diagrams are very similar.  A/S. Australia/3/2011 
is indicated with the blue star.  Phylogenetic clades as defined by phylogenetic analysis and comparisons to WHO 
nomenclature are indicated with colored boxes and labels at the bottom of the second panel.  These diagrams can 
be considered to be very similar, however (B) shows slightly more predicted coverage around viruses with new HI 
data in clades 3c and 1.  These differences move A/S. Australia/3/2011 up in rank from six to one of all viruses 
tested. 
 











A/Hong Kong/4913/2011 25.32% -14.42% -10.90% 17 3 47 2 45 
A/Victoria/208/2009 15.26% -46.12% 30.86% 18 2 80 75 5 
A/Bangladesh/5071/2011 8.47% -0.53% -7.93% 17 3 72 72 0 
A/Perth/16/2009 5.65% -2.21% -3.43% 16 4 77 76 1 
A/Berlin/3/2012 2.64% -2.65% 0.01% 17 3 60 56 4 
A/Alabama/5/2010 2.64% -2.65% 0.01% 17 3 63 57 6 
A/South Australia/3/2011 2.38% 0.04% -2.41% 16 4 6 1 5 
A/Hong Kong/3969/2011 -1.99% -2.61% 4.60% 17 3 22 23 -1 





Figure 21 DASH Diagrams Comparing Antigenic Coverage Prediction for A/Brisbane/299/2011 Without 
(A) and With (B) JCVI HI Data.  The differences between these two diagrams show a large drop in predicted 
antigenic coverage of this virus against the 3c clade.  Phylogenetic and historical analyses reveal clade 6 to be 
older than clade 3c.  This may indicate the waning protective influence of clade 6 viruses versus clade 3c viruses.  
PTP analysis reveals clade 3c to be growing.  Taken together this indicates A/s. Australia/3/2011 to be a better 
potential vaccine candidate than /Brisbane/299/2011. 
During the 2012-2013 season, it was widely reported that the chosen vaccine 
strain (A/Victoria/361/2011) underwent significant antigenic changes during its 
adaptation to growth in eggs (Figure 22).  Although no A/Victoria/361/2011 virus in 
any propagation media was included in the publically available data at the time of its 
selection as a vaccine recommendation, our data support an antigenic difference 
between egg- and cell-propagated H3N2 vaccine strains as early as August 2012, 
which likely contributed to the reduced vaccine effectiveness. 
 
Figure 22 DASH Diagrams Comparing Antigenic Coverage Prediction for A/Victoria/361/2011 Cell (A) and 




prediction of the cell- and egg-passaged A/Victoria/361/2011 virus reveals different coverage prediction patterns 
on the various circulating clades.  The cell-passaged virus matches well against clades 3A, 3B, 3C, and 1, whereas 
the egg-passaged virus shows decreased coverage against all clades with particularly poor coverage predictions on 
clades 1, 5 and 6.  The histogram plots on the right of each DASH plot indicate the overall distribution of the AD 
values used for each prediction.  The shift of median AD value toward the antigenic cutoff of 2 for the egg-
passaged virus explains this discrepancy in coverage predictions. 
A total of 32 H1N1pdm viruses were tested in the CDC HI assay.  JCVI HI 
assay testing of DASH-selected candidates provided data for an additional 16 viruses 
and added additional HI assay data for seven CDC-tested viruses.  Shift in “in” 
predictions ranged from -2.71% to 37.66%.  Shift in “out” predictions ranged from -
8.68% to 0.56%.  Shift in “unknown” predictions ranged from -34.95% to 3.72% 
(Table 6 and Figure 23).   
Table 6 Relative Shift in Observed Predicted Antigenic Coverage for Seven H1N1 Viruses With and 
Without JCVI HI Data. 











A/Quebec/RV1432/2011 37.66% -2.71% -34.95% 54 4 30 9 21 
A/Voronezh/1/2011 6.31% 0.34% -6.65% 49 9 31 31 0 
A/St Petersburg/100/2011 6.20% 0.45% -6.65% 46 12 29 29 0 
A/New York/21/2011 4.96% -8.68% 3.72% 44 14 33 33 0 
A/California/52/2011 0.23% 0.23% -0.45% 52 6 10 10 0 
A/Valparaiso/17275/2011 -2.14% 0.23% 1.92% 53 5 4 8 -4 
A/California/7/2009 -2.71% 0.56% 2.14% 49 9 11 28 -17 
 
 
Figure 23 DASH Diagrams Comparing Antigenic Coverage Prediction for A/Quebec/RV1432/2011 Without 




of circulating H1N1pdm viruses by A/Quebec/RV1432/2011 with the addition of JCVI HI data.  Predicted 
antigenic coverage increased for clades 5, 6 and 7, whereas part of the cluster representing clades 1 through 4 
showed decreased predicted antigenic coverage.  This virus moved from rank 30 without JCVI HI data to rank 
nine with JCVI data.  This result indicates this virus could be a viable vaccine candidate.   
A total of 33 IBV Victoria lineage viruses were tested in the CDC HI assay. 
JCVI HI assay testing of DASH-selected candidates provided data for an additional 
eight viruses and added further HI assay data for two CDC-tested viruses.  Shift in 
“in” predictions ranged from 0.45% to 0.59%.  Shift in “out” predictions ranged from 
0.30% to 0.45%.  Shift in “unknown” predictions were measured at -0.89% (Table 7).  
Table 7 Relative Shift in Observed Predicted Antigenic Coverage for Two IBV Victoria Lineage Viruses 
With and Without JCVI HI Data. 











B/Nevada/3/2011 Egg 0.59% 0.30% -0.89% 10 12 9 2 7 
B/Kansas/1/2012 0.45% 0.45% -0.89% 9 13 25 22 3 
 
A total of 27 IBV Yamagata lineage viruses were tested in the CDC HI assay.  
JCVI HI assay testing of DASH-selected candidates provided data for an additional 
nine viruses and added further HI assay data for three CDC-tested viruses.  Shift in 
“in” predictions ranged from -14.76% to 19.75%.  Shift in “out” predictions ranged 
from 0.42% to 1.25%.  Shift in “unknown” predictions ranged from -20.17% to 
13.51% (Table 8 and Figure 24).   
Table 8 Relative Shift in Observed Predicted Antigenic Coverage for Three IBV Yamagata Lineage Viruses 
With and Without JCVI HI Data. 











B/New Hampshire/1/2012 19.75% 0.42% -20.17% 9 13 26 25 1 
B/Wisconsin/1/2010 8.52% 0.62% -9.15% 10 12 24 9 15 






Figure 24 DASH Diagrams Comparing Antigenic Coverage Prediction for B/Wisconsin/1/2010 Without (A) 
and With (B) JCVI HI Data.  These two DASH diagrams show an increase in predicted antigenic coverage of 
circulating IBV Yamagata lineage viruses by B/Wisconsin/1/2010 with the addition of JCVI HI data, although this 
change does not seem exceptional in the depiction above.  The green double-sided arrow points to one new virus 
tested by JCVI HI assay.  This particular virus contained a HA sequence that was identical to 27 other viruses that 
were circulating during this time period.  DASH applies weights to viruses that are highly represented in the data 
set.  This weighting accounted for an 8.52% increase in predicted antigenic coverage of B/Wisconsin/1/2010 over 
IBV Yamagata lineage viruses. 
Discussion 
The goal of this study was to put forth a method to improve the viral 
surveillance of influenza virus, with the hope of expediting the vaccine selection 
process while simultaneously making improvements to its accuracy.  Although we 
believe these methods achieve that goal, a shift in focus is likely necessary.  Next-
generation sequencing is a key component of that shift, where an unbiased 
sequencing-first approach to surveillance should be used.  It is only through an 
unbiased sequencing philosophy that the epidemiological dynamics of circulating 
influenza viruses becomes most accurate.  This is especially true in light of the high 
variability of the HI assay data (and related computations), and the accuracy achieved 
in modern sequencing techniques.  The assumption of reliability of these data as an 




This study supports the notion that targeted antigenic surveillance after the 
sequencing of influenza genomes, rather than large-scale HI assay testing prior to 
sequencing, is a viable alternative.  This method would have advantages over the 
current method in cost and timesaving.  A sequencing-first methodology would give 
researchers the ability to plan HI experiments in targeted areas of the viral protein 
space, and hence to maximize the increase of phenotypic information gained through 
HI testing.  Furthermore, these methods provide a strong statistical basis for selecting 
viruses as potential vaccine candidates based on antigenicity alone.  We have also 
provided evidence of the ability of these methods to resolve and visualize differences 
in antigenicity in egg- versus cell-propagated viruses, as was the case for 
A/Victoria/361/2011.  This capability may allow for smarter selection of vaccine 
candidates in the future, as poorly matched egg/cell pairs could be screened out as 
potential vaccine seeds.  Similarly, relatively small differences in antigenic distance 
(0.5-1.5 AD) can be shown to have large impacts on the predicted viability of one 
candidate virus over another especially in context of newly emerging clades.  These 
differences only become apparent through our bootstrapping techniques and the use 
of DASH visualizations (See A/Victoria/361/2011 egg/cell example, Figure 23). 
DASH and a related methodology, the PTP, have aided in determining the 
direction that antigenic assays should be taken.  These methods thus enable the 
sequence-first approach discussed above.  PTP is capable of tracking which genetic 
groups are growing or shrinking in prevalence during a given influenza season.  As 
we described earlier, DASH is able to identify gaps in antigenic information.  Taken 




clusters of viruses where data is limited and to prioritize the study of those influenza 
viruses that are seen to have high rates of expansion in prevalence.  Although smaller 
proportion groups are still of interest, since emerging antigenic variant influenza 
viruses can evolve from any sub population – the relative proportion should be taken 
into account.  It can be assumed that genetic groups that show little sign of expansion 
have likely not yet acquired the mutations required for immune evasion.  In designing 
HI experiments, sera panels should be derived from the breadth of recently circulating 
genetic groups, although antigens can be focused on areas with limited antigenic data. 
 HI experiments (and thus the AD calculation) itself are subject to a high 
degree of variability.  This variability is likely derived from the differences in 
methodology between labs.  These include: the use of regents (such as blood cells) 
from differing donor species (e.g. turkey, guinea pig, etc.), the use of additives (such 
as oseltamivir) to aid in NA normalization, and the various polyclonal sera used to 
inhibit hemagglutination.  Not only are polyclonal sera derived from different host 
species (most commonly ferret or sheep), but the use of outbred animals to generate 
these sera will likely lead to qualitative differences in results.  This is because the 
genetic background of the host can influence the specific antibodies produced when 
challenged with a novel pathogen.  During the AD computation, the serial dilution 
processes of the HI experiment can lead to quantization errors where larger distances 
will become increasingly error prone, as small differences in antibody titer will 
become large differences after many dilutions.  For this reason, we believe AD is 
most accurate at ≤ 2 AD units or 4-fold dilutions in an HI assay.  Similarly, low titer 




shortened.  Although it is our belief that these sorts of errors can be somewhat 
ameliorated by centralization of the assays and performing technical replicates of 
each antigen of interest, HI assays will likely not be scalable to the extent that high-
throughput sequencing techniques have become. 
The methods described herein should be seen as an enhancement to current 
viral surveillance and vaccine selection methodologies.  It is through the rigorous 
statistical treatment described above that human biases in the vaccine selection 
process may be eliminated.  It is also our belief that the use of synthetic genomics 
when coupled with computation, will speed the production of selected candidates, 
enhance the evaluation of new candidates, and allow for the manufacturing at-risk 
and stockpiling of viruses in real-time during viral epidemics – ready for later 
production if similar viruses are chosen as the vaccine candidates. 
Conclusion 
We have described methods for performing viral genotype and phenotype 
surveillance, as well as for the mapping of antigenic data on protein dendrograms, for 
the purpose of evaluating novel viruses for use as vaccine components in the annual 
influenza vaccine.  Through an 11-year retrospective analysis we have demonstrated 
the ability of these methods to accurately select the same or similar viruses as the 
WHO-recommended components.  In some cases, our methods have predicted the 
necessary changes in the vaccine seed choice by the WHO, and by our computational 
estimations have selected more suitable vaccine component viruses.  DASH has also 
a demonstrated ability to identify novel antigenic groups through sequence analysis, 




vaccine component candidates for the pharmaceutical industry.  Finally, we have 
demonstrated, through the use of JCVI generated HI assay data, that DASH could be 
used to enhance antigenic surveillance by facilitating directed HI assays of novel 
viruses, by reducing redundancy in the surveillance process, and by ensuring the 




Chapter 3: VirComp: A Novel Method for Viral Comparative 
Analysis Using Cluster-Based Gene Constellations 
Abstract 
Emerging and endemic viral pathogens carry an enormous disease burden on 
human and animal populations.  Morbidity, mortality, and economic losses are just a 
few ways in which disease burden can be calculated.  From the recent reemergence of 
Ebola in West Africa to the annual epidemics of respiratory diseases such as 
influenza and respiratory syncytial virus (RSV), research into viral diseases is of 
utmost importance.  Next-generation sequencing technologies have altered our ability 
to perform viral surveillance and directed research into epidemiological and 
pathogenic phenomenon related to these pathogens.  However, handling of these 
increasingly large data sets is key to making important inferences about viral 
epidemiological dynamics.  Here we describe a novel method, VirComp, for 
performing genome constellation analysis in a context specific manner.  VirComp 
when paired with OrionPlot (a new visualization application) enables detailed 
comparative viral genomics.  We show the utility of this method for understanding 
the reassortment and evolutionary processes in influenza virus, for investigating 
recombination and performing sequencing validation in RSV, and for carrying out 
variant screening in Ebola virus.  This method will aid in the enormous task of 





Emerging and endemic viral diseases are a great threat to human and animal 
populations around the world.  Pathogens such as influenza and RSV cause large 
disease burdens during their annual epidemic seasons (83, 84).  Influenza virus is 
thought to cause between 250,000 and 500,000 deaths annually with 3 to 5 million 
cases (84).  Similarly, RSV causes 199,000 deaths in children under the age of 5 
worldwide and 10,000 deaths in the US in the 65 plus community (85, 86).  The vast 
majority of RSVs disease burden is felt in developing countries (87).  The recent 
reemergence of Ebola virus has caused widespread death and economic calamity 
throughout West Africa since early 2014 (88).  As of this writing the 2014 Ebola 
virus epidemic has killed 11,261 people in six countries with laboratory confirmed 
cases in 10 countries on three continents (89).  A total of 27,609 cases are suspected 
(89).  With the current pace of genomics and the introduction of new technologies to 
expedite viral genome sequencing, new methods for effective viral comparative 
genomics are increasingly needed.  Novel methods for analyzing this onslaught of 
new data will no doubt enhance our understanding of these and other endemic and 
emerging pathogens. 
The most robust method for comparing viral genomes is to perform 
phylogenetic analysis.  However, comparing viral genomes, taking into account 
variations across multiple constituent genes, becomes intractable with large data sets 
across several to dozens of gene-specific phylogenies (90).  Methods for quickly 
categorizing and visualizing categorical assignments are useful in solving the 




analysis is commonly known as genome constellation analysis, or sometimes 
genotype analysis (49, 91).  Constellation analysis has been used extensively in 
influenza virus and rotavirus studies to uncover and examine the nature of genomic 
reassortments in segmented viruses (48, 50, 52, 92).  In principle these techniques 
could just as easily be used to study recombination in non-segmented viruses. 
Constellation analysis comes in two basic forms.  The first method relies on 
distance metrics based on sequence similarity alone to categorize differences in the 
genomic content of the viruses.  These approaches can be further categorized as one-
to-many comparisons (where one subject is compared against many references) (50), 
and many-to-many comparisons (where an all-versus-all comparison strategy is 
employed) (51).  The second method utilizes phylogenentic reconstructions as the 
basis for categorizing the viral genes (48, 91).  Distance methods tend to be less 
computationally rigorous and less time consuming than the phylogenetic approaches, 
especially if maximum likelihood or Bayesian inferences are made.  Furthermore 
many of the methods described in the literature, including the phylogenetic methods, 
involve less straightforward approaches to making cutoffs between categories (91).  
These approaches can make it difficult at times to discern, in a quantifiable way, what 
the differences are between the genotypes or constellations being examined. 
Methods 
Data Collection and Preparation 
All viral sequence data was collected either from GenBank or GISAID’s 
EpiFlu databases.  Viral genomes were selected for analysis according to their 




genomic segment into multifasta files, and labeled according to segment name.  RSV 
and Ebola virus genomes were first annotated with VIGOR 3.0 (22).  The resultant 
CDS file was then separated into gene specific multifasta files, and labeled according 
to gene name.  All sequences were identified by their database accession number.  
Additional accession number to viral strain name mapping files were generated as a 
way to associate unique sequence identifiers in the gene-specific sequence fasta files 
to specific viruses during a later step used to aggregate results.  Viral strain names 
were manually reviewed to ensure consistency in species-specific nomenclature, and 
to enable exact string matches to be made by the constellation processing scripts.   
VirComp Constellation Analysis Pipeline 
The VirComp (https://github.com/sschobel/vir-comp) constellation analysis 
pipeline was implemented in the PERL programming language (Figure 25).  The 
pipeline includes a main workflow wrapper script called run_constellation.pl.  The 
input for the pipeline is a two column tab delimited file (tsv) with the segment or gene 
names in the first column (matching the fasta files prepared previously) and in the 
order by which that segment or gene-specific clusters should appear from left to right 
in the resultant visualization.  The second column of the tsv file should include a sort 
order for the resultant pipeline output.  This allows a user to specify both the order of 
the gene columns and the order by which the columns should be sorted.  For example, 
a useful method is to order the columns by gene synteny in the genome, and sort the 
columns from genes with the most to least diversity.  The pipeline auto-detects the 
fasta files of the segments (or genes), so long as the names in the first column of the 




names are suffixed with fasta.  This script in turn executes six additional data 
processing applications.  The first of these is MAFFT (93).  MAFFT is responsible 
for generating multiple sequence alignments and was selected due to its speed and 
accuracy.  Multiple sequence alignments were output in the ClustalW format (an 
interleaved multiple sequence alignment file).  After MAFFT, run_constellation.pl 
executes ClustalALN_to_RDistancematrix.pl, which transforms the gene or segment 
specific multiple sequence alignments into pairwise distance matrices (39).  This 
script is available through the ANDES suite of deep sequencing analysis software 
(39).  The distance between sequence pairs is calculated using the Hamming distance 
method for nucleotide and protein alignments (94).  These distance matrices are then 
used multiple times to generate gene clusters using farthest neighbor hierarchical 
clustering and a set of predefined percent identity cutoffs (100%, 99%, 98%, 97.5%, 
95% and 90%).  The gene clusters are constructed using 
Partition_Members_byDistanceMatrix.pl, another member of the ANDES suite (39).  
Once the gene clusters are generated for all segments or genes at a particular cutoff 
level the pipeline then executes merge_constellations.pl.  This script is responsible for 
utilizing the accession to strain name maps to match gene cluster assignments for 
each gene or segment to their respective viral strains.  The program then outputs a 
genome constellation of each gene in the viral genome for every viral strain in the 
map files.  The output tsv file is sorted according to gene-specific columns specified 
in the original pipeline input.  For instance if the user specifies a desire to sort on the 
HA gene first, then the NA gene, then all of the rest of the genes in order of segment 




viruses.  This would be followed by HA cluster 1 and NA cluster 2 viruses if such 
combinations existed, and this step is repeated until all viral strains have been output.  
A second constellation tsv file is also outputted by merge_constellations.pl.  This 
output consists of only the set of unique constellations labeled with the count of 
observations of that constellation in the input data set.  This output can be useful to 
assess the abundance of a particular constellation and makes it easier to summarize 
especially large constellation analyses.  The constellation analysis pipeline produces 
two additional files as supplementary annotations for the constellation tsv files, 
produced by merge_constellations.pl.  The first is a list of the viral strain names in 
each of the unique constellations that have been derived from the input set (at the 
cutoff being examined).  The second is the mapping of the viral strain name to the 
constellation number.  Constellations are numbered according to the sort order 
specified by the user in the gene order input tsv file.  These annotation files are 
generated using annotate_constellations.pl and annotate_constellation_map.pl 
respectively.  Once run_constellation.pl has completed the generation of the gene 
clusters, the aggregation of the constellations and the annotation of the constellations 
at a particular cutoff, the pipeline moves on to the next predetermined cutoff until all 
cutoffs have been examined. 
To reduce redundant computational steps the pipeline is designed to run the 
alignment and the distance matrix generation steps only once per gene, as these will 
not change when examining the different percent identity cutoffs.  However, the 
cluster generation, the aggregation of the constellation information, and the 




pipeline simply passes these files on to the later processing steps as it iterates over the 
various cutoffs.  The run_constellation_analysis.pl script is also capable of detecting 
the presence of pre-generated alignments and/or distance matrices.  The purpose of 
this feature is twofold.  First, this allows the pipeline to skip the computational 
expense of producing these files if the user already generated them – for example if 
the user merely wanted to update a viral strain name in a map file.  Second, it allows 
the user to provide edited alignments or pairwise distances calculated according to a 
different algorithm. 
Maximum Likelihood Phylogenetics 
The H3N2 and RSV data sets were used to generate phylogenies of each viral 
gene for comparison to the gene-based clustering technique used in this method.  The 
phylogenies were inferred using GARLI Web 2.0 (95) using the general time 
Figure 25 Workflow of The VirComp Constellation Analysis Pipeline.  Scripts responsible for various aspects 
of the computational pipeline are listed next to the processing step.  Inputs and outputs of each step of the analysis 




reversible substitution model using a discretized gamma distributed site-specific 
variation model, with four rate categories, and an invariant site parameter. 
Sequence Analysis 
Sequence analysis for RSV recombination analysis was performed using 
MAFFT (73) for sequence alignment and CLCBio (96) for alignment visualization.  
Recombination analysis for confirmation of VirComp results was performed using 
RDP3 (53).   
Constellation Visualization using OrionPlot 
OrionPlot (https://github.com/sschobel/orion-plot) is a Java application that 
processes categorical matrix data sets and generates a concise visual representation 
from them.  The final output is provided in SVG and PNG formats.   
The tool provides a multi-platform GUI front-end.  This desktop application 
displays a preview of the output image and allows the user to modify the visualization 
parameters in real time before generating the final output.  A command-line interface 
is also provided. 
Results 
During the development of the VirComp constellation analysis software five 
separate analyses were performed to assess the utility of this method and to further 
develop functionality for the software.  These analyses consisted of a swine influenza 
data set, a human seasonal influenza data set, an avian influenza data set, a human 
RSV data set, and an Ebola virus data set.  The former three data sets represent a 




possible if not commonplace.  The RSV data set represents a single-segmented viral 
genome where reassortment does not occur; however, genomic recombination should 
be assessed, especially prior to performing any in-depth phylogenetic or other 
evolutionary based analyses.  Finally, the Ebola data set represents a low-variation 
genome, where the screening of the protein variants can provide support for the 
design of in vitro assays. 
Exhibition Swine Influenza Virus Analysis 
The swine data set included a set of viral samples from collected from pigs at 
several county and state fairs in Ohio during the summers of 2009-2011.  In addition 
to the viruses from this study, our analysis included North American swine sequence 
from the same period, human vaccine virus and H1N1, H1N2, and H3N2 variant 
viruses (collected as a result of human infections).  The cutoff used for this data set 
was 97.5% (Figure 26).  The results of the constellation analysis show a relatively 
static set of viruses circulating within the Ohio fairs during 2009 and 2010; however, 
during 2011, a much more dynamic viral landscape emerged.  During 2009, two viral 
constellations were circulating in pigs, one from the H3N2 subtype and one the H1N2 
subtype.  Similarly, in 2010 just one H3N2 viral constellation was present.  In 2011, 
however fair sampling showed nine distinct viral constellations circulating from both 
the H3N2 and H1N2 subtypes.  Single fairs in 2011 showed the presence of multiple 
constellations and subtypes.  During one fair in particular, sampling showed the 
presence pigs co-infected with more than one subtype, the hallmark of the 
reassortment process.  During 2011 and 2012, reassorted variant H3N2 virus was 




fairs.  The constellation analysis shows a close relationship between the H3N2 variant 
sequences found in human children who visited or were in contact with those who 
had visited county and state fairs.  This suggests that swine viruses were being 
transmitted to humans at these events, and possibly, vice versa.  One other interesting 
feature of the constellation analysis for this study was the switch over from the 
classical matrix to the pandemic matrix gene (a signature sequence from the 2009 
H1N1 pandemic) during the 2011 fair sampling.  This suggests a continual mixing of 
various human and avian origin gene segments within the swine population. 
Figure 26 Influenza A H3N2 and H1N2 Genome Constellations Present in Exhibition Swine From Ohio 
Fairs Between 2009 and 2011.  The constellation analysis shows the presence of numerous distinct genome 
constellations at the 97.5% cutoff in exhibition swine during the time period specified.  2009 and 2010 
constellations show no mixed infections or reassortment events.  2011 constellations do show evidence of mixed 
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98% nucleotide             
identity clusters*:
1 1 0 1            Cluster 1 
2 3A 17 3            Cluster 2
3 3B 0 11            Cluster 3
4 3A 1 0            Cluster 4
5 6 1 2            Cluster 5
6 6 0 6
7 5a 3 0
8 5 0 3
9 6 1 1
10 5 18 1
11 3C.1, 3C.2, 3C.3, 3C-2012/13 106 16
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99% nucleotide               
identity clusters*:
1 3C.1 1 1            Cluster 1 
2 3C.1 1 2           Cluster 2
3 3C.1 0 1           Cluster 3
4 3C.3 1 2          Cluster 4
5 3C.3, 3C.2c 12 3          Cluster 5
6 3C.3d 5 1          Cluster 6
7 3C.2 20 1
8 3C-2012/13 5 1
9 3C-2012/13 61 0
10 3C.2b 7 0
aThese study samples form their own HA monophyly within clade 5.
bThese study samples form their own HA monophyly within clade 3C.2.
dThese study samples form their own HA monophyly within clade 3C.3.
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cOf the 13 strains in this constellation that are also in the HA phylogeny, conly 
one strain falls within clade 3C.2.
Genome Constellation Count
Genome Constellation Count
* Please note that each column               
is evaluated independently and 
cluster numbering is arbitrary.
* Please note that each column             
is evaluated independently and 
cluster numbering is arbitrary.
Figure 27 Human Influenza A H3N2 Genome Constellation Analysis from Huston, Texas During the 
2012-2013 Influenza Season.  Constellation analysis was conducted at the 98% cutoff for the whole data set in 
panel (A).  Panel (B) depicts a 99% cutoff constellation analysis conducted on clade 3 viruses only.  




The human H3N2 influenza data set included a set of viruses collected during 
the 2012-2013 North American influenza season in Huston, Texas.  In addition to 
these viruses the analysis also included vaccine viruses as well as manufacturing 
seeds, a set of viruses used as references in the HA phylogenies of the NIMR 
September 2012 report and in the CDCs VIRPAC report to the FDA in February of 
2012 (97).  A sample of sequences from the 2012-2013 season outside Texas was also 
included as context for the analysis.  This data set was examined at the 98 and 99% 
identity cutoffs (Figure 27).  The complete set of genomes was examined at a 98% 
cutoff, and the predominant circulating clade (3C)  (in influenza, phylogenetic clades 
are defined by the HA gene) and its subclades was examined at 99% for finer 
resolution of variation.  At the 98% cutoff our analysis revealed intrasubtypic 
reassortment, especially between HA clades 5 and 6.  This pattern was confirmed 
through a comparison of the HA clades and a NA ML tree.  Several long-branch-
length monophylies were apparent in the NA tree, interleaved with opposite clade NA 
sequences.  Interleaving was also apparent within the 3C clade and subclades.  These 
reassortments were visible in our constellation analysis at a cutoff of 99%.  In 
addition to reassortment, the constellation analysis allows for the visualization of the 
variability in circulating viruses.  During one season, we saw nine distinct viral 
genotypes at the 98% cutoff level circulating in the Houston area.  The ability of 
influenza to reassort is a key component to its epidemiological success (98). 




























Figure 28 Influenza A H7 Genome Constellation Superimposed on A Bayesian 
Phylogeny of The HA Gene of Influenza Collected from North American Wild and 
Domestic Birds.   In this figure shore bird, duck, and poultry species are indicated with 
light blue, dark blue and green strain labels respectively.  Divergence date estimates for 
North and South American H7 lineages are indicated with arrows, as are American and 
European lineages of H7.  H7N3 outbreaks in poultry are indicated with red boxes.  
Highly pathogenic (HP) H7 outbreaks are indicated with red dots.  Each outbreak of HP 




for context, as well as several important reference sequences known to have produced 
highly pathogenic outbreaks of avian H7 influenza in poultry and humans.  Although 
few, if any, complete genomes were available from South America, several nearly 
complete genomes were included for this analysis. 
The constellation analysis was examined at 90 and 95% cluster sequence 
identity.  At both cutoff levels, unique constellations were seen for all highly 
pathogenic outbreaks (as well as the related low pathogenic poultry viruses) (Figure 
28).  The wild bird viruses with the HA gene most similar to that of the poultry 
outbreak viruses were often highly reassorted in comparison to the outbreak viral 
constellations.  This suggests that highly pathogenic outbreaks occur through 
convergent evolutionary processes (Figure 28 red boxes), and that there are no 
lineage-specific genes required for this convergent evolution to occur.  Although 
small numbers of surveillance sequences from the time and location of the outbreaks 
are available, the sequence analysis suggests that these viruses evolve highly 
pathogenic influenza features once they have infected domestic birds rather than 
evolving in the wild birds first.  Also, Anseriformes appear to be the reservoir host for 
the poultry outbreaks examined here.  The constellation diagrams highlight how much 
missing surveillance data there is about avian influenza as it circulates in wild 
populations, and how increased avian surveillance will help to fill in these gaps. 
Identification of Respiratory Syncytial Virus Chimeras 
The RSV data set included a set of viruses collected from children in the US 
during the 2012-2013 RSV season.  In addition to these viral sequences all available 




complement of full RSV genomes in GenBank is fairly small (as of this writing, 
approximately five hundred total genomes).  After phylogenetic analysis the data set 
was reduced to 245 genomes including 72 study sequences with complete gene 
counts. 
The RSV genome constellations were examined at 95 and 97.5% cluster 
sequence identity.  At 95% 22 constellations were inferred in the RSV data set 
(Figure 29).  The study sequences fell into five genome constellations: four RSV-A 
constellations and one RSV-B constellation.  All but one constellation with study 
sequences contained multiple genomes, including non-study genomes.  On closer 
examination of constellation 2, containing just one genome, it was noted that the M2-
2 gene more closely matched the M2-2 gene from constellation 14.  This pattern 
continued when examining the genomes at 97.5%; however, the mismatched genomic 
region expanded to include the M2-1 gene.  These results suggest a putative 
recombination event between the genomes derived from the two separate RSV-A 
Figure 29 Respiratory Syncytial Virus Genome Constellation Analysis Reveals Putative Recombinant.  The 
genome constellation analysis of RSV highlights the ability of OrionPlot to expand column widths according to 
markup contained within the matrix tsv file.  In this case column widths have been scaled to relative gene lengths.  
This depiction highlights study sequences with red boxes.  A constellation cutoff of 95% was used here.  The 
genome constellations of our study genomes show a potential recombinant depicted with a purple box around the 




linages.  An examination of the SNPs of this potential recombinant comparing the 
two parent lineages further supported a recombination event, as did the results from 
using the RDP3 recombination detection software.  Taken together these results 
strongly support the hypothesis that recombination occurred between these two RSV-
A lineages to form the virus in constellation 2.  
To confirm the recombination hypothesis, the sequencing methodology for 
this genome project was reviewed.  The study viruses were sequenced by first making 
four PCR amplicons tiled across the genome.  The PCR amplicons are then pooled 
and sequenced using the IonTorrent platform.  The PCR primers used for the 
amplification were compared to the coordinates of the putative recombination event.  
The coordinates for the primers for amplicon 3 were within 100 nucleotides outside 
the location of the putative recombination site.  As part of the assembly process, a 
deep sequence analysis of the assembly was produced.  Variant sites were detected in 
the assembly within these same regions where ampicon 3 overlapped with amplicon 2 
and amplicon 4.  These results suggest the putative recombinant was derived 
artificially as a result of an error in the sequencing methodology, specifically at the 
amplicon pooling step.  To confirm this, PCR primers were designed flanking the 
putative recombination site.  PCR products were obtained for the amplicon 3 and 4 
junction and were Sanger sequenced.  The resultant sequences were aligned to the 
major parent, the minor parent and the putative recombinant using MAFFT (73) and 
visualized using CLCbio (96).  All PCR product derived sequences matched the 
major parent, demonstrating the likelihood of a methodologically derived error in the 




Diversity in Zaire Ebola Virus and Identification of Protein Variants 
The Ebola virus 
data set includes all 
complete Zaire Ebola 
virus genomes 
available as of 
September 2014.  The 
majority of the 
genomes available 
were from the recent 
Ebola virus outbreak in 
West Africa (99).  
Ebola virus has a 
relatively low mutation 
rate compared to many 
RNA viruses (100).  
Few non-synonymous 
mutations were 
observed in the 
majority of the Ebola 
genes during the early 
outbreak sampling.  The 
goal with this analysis 
Figure 30 Zaire Ebola Virus Protein Constellation Plot.  (A) Protein 
constellation at a 100% cutoff.  Variability in the each gene is apparent. (B) 
At the 98% cutoff no within outbreak constellation differences are present for 
all known Zaire Ebola outbreaks.  It is worthy to note how little variation 
occurs in Ebola within and between outbreaks.  The Zaire outbreak genomes 
include several of the same strain that have been resequenced with variable 
results. (C) The genome structure has been included for reference.  Thanks to 




was to screen the variant viruses that had some level of detectable mutation, so that 
assays could be performed to assess the effect of the mutations on the viral protein 
phenotypes in vitro.  The available Ebola virus genomes were annotated with VIGOR 
3.0 (22) and the protein sequences were binned by gene product into amino acid fasta 
files.  Here we used the amino acid sequence since we were primarily interested in 
screening protein variants for further study.  We set the cutoff at 100% identity, 
meaning sequences with only one amino acid change would establish a new protein 
cluster and thus new constellation.  The results of this clustering revealed just 32 
distinct Ebola virus constellations in all the known Zaire Ebola virus genomes 
available in GenBank at that time (September 2014) (Figure 30).  Twenty L protein, 
fifteen NP protein, fourteen GP protein, ten sGP protein, nine SsGP protein, nine 
VP24 protein, four VP30 protein, eight VP35 protein, and six VP40 protein variants 
defined these constellations.  The 2014 outbreak showed 15 distinct constellations, 
with more than two variants observed in just five of the nine Ebola virus proteins we 
used to generate the constellations.  Of the proteins with mutations, three variants 
were uncovered in the GP, sGP, and SsGP proteins, five in the NP protein, and six in 
the L protein.  This low level of variation is consistent with previous studies on Ebola 
virus evolutionary rates (99, 100). 
Comparison of Constellation Clusters to Phylogenies 
A comparison of constellation clusters to phylogenetic trees generated using 
the maximum likelihood estimation method revealed cluster dendrograms with 
similar overall topologies to the respective phylogenetic trees – with a couple notable 




from indels in the sequence alignments were calculated differently in the VirComp 
pipeline as compared to phylogenetic methods.  This can been seen when comparing 
the phylogenetic placement (Figure 33, Chapter 4) of the four RSV strains (LA2_27, 
LA2_39, LA2_45, and LA2_78) in the lower group (TN1) of viruses to their 
placement in the constellation clustering (Figure 29) (where they are placed with the 
top group of viruses, constellation 1).  A closer examination shows that these viruses 
have a variation pattern more similar to the group of viruses they are placed with in 
the phylogeny.  A closer examination of the alignments shows a large indel of 72 
nucleotides within the G protein.  The G protein is the only gene that has a different 
cluster assignment between constellations 1 and 3.  In constellation 3 the insertion 
does not appear, whereas constellation 1 the insert does appear.  The strains that 
matched the lower phylogenetic group (but are placed with constellation 1 strains) 
have the insert.  It would appear that the added distance calculated from the mismatch 
(derived from gap to insertion sequence) is enough to group these strains in 
constellation 1, even though evolutionarily they appear to be closer relatives to the 
constellation 3 viruses. 
Second, at times, members of constellation clusters on the edge of 
phylogenetic clades sometimes appeared to have questionable cluster assignments.  
This assignment disparity may be due to the differences in the way that the 
phylogenetic methods evaluate evolutionary distances compared to the strict 





Detection of Genomic Rearrangements 
The VirComp method for 
constellation analysis of viral genomes 
provides a useful framework for generating 
publication worthy visualizations of genome 
constellations.  These visualizations allow 
users to establish evidence of reassortment 
in segmented viruses and can also be used 
to demonstrate recombination in non-
segmented genomes.  By creating 
visualizations at several cutoff levels, the 
relative age of these reassortment events can 
be established as well.  Although it may be 
important to verify these findings with one 
of the more rigorous reassortment detectors, 
such as GiRaF (101), VirComp provides a 
fast and context-specific approach to 
constellation analysis.  As demonstrated 
from the RSV example, the detection of 
genomic rearrangements is not limited to naturally derived rearrangements.  As such, 
this method could be coupled with the genome assembly process to detect errors in 
sequence production and to confirm (or rule out) true genome rearrangements (Figure 
31). 
Figure 31 Reanalysis of Putative RSV 
Recombinant Virus in the Context of Study 
Sequences Only and Lab-generated Amplicon 
Segments. (A) Study samples examined by 
amplicon at 98% cutoff (B) The same data set at 
the 99% cutoff.  These plots show RSV 
recombinant over laps with the region of the third 
amplicon we used to amplify and sequence the 
genomes.  This finding suggests in the 
constellation with the amplicon in the purple box 
was mispooled into the genome with the red box 





VirComp has been demonstrated to be a species agnostic method, in that any 
viral species gene complement can be compared with this methodology and the code 
base is not specific to either influenza or RSV.  This fact suggests that comparisons in 
other domains of life could be performed, such as analyses on the pathogenicity of 
specific genes across several bacterial strains.  RNA virus genomes especially lend 
themselves to this type of comparative analysis, due to their small genome size.   
Diversity and Visualization 
Biological relevance and ease of visualization can be balanced with the 
context specific diversity in the data sets being analyzed by selecting a meaningful 
cutoff.  Furthermore, cutoffs can be adjusted recursively to look more closely at 
specific subsets of the diversity being surveyed, as evidenced by the analysis of H3N2 
viruses described herein.  This allows for the examination of data sets at various 
levels of diversity, and of the timing of specific diversifying events (such as genomic 
recombination and reassortment). 
Variant Selection 
As evidenced by the Ebola example, with strict cutoffs (100%) in amino acid 
space, protein sequence variants can be quickly screened and analyzed for further 
study in lab-based assays.   
Performance and Algorithms 
VirComp uses fast, deterministic algorithms for its comparisons.  Farthest 




produce only one result for a given input data set (102).  This allows for 
reproducibility.  These types of hierarchical clustering algorithms are fast, especially 
then compared to maximum likelihood or Bayesian phylogenetic approaches (which 
are also non-deterministic).  An analysis of several hundred viruses with eight genes 
may take on the order of 30 minutes with VirComp.  A similar Bayesian or maximum 
likelihood analysis could take hours or days depending on the complexity of the 
evolutionary model used and the size of the data set.  Furthermore, farthest neighbor 
coupled with the use of Hamming distances as implemented by the ANDES software 
(39) provides a distance metric (percent identity) which is easy to measure and 
therefore provides a consistent mode for establishing clusters that is more readily 
understandable across analyses. 
Drawbacks and Limitations 
It should be noted that there are a couple of drawbacks to the approach 
VirComp uses.  First even though simple distance-based calculations are fast, they do 
not always provide the best reconstruction for the evolutionary history of the 
sequences being examined.  This fact could lead to localized miscategorizations of 
genes made by using sequence similarities that could have derived from convergent 
evolutionary events.  Our analysis suggests the main differences seen between the 
VirComp and the phylogenetic-based methods are seen at the boundaries of clades.  A 
second drawback is that the distance method used is incapable of calculating distance 
differently when a difference between two genomes is derived from a single 
evolutionary event or several events.  An example of this was seen with in our RSV 




3.  Our method calculated more distance between these four viruses and their correct 
constellation 3 because of a 72bp insertion in the G gene of the four genomes in 
question.  This insertion matched one seen in all the genomes of constellation 1.  This 
similarity in duplication status was enough to miscategorize the four genomes with 
constellation 1, despite having more similarity to constellation 3 at all other sites 
within G.  Essentially, the distance only approach treats each additional base as a 
separate evolutionary event, and thus calculates more distance than would be inferred 
using an evolutionary model that can score indels appropriately, or simply treat them 
as missing data. 
Similar Methods 
The literature highlights a few similar methods to this type of constellation 
analysis.  An example of this is a heat map style approach to compare a single 
reference strain to a small collection of viruses of interest, such as presented in 
Gonzalez-Reiche et al (50).  This type of approach is only useful when the context of 
the question of similarity is 2-dimensional, i.e. a single subject compared to a small 
set of references.  This type of comparison establishes a one-to-many relationship 
centered on the reference in question.  This methodology does not provide 
comparisons of the various comparators, and thus these analyses are prone to miss 
important relationships between those comparators.   
Another method highlighted in the literature is that of RotaC (91) and 
FluGenome (51).  These methods, although on a more firm methodological footing, 
in that they do the necessary all-versus-all comparison of genome components, they 




constellation categories inferred over time.  Although this is highly useful for putting 
a particular set of virus constellations into the context of all the known viral strains of 
a particular species, this type of analysis will become increasingly complex as the 
databases of viral sequences expand.  It also requires the adherence to an established 
nomenclature for genotypes that may be difficult to establish, especially in large viral 
research communities.  VirComp mitigates that issue simply by providing only a 
study specific analysis and does not aim to integrate its constellation results with 
established or yet to be established nomenclatures.  Once such nomenclatures have 
been established it should be a goal to extend those standards to the constellation 
annotation features of VirComp.  Additionally, the RotaC approach applies differing 
cutoffs for the various genes.  This makes it difficult understand quantitatively how 
much mutation has occurred between defined genotypes.  
Conclusions 
In summary, here we describe a novel constellation analysis method and 
visualization software useful in performing viral comparative genomics analyses.  
This method is a distance-based approach that utilizes several preselected cutoffs to 
create genome constellations at various levels of resolution.  Although, this method 
does not perform phylogenetic reconstructions (and therefore does not provide 
evolutionary clade-based genotypes), it does employ a straightforward percent 
identity metric that is systematic and not arbitrary.  We have also provided five 
examples of using this method to perform viral surveillance, reassortment analysis, 
protein variant screening, and recombination and sequencing chimera screening.  The 




important advancement in viral comparative genomics – especially in light of the 




Chapter 4: Large-Scale Respiratory Syncytial Virus Whole- 
Genome Sequencing Identifies Sequence Duplication in G Gene 
Associated with Reduced Diseases Severity 
Abstract 
Respiratory syncytial virus (RSV) is the most important respiratory pathogen 
for children under the age of five.  RSV is responsible for considerable morbidity and 
mortality worldwide.  Variability within and between RSV group A and B viruses and 
the ability of multiple strains of RSV to co-circulate are likely mechanisms for the 
evasion of herd immunity.  Detailed studies following the whole-genome variability 
of RSV over time are required to understand these dynamics and to understand the 
phenotypes these variants possess.  In this study, we performed complete-genome 
next-generation sequencing of 71 RSV isolates from infants in central Tennessee 
during the 2012-2013 RSV season.  We identified multiple co-circulating clades of 
RSV from both the A and B groups.  Each clade is defined by signature N- and O-
linked glycosylation patterns.  A detailed look at specific RSV genes revealed high 
rates of positive selection in the attachment (G) gene.  Furthermore, we identified 
RSV-A viruses in circulation with and without the recent 72-nucleotide G gene 
duplication.  In our study, this duplication appears to be associated with less severe 
RSV infections.  Pairing of high-throughput next-generation sequencing with a large 
cohort study of RSV-infected infants enabled a detailed look at both molecular 
evolutionary dynamics and exploratory clinical phenotype analyses looking for 





Respiratory syncytial virus (RSV) was first isolated in 1955 (83, 103) and has 
been associated with mild to severe acute lower respiratory infections (ALRIs), 
especially in infants, premature babies, the elderly and immunocompromised 
individuals (85, 104-106).  In 2005, RSV caused an estimated 33.8 million new 
episodes of ALRIs in children under five worldwide, with 3.4 million cases requiring 
hospitalization due to severe illness (83, 85, 86).  Global estimates of disease burden 
show RSV to account for 30 million ALRIs and 50,000 annual deaths of children < 
five years of age (83, 85, 86).  Nearly all children have had at least one RSV infection 
by two years of age (85).  However, a recent study has established that RSV 
infections during infancy (less than six months of age) are associated with an 
increased incidence of subsequent childhood wheezing and asthma (43). Despite its 
global public health impact, no licensed vaccines or effective medications for young 
children infected with RSV are currently available (43).  The only approved 
prophylaxis is passive immunization with palivizumab (Synagis from MedImmune), a 
humanized mouse antibody (mAb) against the RSV F protein (107, 108).  The 
original clinical trial of palivizumab indicated a 39-78% decrease in hospitalization 
rates for RSV in premature infants and children with chronic lung disease, although 
subsequent analyses have suggested lower affectivity (107). 
RSV is an enveloped virus with a negative-sense, single-stranded, non-
segmented RNA genome belonging to the Paramyxoviridae family.  The 11 RSV 
proteins are: the polymerase (L) protein, the nucleocapsid (N) protein, the 




(M) protein, the small hydrophobic (SH) protein, the non-structural proteins (NS1 and 
NS2) proteins, and two major surface glycoproteins (F and G).  The F and G proteins 
are responsible for virus entry and are the major target of human immune responses.  
The F protein is responsible for the fusion of the viral envelop with the host cell 
membrane.  The G protein is responsible for cellular attachment and has an immune 
decoy function in its soluble, extracellular, secreted form.  The G protein is organized 
from N to C terminal as follows: cytoplasmic domain, transmembrane domain, 
mucin-like domain, conserved domain, attachment domain, and finally a second 
mucin-like domain.  
RSV has an epidemic seasonality, with increased cases during the winter in 
temperate climates and during the monsoon season in tropical climates (43, 83, 109).  
RSV can be classified into two antigenic groups (A and B), each containing several 
distinct subgroups based on antigenic and genomic sequence differences, especially 
in the G glycoprotein (110, 111).  Studies suggest group A viruses cause more severe 
disease and transmit more readily than group B viruses in infants (43).  These two 
groups tend to alternate in prevalence between RSV seasons.  There is also evidence 
of multiple co-circulating intra-group viral genotypes, or clades, during any given 
season (109, 111), resulting in a diverse set of circulating viruses that can adapt to 
herd immunity.  It is unclear if this represents a gradual evolution of the viral 
genomes or stochastic differences in infection rates by co-circulating strains. 
Previous RSV sequencing studies have largely focused on sequencing 
complete or partial G gene sequences because the C-terminal (the second 




groups and the various genotypes within each group (109, 112).  In 1999, a G gene 
variant was identified in RSV-B that contained a 60-nucleotide (20 amino acid) 
duplication in the C-terminal third of the G gene, within the second mucin-like 
domain (113, 114).  This genotype has now spread globally (115).  In 2011, a similar 
G gene variant was identified in RSV-A from several locations around the globe that 
contained a 72-nucleotide (24 amino acid) duplication in the second mucin-like 
domain (110, 115, 116).  
To better understand RSV evolutionary dynamics, we sequenced RSV 
genomes from acutely infected infants from middle Tennessee who were enrolled as 
part of the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV 
Exposure (INSPIRE) study.  The objective of our sequencing efforts was to identify 
new variants in these RSV genomes and investigate any correlations with clinical 
aspects of RSV-associated upper respiratory infections (URIs). 
Methods 
Study Population 
INSPIRE is an observational, population-based, longitudinal study of 
previously healthy, full-term infants enrolled near birth, which conducts surveillance 
for respiratory illnesses during their first winter viral season.  Eligible infants were 
born between June and December and were on average 6 months of age or older 
during sampling for this study.  Informed consent was obtained from the legal 
guardians of each infant.  All procedures were in accordance with the ethical 




data – including age, sex, race and ethnicity – were recorded at the time of 
enrollment. 
RNA Extraction and RT-PCR 
 Extraction of the viral RNA was performed at the J. Craig Venter Institute 
(JCVI) in Rockville, MD with 140 µl of nasal wash sample using the ZR 96 Viral 
RNA kit (Zymo Research Corporation, Irvine, CA, USA).  Four forward reverse 
transcription (RT) primers were designed and four sets of PCR primers were 
manually picked from primers designed across a consensus of complete RSV genome 
sequences using JCVI's automated primer design tool (12).  The four forward reverse 
transcription (RT) primers were diluted to 2 µM and pooled in equal volumes.  cDNA 
was generated from 4 µl undiluted RNA, using the pooled forward primers and 
SuperScript III Reverse Transcriptase (Thermo Fisher Scientific, Waltham, MA, 
USA).  Four independent PCR reactions were performed on 2 µl of cDNA template, 
using either AccuPrime Taq DNA Polymerase (Thermo Fisher Scientific) or Phusion 
High Fidelity DNA Polymerase (New England Biolabs, Ipswich, MA, USA) to 
generate four overlapping amplicons (approximately 4-kb each) across the genome.  
Amplicons were verified on 1% agarose gels, and excess primers and dNTPs were 
removed by treatment with Exonuclease I (New England Biolabs) and shrimp 
alkaline phosphatase (Affymetrix, Santa Clara, CA, USA) for 37°C for 60 min, 
followed by incubation at 72°C for 15 min.  Amplicons were quantitated using a 
SYBR Green dsDNA detection assay (SYBR Green I Nucleic Acid Gel Stain, 





RSV Whole-Genome Sequencing  
 For samples sequenced using the Ion Torrent PGM (Thermo Fisher 
Scientific), 100 ng of pooled DNA amplicons were sheared for 7 min, and Ion-
Torrent-compatible barcoded adapters were ligated to the sheared DNA using the Ion 
Xpress Plus Fragment Library Kit (Thermo Fisher Scientific) to create 400-bp 
libraries.  Libraries were pooled in equal volumes and cleaned with Ampure XP 
reagent (Beckman Coulter, Inc., Brea, CA, USA).  Quantitative PCR was performed 
on the pooled, barcoded libraries to assess the quality of the pool and to determine the 
template dilution factor for the emulsion PCR.  The pool was diluted appropriately 
and amplified on Ion Sphere Particles (ISPs) during emulsion PCR on the Ion One 
Touch 2 instrument (Thermo Fisher Scientific).  The emulsion was broken, and the 
pool was cleaned and enriched for template-positive ISPs on the Ion One Touch ES 
instrument (Thermo Fisher Scientific).  Sequencing was performed on the Ion Torrent 
PGM using 316v2 or 318v2 chips (Thermo Fisher Scientific). 
 For samples requiring extra coverage, in addition to Ion Torrent sequencing, 
Illumina libraries were prepared using the Nextera DNA Sample Preparation Kit 
(Illumina, Inc., San Diego, CA, USA) with half reaction volumes.  Briefly, 25 ng of 
pooled DNA amplicons were tagmented at 55°C for 5 min.  Tagmented DNA was 
cleaned with the ZR-96 DNA Clean & Concentrator Kit (Zymo Research 
Corporation) and eluted with 25 µl of resuspension buffer.  Illumina sequencing 
adapters and barcodes were added to tagmented DNA via PCR amplification, where 
20 µl of tagmented DNA was combined with 7.5 µl of Nextera PCR Master Mix, 2.5 




DNA Technologies, Coralville, IA, USA) for a total volume of 35 µl per reaction.  
Thermocycling was performed with 5 cycles of PCR, as per the Nextera DNA Sample 
Preparation Kit protocol (3 min at 72°C, denaturation for 10 sec at 98°C, annealing 
for 30 sec at 63°C and extension for 3 min at 72°C) to create a dual-indexed library 
for each sample.  After PCR amplification, 10 µl of each library was pooled into a 1.5 
mL tube, and the pool was cleaned twice with Ampure XP reagent (Beckman Coulter, 
Inc.) to remove all leftover primers and small DNA fragments.  The first cleaning 
used a 1.2x volume of the Ampure reagent, whereas the second cleaning used a 0.6x 
volume of the Ampure reagent.  The cleaned pool was sequenced on the Illumina 
MiSeq v2 instrument (Illumina, Inc.) with 300-bp paired-end reads. 
RSV Genome Assembly and Annotation 
Sequence reads were sorted by barcode, trimmed, and de novo assembled 
using CLC Bio’s clc_novo_assemble program (16).  The resulting contigs were 
searched against custom, full-length RSV nucleotide databases to find the closest 
reference sequence.  All sequence reads were then mapped to the selected reference 
RSV sequence using CLC Bio’s clc_ref_assemble_long program (18).  At loci where 
both Ion Torrent and Illumina sequence data agreed on a variation (compared with the 
reference sequence), the reference sequence was updated to reflect the difference.  A 
final mapping of all next-generation sequences to the updated reference sequences 
was performed with CLC Bio’s clc_ref_assemble_long program (18).  Curated 
assemblies were validated and annotated with the viral annotation software called 
Viral Genome ORF Reader, (VIGOR) 3.0 (22), before submission to GenBank.  




reading frames, correlate nucleotide polymorphisms with amino acid changes, and 
detect any potential sequencing errors.  The annotation was subjected to manual 
inspection and quality control before submission to GenBank.  All sequences 
generated as part of this study were submitted to GenBank as part of the Bioproject 
ID PRJNA225816. 
Phylogenetic Analyses 
Sequence collection – All available full-length human RSV-A and RSV-B genomes 
were downloaded from GenBank on June 24, 2014.  Any viral isolates that contained 
“mutant” or other key words indicating in vitro modifications were removed from the 
data set after an initial ML phylogenetic analysis.  The remaining public genomes 
were then combined with the 71 RSV genomes from the study samples collected 
during the 2012-2013 winter RSV season.  Full genomes were then annotated using 
VIGOR 3.0 (22) to ensure consistent gene annotations across all genomes.  Each of 
the 11 RSV genes were separated into gene-specific fasta files for gene-based 
phylogenetic analyses.  Although in principal this data set should have included only 
complete gene sets, genomes without complete gene counts or containing partial gene 
annotations after processing with VIGOR were excluded from further analysis. 
Maximum likelihood analyses of whole-genome and G-gene-specific RSV 
sequences – The nucleotide substitution model used for all phylogenetic analyses was 
a general time reversible model with a nucleotide site-specific rate heterogeneity with 
four rate categories, and invariant sites (GTR-IG, as determined by jModelTest2.4) 
(117).  MAFFT (93) was used to create whole-genome and G-gene-specific 




likelihood phylogenies were inferred using an adaptive best tree search on the GARLI 
Web Service 2.0 (95) to statistically ensure the best tree (as measured by log 
likelihood scores) was found over 1000 replicates.  The resultant tree was labeled 
with the viral strain names, and colored using in-house PERL scripts.  Clade 
designations for the study sequences were defined using the reduced G gene 
phylogeny (S2) by examining boostrap support on branches leading to clades with 
study sequences.  All branches leading to the study sequences were supported by 
boostrap values > 70. 
Bayesian phylogenetic analyses of RSV-A and RSV-B genomes – The whole-
genome maximum likelihood tree was used as a guide to select a subset of viral 
genomes for Bayesian phylogenetic analyses, including genomes with unique 
phylogenetic histories and commonly used reference genomes.  To determine if our 
data exhibited temporal qualities, we performed an exploratory analysis with Path-O-
Gen (available at http://tree.bio.ed.ac.uk/software/pathogen/).  Neighbor joining trees 
generated with RSV-A-only and RSV-B-only genomes were used to measure root-to-
tip divergence using Path-O-Gen, which showed that both RSV data sets contained 
enough temporal signal to proceed with time-based Bayesian analyses.  All Bayesian 
analyses were performed using BEAST v1.8 (38, 118) on the CIPRES Science 
Gateway (33).  Whole-genome and gene-specific phylogenies were inferred using 
Markov chain Monte Carlo sampling chains (100 million to one billion in length), 
with parameters and trees recorded to ensure 10,000 samples per run.  The GTR-IG 
substitution model was used and tip dating with precision to the sampling year was 




We utilized the SkyGrid (119) coalescent model, with 50 partitions over 50 years.  
Default priors were used for each analysis – except for the ucld.mean prior for which 
we used the CTMC rate reference prior (120).  For the G gene analysis, we performed 
divergence dating on RSV-A by constraining the four clades and genotypes most 
closely related to two separate lineages of viruses with G-gene duplications present.  
All analyses were evaluated with Tracer v1.6 (available at 
http://tree.bio.ed.ac.uk/software/tracer/) to determine the success of the chain 
sampling based on effective sample size values for each parameter, and additional 
chains were run as needed.  For each analysis, we constructed a maximum clade 
credibility tree using TreeAnnotator v1.8.1, available for download with BEAST. 
Glycosylation Prediction  
Two surface glycoproteins, F and G, were analyzed using NetNGlyc (121) 
and NetOGlyc (122) software.  Multifasta files were loaded into the web interface and 
the output was saved, and then parsed with custom PERL scripts to produce a 
spreadsheet of glycosylation sequons and amino acid coordinates for the N-linked 
glycans and amino acid coordinates for the O-linked glycans.  The coordinates were 
then used to produce visualizations in R, using the ggplot2 package (123), of the 
overall consensus glycosylation patterns on the G protein for the various clades and 
genotypes identified in this study. 
Statistical Analyses  
The distribution of categorical clinical characteristics was compared across 




covariables were compared using the Wilcoxon rank-sum test.  The BSS2 metric was 
used to compare against genetic data, since several study samples were missing 
values using the BSS metric, which requires clinicians to use a pulse oximeter during 
site visits.  All statistical tests were performed in R (124), and visualizations were 
done with the R package, ggplot2 (123). 
BaTS Analysis for Detecting Global Versus Local Circulation Patterns with Tree 
Topologies 
The Bayesian RSV-A G gene phylogeny data set was used to analyze signals 
of global versus local circulation within our data set.  Local versus global circulation 
status was assigned to each G gene sequence.  BaTS analysis (58) was performed 
using a total of 9001 Bayesian phylogenies of RSV-A G gene sequences from the 
previous analysis.  The BaTS analysis was run in single mode with 100 replicates 
using two states (local and global).  
Results 
Large-Scale RSV Whole-Genome Sequencing from Nashville, Tennessee During 
the 2012-2013 Season 
The INSPIRE study was designed to collect samples from study participants 
to identify any respiratory viral infections during the RSV season in an unbiased 
manner.  A selection of nasal wash samples from patients with acute respiratory tract 
infections was screened for RSV using qRT-PCR.  One hundred six samples from 99 




and positive RSV serology results.  Characteristics of these study subjects are listed in 
Table 9.  
Table 9 Demographics and Clinical Characteristics of Enrolled Infants (n=99) 
ARTIs = acute respiratory tract infections; RSV = Respiratory Syncytial Virus 
*Data are presented as the number (%) for binary variables or median (interquartile 
range) for continuous variables. 
†Percentage calculated for children with complete data. 
§Category includes subjects of mixed race. 
 Six patients were shown to be RSV-positive twice and one patient was RSV-
positive three times during the 2012-2013 season.  However, in only four patients 
were we able to obtain consensus sequences.  For one of those infants, sequence data 
was obtained for both samples and the consensus sequences were identical.  The 
clinical data from the second isolation case was excluded from the statistical analysis, 
but was included in the phylogenetic analyses.  Infants were evenly enrolled in the 
study by sex; most were non-Hispanic, white, and were between one and seven 
months old at the time of sample collection, with a mean age of 2.97 months 
(standard deviation = 1.62).  
Demographics and Clinical 
Characteristics 
Infants with RSV ARTIs 
(n=99)*† 
Age (months) 2.97 (1-7) 
Female 42 (42.42%) 









Hispanic ethnicity 11 (11.11%) 




Of the 106 RSV-positive 
study samples, 71 whole-genome 
sequences were obtained, annotated 
and submitted to GenBank.  Partial 
genome sequences were obtained 
for three additional samples that 
contained gaps, lower coverage 
areas, or otherwise did not meet 
quality standards, because these 
incomplete genome sequences 
prevented accurate gene-specific 
analysis, they were removed from 
the data set.   
Maximum Likelihood 
Phylogenetic Analyses 
Demonstrate the Convergent 
Emergence of G Duplications  
Figure 32 Maximum Likelihood Phylogeny 
of 545 RSV Whole-Genome Sequences 
Including 474 Downloaded from GenBank 
on June 24 2014 and 71 Study Sequences.  
Whole-genomes sequences include mutant and 
lab-constructed strains.  RSV-A study isolates 
are depicted in purple, whereas RSV-B study 
isolates are depicted in green.  Co-circulating 
strains from multiple clades were present 





A maximum likelihood phylogeny that combined the RSV-A and RSV-B 
lineages was generated using whole-genome sequences from 474 publicly available 
Figure 33 Maximum Likelihood Phylogeny of RSV G Gene Sequences from a Pruned Whole-Genome Data 
Set.  Lab mutants, redundantly sequenced strains, and over-represented branches in the whole-genome phylogeny 
were removed or thinned out for subsequent analysis of the G gene coding region.  RSV-A study isolates are 
depicted in purple, whereas RSV-B study isolates are depicted in green.  Bootstrap support was included for nodes 
that were important for establishing the clades and genotypes in the Bayesian divergence dating analysis.  Bootstrap 




sequences and the 71 study genomes from the 2012-2013 season (Figure 32).  A 
subset of these samples was used to infer a maximum likelihood phylogeny using 
only the G gene coding sequence, and a similar topology was obtained (Figure 33).  
The 71 study genomes were aligned to three separate clades: BA RSV-B (seven 
genomes), GA5 RSV-A (five genomes) and GA2 RSV-A (59 genomes).  The RSV-A 
clade GA2.1 (a continuation of the GA2 clade) recent isolates were further divided 
into three monophilies, representing genotype ON1 with 35 genomes.  These 
genomes are a new group of viruses, specific to the study samples from Tennessee, 
that we are calling genotype TN1.  The TN1 genotype has 22 sequences, and has two 
genome sequences proximal to the divergence point of GA2.1 that we have named 
genotype TN2 for this study.  This confirmed the co-circulation of multiple RSV 
clades and genotypes in one season and in the same geographical location.  
Interestingly, seven RSV-B and 39 RSV-A study sample genomes contained a 
previously reported (110, 113, 115) insertion within the C-terminal third of the G 
gene coding sequence.  The insertion is present as an exact, tandem, in-frame 
duplication of the same gene region in both the RSV-B and RSV-A genomes, but is 
60 nucleotides in length in RSV-B and 72 nucleotides in RSV-A. 
Phylogenetic and sequence analyses of the G gene duplications suggest that 
the duplication occurred convergently at separate times in the RSV-A GA2.1 
genotypes (ON1 and TN1), as well as in the RSV-B group (Figure 32).  All 35 strains 
from genotype ON1 contained the G gene duplication, whereas only four out of 22 




contained the G gene duplication, whereas none of the RSV-A GA5 genomes had the 
G gene duplication.  
Bayesian Phylogenetic Analysis Provides Estimates of RSV Evolutionary 
Dynamics 
Maximum clade credibility (MCC) trees were constructed using the G gene 
analyses for both RSV-A and RSV-B (Figure 34).  Bayesian analyses of each 
individual gene, as well as the whole genome, provided mutation rates similar to 
those reported in previous studies (43, 106) for all RSV genes (Figure 35).  We also 
observed a high rate and Bayesian highest posterior density interval (HPD) of 
mutation within the SH gene of RSV-B, similar to previous reports (43, 106).  The 
Bayesian time to most recent common ancestor (tMRCA) mean estimates for the 
Figure 34 Bayesian Maximum Clade Credibility Trees for RSV-A (A) and RSV-B (B) G Gene Sequences.  
Strain names are colored by the presence (red) or absence (blue) of the large G gene duplication, with study 
samples in darker shades of red and blue.  Multiple co-circulating lineages of RSV are observed during the 2012-
2013 RSV season.  These phylogenies and related analyses suggest that the G gene duplication occurred 




whole-genome data set suggests circulating and historical RSV-A share a common 
ancestor from 1951, whereas available whole-genome RSV-B sequences likely 
diverged in 1967 (Table 10). Comparison of the RSV-B whole-genome phylogenies 
to the G gene phylogenies that contain more extensive sampling of all the available 
GenBank full G gene sequences (Figure 36) indicates that the whole-genome data set 
is missing the diversity that exists within several RSV-B G clades. 
 
 
Figure 35 Times to Most Recent Common Ancestors (tMCRAs) and Mean Evolutionary Rate Estimates 
Inferred by Bayesian Analyses.  Estimates are provided for RSV-A (purple) and RSV-B (green) for the whole 
genome (WG) and each individual gene.  (A) Mean tMRCAs for RSV-A and RSV-B data sets and (B) 
evolutionary rates (substitutions/site/year) for RSV-A and RSV-B data sets are provided with 95% HPD intervals 
indicated over the box and whisker plots.  The whiskers in each plot extend to the full 95% interval, the boxes 
indicate the 25-75% interquartile range of the posterior distribution, thus describing its central tendency.  Mean 




Table 10 Mean Evolutionary Rates (substitutions/site/year) and Times to Most Recent Common Ancestor 
(tMRCA), as Inferred by Bayesian Analysis   
  tMRCA (95% HPD) MeanRate (95% HPD) 
RSV-A WG 1951 (1937-1964) 5.68 × 10-4 (6.55 × 10-4 to 4.87 × 10-4) 
RSV-B WG 1967 (1964-1970) 7.47 × 10-4 (8.22 × 10-4 to 6.64 × 10-4) 
RSV-A G 1949 (1928-1966) 1.35 × 10-3 (1.60 × 10-3 to 1.10 × 10-3) 
RSV-B G 1972 (1966-1978) 2.59 × 10-3 (3.28 × 10-3 to 1.98 × 10-3) 
WG = whole genome; G = G gene; HPD = highest posterior density 
The Bayesian analysis of the G gene MCC phylogeny of RSV-A also 
supported the hypothesis that the G gene duplication occurred at least twice in a 
convergent manner within the RSV-A genotypes ON1 and TN1 (Figure 34A). This is 
Figure 36 Bayesian Maximum Clade Credibility Trees for All Available Full G Gene Sequences 
Downloaded from GenBank and Down Sampled to Include Representative Centroid Sequences from 98% 
Sequence Identity Gene Clusters.  (A) The RSV-A G gene phylogeny shows that relatively little new diversity is 
added compared with the whole-genome analyses.  However, the RSV-B G gene phylogeny (B) shows that 
additional diversity is being sampled by including additional G gene sequences compared with the whole-genome 




evident from the interleaving of the RSV-A G sequence duplicated genomes with the 
non-duplicated genomes within these genotypes in the G gene phylogeny, as well as 
by the divergence dating estimates for the recent GA2.1 strains and the genotypes 
contained within it: ON1, TN1, and TN2 (Figure 37).  These results suggest that 
genotype ON1 diverged first in late 2009, followed by genotype TN1 in early 2011 (a 
local Tennessee clade), and finally by genotype TN2 in late 2011.  Because the latter 
two genotypes appear to have evolved from a non-duplicated ancestral G gene 
sequence, genotype TN1 most likely acquired the duplication convergently.  This 
hypothesis is also supported by the minimal overlap in the 95% HPD interval of the 
divergence time estimates for genotypes ON1 and TN1. 
Figure 37 Divergence Time Estimates from a Bayesian Divergence Dating Analysis of the RSV-A G Gene 
Sequences.  The GA2.1 clade consists of genotypes ON1 containing only sequences with the G gene duplication, 
TN1 containing sequences with mostly non-duplicated G genes and four interleaved G gene duplication sequences 
and TN2 containing only sequences lacking the G gene duplication.  Divergence estimates suggest clade GA2.1 
originated from a non-duplicated ancestor, with the duplication being convergently gained first in genotypes ON1 
and then TN1.  This hypothesis of convergent G gene duplications is supported by divergence estimates that 




Bayesian SkyGrid analyses indicate a change in population dynamics for both  
the RSV-A and the RSV-B viruses during the introduction and global spread of their 
















the G gene 
phylogenetic 




Figure 38 Bayesian SkyGrid Reconstruction of Population Dynamics for RSV-A (A) and 
RSV-B (B) G Gene Data Sets.  The purple arrow indicates a bottleneck event in RSV-A 
corresponding to the G gene duplication entering global circulation and undergoing a 
subsequent population expansion.  Similarly, the green arrow indicates the same phenomenon 
occurring around the time that the RSV-B G gene duplication reached global predominance.  
These data suggest that the G gene duplication provided RSV-A and RSV-B with selective 




Glycosylation Analysis Reveals Genotype Specific Glycosylation Patterns in the 
G Protein 
Results of NetNGlyc across all study samples showed that the N-linked 
glycosylation in the F gene was relatively conserved.  Nearly all of the RSV-A and 
RSV-B samples had the same N-linked sites (27, 70, 116, 120 and 126) within the F2 
domain.  N-linked glycosylation on the G gene appeared to follow a genotype specific 
pattern, with multiple glycosylation patterns co-circulating simultaneously.  Genotype 
ON1 had three predicted N-linked glycosylation sites, clade TN1 had five sites, clade 
TN2 had four sites, and our study viruses from GA5 had five sites (Figure 39).  RSV-
B genomes showed two different glycosylation patterns.  Genotype BA.1 had four 
glycosylation sites, three of which were consistent with the majority of circulating 
Figure 39 Consensus N- and O-Linked Glycosylation Patterns for the Seven Study Genotypes.  The seven 
genotype specific consensus glycosylation patterns for O and N-linked (bars and dots respectively) glycans are 
displayed in rows.  RSV-A and RSV-B genotypes are indicated with purple and green bars to the right.  Each 




RSV-B genomes.  Genotype BA.2 showed a novel RSV-B glycosylation pattern with 
just one glycosylation site present toward the C-terminal end of the G protein after the 
G duplication.  Similarly, NetOGlyc showed that the O-linked glycosylation patterns 
for the G protein followed a genotype specific pattern as well.  Seven distinct O-
linked patterns were observed in the G protein sequences from our study cohort.  
Genotype ON1 showed 85 predicted O-linked glycosylation sites, whereas genotype 
TN1 had 74 and 83 sites (in non-duplicated and duplicated genomes, respectively), 
genotype TN2 had 74 sites, and genotype GA5 had 72 sites.  The RSV-B genomes 
showed two different glycosylation patterns: 82 sites for genotype BA.1 and 85 sites 
for genotype BA.2.  There were no significant numbers of O-linked glycans predicted 
for the F protein. Consensus genotype specific glycosylation patterns were plotted for 




Table 11 Observed Indels and Start and Stop site Variants within RSV-A, RSV-B and Between A and B 
Groups.  More indels are observed within the RSV-B group, particularly in the G gene suggesting greater 
plasticity of G in RSV-B.  Additionally, RSV-A -B differences, especially in L suggest the potential for functional 
difference in the polymerase that may lead to this apparent greater rate of indels in -B. 
	  
Gene Sequence Plasticity 
Contributes to Variability 
Between and Within RSV 
Groups 
Analysis of gene 
alignments within and between 
RSV groups showed various 
indels (especially in the G gene) as 
well as various start site and stop 
site variant sequences (Table 11).  
In RSV-A, we observed one indel 
each in the G and L genes, and 
two start site variants in the M2-2 
gene.  There were also two stop 
site variants in the G gene data set.  
Within the RSV-B data set we 
observed four indels in the G gene with three stop site variants.  We also observed 
two start site variants in the M2-2 gene.  Comparing RSV-A to RSVB we observed an 
additional seven indels: two in the G gene, four in the L gene, and one in the SH 
gene.  In addition to these intergroup indels, there were two variant stop sites found in 

















G 471-477, 673-685, 704-707, 793-













G 471-477, 634-637, 673-685, 704-
707, 793-853, 857-929, 1003-1008, 
1029-stop, 1038-stop, 1042-stop, 
1045-stop, 1050-stop 
L 400-406, 5193-5196, 5280-5283, 
6504-stop, 6507-stop 
M none 
M2-1 582-stop, 585-stop 









the M2-1 gene between groups.  Interestingly, one M2-2 start site variant was shared 
between subtypes, whereas one each was unique in RSV-A and RSV-B, leading to 
only three sites 
observed in the 
intergroup comparison, 
although none were 
novel observations.   
Detection of Global 
and Local Circulation 
Patterns Ssing BaTS 
Analysis 
Bayesian Tip-
association Significance (BaTS) testing of the RSV-A G gene phylogeny resulted in 
AI and PS scores of 0.0, and MC scores of 0.009 for the global and local state 
assignments.  These results are indicative of strong evidence for these states being 
topologically associated with the Bayesian phylogenies. 
RSV-A 72-Nucleotide G Gene Duplication was Associated with Reduced Disease 
Severity in Infants 
Figure 40 Comparison of Bronchiolitis Severity Scores (BSS2) with the 
Presence or Absence of the 72-nucleotide RSV-A G Gene Duplication.  A 
violin plot of severity scores by duplication status shows lower median BSS2 
(indicated with grey dots) in patients with the G gene duplication.  The shape of 
the violin plot shows this effect is mainly observed for lower BSS range, 
suggesting that other factors (e.g., host immune response or microbiome) also 







terminal of the G 
sequence duplications 
and the clinical 
severity data via the 
bronchiolitis severity 
score 2 (BSS2) 
metric, using Wilcox-
rank sum test.  The 
BSS2 score measures 
the severity of lung 
involvement with 
RSV infections by 
assessing infants on 
the following criteria: 
respiratory rate, pulse 
rate, retractions, 
dyspnea, and 
auscultation (125).  
Within infants whose samples had the RSV-A strain, those without C-terminal G 
sequence duplication had significantly higher BSS2 values (p=0.2094) when 
Figure 41 Maximum Likelihood Phylogeny of a Pruned RSV Whole-Genome 
Data Set.  The data set for this phylogeny is the same as for Figure 29, with the 
addition of 20 genomes collected during the INSPIRE study in Tennessee during 
the 2013-2014 RSV season.  RSV-A study isolates are depicted in purple, 
whereas RSV-B study isolates are depicted in green; the 2013-2014 genomes are 
depicted in orange.  The 2013-2014 season in Tennessee witnessed a switch to 
RSV-B dominance, as well as the continued circulation of RSV-A genomes 




compared with infants with the duplication (Figure 40).  These results suggest that 
there is a difference in mean severity between the disease caused by the viruses with 
the duplication and those without – severity is higher in the older viruses without the 
duplication.  Also, a difference was seen between the proportion of male and female 
hosts infected with viruses with and without the G gene duplication, however this 
result was not significant.  
We performed a whole-genome phylogenetic analysis using the 2012-2013 
data set along with a limited number of 2013-2014 genome sequences.  The resulting 
maximum likelihood phylogeny (Figure 41) showed a switch from RSV-A to RSV-B 
predominance.  We also noted the continued exclusive circulation of RSV-A ON1 
genotype viruses, all of which contain the G gene duplication.  
Discussion 
Here, we have identified multiple co-circulating RSV variants infecting 
infants within the central Tennessee region during the 2012-2013 season.  Substantial 
RSV genetic diversity was observed during the 2012-2013 RSV season in central 
Tennessee, both between and within the RSV-A and -B groups.  This diversity was 
especially evident within the G gene, although additional evidence was present in the 
F and select regions of the L gene.   We observed seven distinct G gene genetic 
variants in our data set, as defined by both G gene duplication and glycosylation 
status.  This observed diversity is likely part of the mechanism RSV uses to evolve 
and evade host adaptive immune responses (126-128).  We have also described a 
possible phenotype for the recent G gene duplications seen in RSV-A and RSV-B.  A 




enhanced viral attachment (129).  Our data suggests an association between the G 
gene duplication in RSV-A and lowered disease severity, as measured through BSS2. 
These data demonstrate that during the 2012-2013 RSV season, three distinct 
lineages of RSV (each containing multiple genomes) were co-circulating within the 
central Tennessee region.  This supports previous reports of multiple RSV types co-
circulating (109, 111, 130).  Furthermore, RSV-A clade GA2.1 appears to have 
predominated, accounting for 83.1% of the observed infections in our study cohort.  
In this study, we observed a local subgroup of RSV-A within clade GA2.1 that 
appears to be circulating only in central Tennessee (genotype TN1). The continued 
circulation of the ON1 genotype viruses during the 2013-2014 season supports the 
hypothesis that the 72-nucleotide duplication within the G gene is moving toward 
fixation in the RSV-A population.  Missing sequence diversity in the RSV-B whole-
genome data set may explain the relatively large ranges obtained for the Bayesian 
substitution rate estimates for many of the genes compared with those for RSV-A.  
The population dynamic analyses using Bayesian SkyGrid plots indicate that the 
introduction of the G gene duplication into RSV genomes reduced viral genetic 
variability (shown as a bottleneck event), which was quickly followed by an 
exponential expansion of the population size, suggesting a fitness advantage for the 
duplication variants.  
Comparing publicly available whole-genome RSV sequences to all available 
full-length G gene sequences indicated that, although whole RSV-A genomes are 
largely representative of known RSV-A diversity, the corresponding RSV-B whole-




suggests that additional whole-genome sequencing of historical samples would 
greatly improve our understanding of RSV-B diversity.  Similarly, a comparison of 
RSV-A and RSV-B whole-genome sequences shows that RSV-B contains more 
insertions and deletions (indels) within the G gene, suggesting that different selection 
pressures exist between these groups.  Overall higher mutation rates in RSV-B and 
specifically the difference in the SH gene mutation rates between RSV-B and RSV-A 
further support this, although this could also be a result of poor RSV-B surveillance.  
The fact that intergroup indels occur in genomic regions other than the G gene 
supports the need to adopt a whole-genome sequencing approach for future RSV 
studies. 
In this study, we observed tree topologies with little or no temporal and or 
geographic patterns and others with strong geographic and temporal patterns.  Over 
the long-term, most genetic diversity within both RSV-A and RSV-B appears to 
circulate globally on relatively short time scales.  However, in our study and other 
studies, such as Agoti et al. (43), localized RSV evolution is sometimes apparent.  
Genotype TN1 appears to be a central Tennessee RSV-A cluster, whereas several 
groups of RSV-B that were noted to be local to Kilifi, Kenya in the Agoti study (43).  
We tested the assumption of localized clades using BaTS with a significant result, 
suggesting that genotype TN1 and Tennessee GA5 viruses were being locally 
transmitted during the 2012-2013 season.  With broader genomic surveillance of 
RSV, these epidemiological patterns can be studied more closely and the origins of 




With the addition of 7 new RSV-B whole-genomes (11% of total publicly 
available RSV-B whole-genome sequences), our tMRCA estimate for RSV-B is 
likely improved over previous estimates (106); however, the estimate would likely be 
improved with additional whole-genome sequences of historical RSV-B genomes 
since RSV-B was first identified in 1960. 
The convergent appearances of large G gene duplications in the same genome 
location for multiple RSV lineages suggest that the G protein is highly permissive for 
these types of insertions and that a specific replication mechanism is responsible for 
their generation.  These duplications demonstrate the plasticity of the G protein and 
its tolerance for insertions, and they potentially indicate a mechanism for the 
development of novel immune evasion strategies.  We observed just one large 72nt 
duplication in the G protein of RSV-A, as well as two stop-variants, and four indels 
of various sizes with three stop-variants in the RSV-B G protein data set.  The 
existence of two major duplications may also indicate that the duplications imparts 
some level of selective advantage for the virus, because the duplication appears to 
have reached fixation in RSV-B genomes and may be moving toward fixation in 
RSV-A, although improved RSV surveillance/sampling is required to know this for 
sure.  A recent study by Hotard et al. showed an association between the 60nt G gene 
duplication in RSV-B and an enhancement of the attachment function of the G 
protein (129).  It is possible that the 72nt duplication in RSV-A similarly enhances 
the G protein, thus providing a selective advantage to duplicated viruses.  As 
previously reported, there may be a mutation in the G gene that primes duplication to 




that stem loop structures form in the replicating RNA strand, causing the polymerase 
to pause and reinitiate replication further back on the template (110).  The apparent 
observation of this duplication occurring repeatedly in RSV-A, and the duplication 
being of the same length and location, supports this proposed mechanism as an 
explanation for the duplication events.  From an evolutionary perspective, coalescent 
theory suggest that most currently observed genomes arose for a relative few 
ancestral sequences.  Similarly, most contemporary genomes will not continue on to 
become ancestors of future viruses.  Any given transmission chain is likely to die out; 
thus, repeated introductions of the same mutation makes it more likely that 
advantageous mutationss such as the G gene duplications will begin to circulate 
globally.  The observation that the local Tennessee genotype, TN1, didn’t reach 
global circulation supports this notion, although poor global surveillance of RSV is an 
alternative explanation.  Similarly, at least one RSV-B duplicated genome exists in 
our data set from 1996, earlier than the previous first observation in 1999 of a 60nt 
duplication in the G gene of RSV-B (114).  It should be noted that the 1996 genome 
was located in a separate clade from the BA clade where RSV-B duplicated genomes 
originate, supporting convergence as a mechanism for the increased probability of the 
success of these mutations in reaching global circulation. 
Our results suggest that, although the G gene duplication does appear to 
influence disease severity, it is likely a relatively small effect.  RSV severity, as has 
been reported elsewhere (85, 104-106), is largely influenced by known risk factors, 
such as prematurity, gender, chronic lung and heart diseases, and immune 




genetic factors, nasopharyngeal and upper respiratory microbiomes and viral genetic 
characteristics all play significant roles in the development of severe RSV disease.  
Future studies that incorporate either genome-wide host genetic associations or 
targeted genetic analysis (e.g., of the HLA region) with microbiome and viral genetic 
information will be important in developing models that elucidate the interplay 
between the host, the microbiome and the pathogen in severe RSV disease 
progression.  
In general, glycosylation patterns in the RSV-B data set appear more varied 
than in the RSV-A dataset (data not shown), which is supported by the idea that RSV-
B seems to have more G gene plasticity than RSV-A.  These results reveal a relatively 
static F protein, in terms of glycosylation, compared to a dynamically glycosylated G 
protein that swaps in and out different glycosylation sites relatively quickly.  These 
differences in G glycosylation may help the virus spread and overcome herd 
immunity, in addition to the other differences noted in the G protein.   
The high degree of conservation in the F1 domain likely is required to 
maintain a functional fusion mechanism, as this protein undergoes a complex 
conformational change once attachment triggers fusion (131).  This function would 
likely be greatly hindered by variability within F1, possibly due to steric hindrance 
(131).   The F protein has a conserved glycosylation pattern across RSV-A and RSV-
B viruses and appears to only permit N-linked glycans in the F2 domain.  Again, this 
may be due to the need for F1 to be sterically free to change confirmation to perform 




variability of the G gene suggests that the F gene is a more suitable target for 
universal therapeutics and vaccines (132). 
One major limitation of this study was the lack of extensive historical and 
contemporary sampling to place our whole-genome sequences in context.  For 
instance, without a robust surveillance network for RSV, it is hard to know for sure if 
the TN1 genotype was truly geographically isolated to Tennessee during the 2012-
2013 season.  Another notable limitation is the relatively small sample sizes with 
which to perform the statistical associations of clinical and genetic data.  Both point 
toward the need for expanded surveillance and coordination of clinical data 
collection. 
Conclusions 
Here we have identified several co-circulating RSV variants infecting infants 
within the central Tennessee region during the 2012-2013 infectivity season.  
Differing selective pressures and variation patterns were apparent in our data set 
suggesting epidemiological and evolutionary mechanisms for immune evasion.  For 
the first time, possible phenotypes for the recent G gene duplications seen in RSV-A 
have been described.  We have associated the G gene duplication in RSV-A with a 
trend toward decreased pathogenicity.  Further investigation of these patterns and 
surveillance of RSV is called for.  Additionally, studies that aid the identification of 




Chapter 5:  The Future of Viral Comparative Genomics 
 The work described above is an example of a new approach to data-driven 
bioinformatic research that aims to integrate experimental results, from sequencing to 
phenotype analyses, with metadata describing those data in a new and meaningful 
way.  In study one, we have described a novel method that extends the current 
capabilities of antigenic distancing techniques by directly connecting sequence-based 
hierarchical clusters with phenotypic measurements.  We have incorporated bootstrap 
analysis into these phenotype/genotype correlations to take into account the 
variability in the antigenic measurement, and hence to provide a more robust 
estimation of the reliability of our predictions than has previously been possible.  By 
cross-referencing our results with the established phylogenetically defined clades, this 
technique establishes an even more powerful method for conducting viral sequence 
and antigenic surveillance – in addition its valuable vaccine selection function.  
Consequently, our methods point toward a future of antigenic surveillance where all 
the viral samples collected are first sequenced and then this sequence data is used to 
determine which viruses to perform antigenic characterization on.  One notable 
extension to the analysis described here would be to perform similar predictions on 
especially important avian influenza subtypes with human pandemic potential, such 
as H5N1 and H7N9.  Additionally, the methods described in this study could 
conceivably be applied to other viral species for which antigenic characterization is 
needed.  Similarly, assays that generate data pertaining to other phenotypes could 





 In our second study, we extended the current offerings of methods for 
performing viral genome constellation analysis.  We described VirComp and 
OrionPlot as two separate, but related, pieces of software for performing constellation 
analysis based on gene clusters and providing publication ready figures.  The creation 
of OrionPlot greatly extends the abilities of researchers to publish this type of 
genotype analysis, as no similar tools currently exist for generating constellation 
figures so quickly.  We described one application of VirComp and OrionPlot outside 
gene-based constellation analysis: it was used to uncover methodological errors in the 
amplicon-based sequencing approach that lead to the discovery of a recombinant 
virus false positive.  This establishes these tools as excellent candidates for 
incorporation into sequencing quality control analysis pipelines for viral or other 
amplicon-based sequencing projects.  In addition to this use, VirComp and OrionPlot 
could easily be incorporated into the viral the BRCs, ViPR and IRD, as a novel 
comparative genomics tool.  The methodology could be used to perform analysis on 
non-viral genes as well.  It would be most useful on small groups of related genes, 
possibly in metabolic pathways, or perhaps multi-locus sequence type (MLST) genes.  
OrionPlot could conceivable be used as a stand-alone analysis program to generate 
visualizations of categorical metadata.  Although the current implementation of 
OrionPlot requires a data matrix with numerical categories, an adjustment to the code 
to allow for character data instead of numerical data would allow OrionPlot figures to 
be made for various categorical metadata.  Plots of metadata could then be combined 
with phylogenies to provide powerful visuals showing the associations of the 




 In study three, we directly examined the relationship between genetic variants 
and phylogenies with clinical metadata gathered from infants infected with RSV.  We 
showed that multiple lineages of RSV-A and -B co-circulated in central Tennessee 
during the 2012-2013 RSV season.  These co-circulating lineages are defined by 
distinct O and N-linked glycosylation patterns on the G protein.  Some of the lineages 
appeared to be locally transmitting within our study region, whereas others were 
globally circulating.  One lineage in particular was shown to contain a duplication 
within the G protein.  This duplication appears to have arisen in a convergent fashion 
within its global lineage and with four members of a locally circulating lineage.  
Through statistical associations with the clinical metadata collected for this study, we 
have shown an increased number of infections of infant females with viruses having 
genomes containing the G duplication, as compared to those without the G 
duplication.  Similarly, we have shown a decrease in the severity of the disease, as 
measured via BSS2, in hosts infected with the G gene duplicated genomes.  Although 
the overall effect of this virus-derived genetic signature of severity was small, it 
suggests avenues of research to examine specific mutations that may be associated 
with particular viral phenotypes.  Additionally, expanding the scope of this study to 
integrate heterogeneous data types beyond viral genetic data and clinical metadata 
could provide further insights into the interplay between host, pathogen and 
environment that determine the course and outcome of an infection. 
 Viral whole-genome studies will undoubtedly play a large role in the future of 
viral research, from basic research into viral pathology and epidemiology, to novel 




drugs.  The proliferation of large-scale sequencing efforts in viral cohort studies is of 
the utmost importance in transforming viral research into a science capable of 
benefiting from the enhancements of big data.  To that end the near term requires the 
development of both tools and standards in practice for conducting viral research in 
an age of big data.  Efforts to standardize metadata, such as those by the GSCID-BRC 
Metadata Working Group (31), are key first steps in achieving data integration.  An 
example of the type of data standard that is necessary is controlled vocabularies (or 
ontologies), such as those available from the Open Biomedical Ontologies Foundry 
(OBO) (133).  It should be noted that resources such as the OBO Foundry require 
ongoing curation as new data types come into use and older ones are retired or 
refined.  Similarly, use of these ontologies requires data expertise.  Tools for 
expanding viral genomics into an age of big data could include technologies such as 
representational state transfer (RESTful) web services.  Through RESTful interfaces 
labs across a spectrum of biological or clinical settings could expose and integrate 
their experimental data types (134) in near-real time, and to gain access to 
computational resources (135).  This would have applications for expediting the 
processing of viral outbreak surveillance data, emergency management, and the 
development of vaccines and therapeutics. 
 The integration of viral sequence data with, host sequence data (either whole 
genome or targeted to specific host-pathogen interfaces), and environmental sequence 
data (such as microbiome or metagenomic data) is on the cusp of becoming 
commonplace.  Integrating these disparate data sources in meaningful ways will 




of visualization and algorithmic tools (136, 137).  For instance, sequencing the host 
HLA region of RSV-infected subjects has the potential to establish immune related 
host factors that may determine the severity of infection (132).  Similarly, the 
metagenomic characterization of RSV-infected individuals would provide an 
additional dimension to the understanding the pathogenesis of the virus.  
Understanding the interplay between host, environment (microbiome or metadata), 
and pathogen will require novel applications of statistical models to adequately assess 
these relationships.  We have described a data exploration technique above known as 
MDS, which falls into a class of exploratory techniques known as ordination (138).  
Ordination techniques also include principal component analysis (PCA) (138).  We 
have also described hierarchical clustering techniques for performing sequence 
analysis, such as Wards’s or farthest neighbor clustering (74, 102).  Other methods of 
clustering, such as k-means, will also continue to be a useful data exploration 
technique for heterogeneous data (138).  In the recent NCI-DREAM experiment, 
candidate chemotherapies were assessed using a variety of statistical prediction 
models (139).  These models included: support vector machines, linear and non-linear 
regression models, and ensemble models (the use of multiple models composited 
together for a more informative result) (139).  Many of these techniques fall into the 
category of machine learning algorithms that are used to make predictive 
associations.  Needless to say, there are countless approaches to modeling that could 
be applied to viral comparative genomics using big data.  These types of approaches 
will hopefully produce novel insights into the pathogenic and epidemiologic 




 Public health policy has and will continue to be influenced by heterogeneous 
data.  For instance, as described above, the WHO utilizes both antigenic 
characterizations and sequence data to determine the selection of vaccine candidates 
for the annual influenza vaccine.  Our methods will certainly enhance the integration 
of these data to establish a more informative vaccine selection process.  
Epidemiological modeling has been suggested as a target for further integration of 
data types to aid in developing public policy around specific infectious disease agents 
(140).  An example of this is the integration of social media reports of disease with 
public data relating to the epidemiological progress to create real-time risk maps of 
infections based on geographical location (137).  These integrated data will certainly 
aid in development of the public policies surrounding viral pathogens. 
 The work described in this dissertation and the directions laid out above are 
but a few of the myriad of efforts to integrate data, compare viral pathogens, and 
make inferences about pathogenesis and epidemiology.  These efforts aim to glean 
new insights into the world of infectious disease and to better understand the interplay 
between the host, the pathogen, and the environment.  Through this research, novel 
vaccine targets and therapeutics will undoubtedly be identified.  Big data approaches 
to biological research are certainly the future of the science and the need for data 








Appendix A. Interim PTP and DASH report of Influenza 
activity from December 2013 
 
December 1, 2013 Interim Manufacturing-at-Risk (MAR) 
Candidate Selection Report 
JCVI NFLU Team 
January 22, 2014 
Summary of MAR Candidates 
The following is a summary of MAR candidate viruses based on DASH and PTP 
analysis.  A detailed report of the analyses that produced these results follows Table 
12 and is broken down by Influenza A subtype and Influenza B lineage 
Table 12 Summary of MAR Candidates with Priority and Rationale. 
Strain Name Type Priority Rationale 
A/Almaty/2958/2013 H3N2 High WHO candidate virus 
A/Estonia/76676/2013 H3N2 High High scoring DASH vaccine candidate 
A/Norway/2255/2013 H3N2 High High scoring DASH vaccine candidate 
A/Estonia/76614/2013 H3N2 Medium High scoring DASH vaccine candidate 
A/Cameroon/12V-5136/2012 H3N2 Medium High scoring DASH vaccine candidate 
A/England/358/2013 H1N1pdm High High scoring DASH vaccine candidate 
A/Bolivia/559/2013  H1N1pdm High WHO candidate virus 
A/Estonia/74816/2013 H1N1pdm Medium High scoring DASH vaccine candidate 
A/Dominican Republic/7293/2013  H1N1pdm Medium WHO candidate virus 
B/Massachusetts/2/2012* Influenza B Yam High High scoring DASH vaccine candidate 




B/Belgium/G886/2012 Influenza B Vic High High scoring DASH vaccine candidate 
B/Texas/2/2013 Influenza B Vic High High scoring DASH vaccine candidate 
B/Formosa Province/V2367/2012 Influenza B Vic High High scoring DASH vaccine candidate 
A/Colorado/21/2012 H3N2 Low DASH gap filling MAR candidate 
A/Wisconsin/6/2013 H3N2 Low DASH gap filling MAR candidate 
A/New York/3214/2013 H3N2 Low DASH gap filling MAR candidate 
A/Helsinki/823/2013 H3N2 Low DASH gap filling MAR candidate 
A/Puerto Rico/1/2013 H1N1pdm Low DASH gap filling MAR candidate 
A/Florida/43/2013 H1N1pdm Low DASH gap filling MAR candidate 
A/New Hampshire/4/2013 H1N1pdm Low DASH gap filling MAR candidate 
A/Minnesota/26/2012 H1N1pdm Low DASH gap filling MAR candidate 
A/Nizhny Novgorod/RII02/2013 H1N1pdm Low DASH gap filling MAR candidate 
B/Iowa/4/2013 Influenza B Vic Low DASH gap filling MAR candidate 
B/Sao Paulo/2-22035/2013 Influenza B Vic Low DASH gap filling MAR candidate 
B/Indonesia/Nihrd-Buas704/2013 Influenza B Vic Low DASH gap filling MAR candidate 
*Current Vaccine Seed 
Proportion Tracking Pipeline (PTP) Analysis 
The proportion tracking graphs depict bars that represent partitions windowed across 
three seasons.  Each partition is weighted for the three seasons, e.g., the windowed 
partition “2012_11” represents data from three seasons viz. from November 2012 
through April 2013, from May 2012 through October 2012, and from November 2011 
through April 2012, with weighting factors of 0.50, 0.33, and 0.16, respectively.  
Thus, we achieve a sliding window (spanning 3 seasons) that slides across the seasons 
at the rate of one season per partition.  Each partition is split into its component 
clusters based on sequence similarity and the arrows across partitions indicate 
similarity between the clusters they connect.  A strong (bolder) arrow suggests a 




The clusters with colored circles contain and track the vaccine seed recommendations 
across partitions.  A green circle indicates that the vaccine seed recommendation 
remained unchanged from the previous partition; a red circle represents a change in 
vaccine seed recommendation during the most recent time slice represented within 
that partition.   
Distancing of Antigenicity by Sequence-based Hierarchical 
Clustering (DASH) Analysis 
DASH analysis was performed using sequence data from strains collected during the 
period between December 2, 2012 and December 1, 2013.  The HI data used was 
collected between December 2, 2012 and December 1, 2013.  This selection of HI 
data includes February 2013 tables from NIMR, as well as February 2013 tables from 
CDC presented at the VRBPAC meeting on February 27, 2013.  September 2013 
NIMR HI tables have also been processed and included in the analysis for this 
reporting period. 
H3N2 Analyses 
H3N2 Proportion Tracking 
Windowed proportion tracking analysis was performed on H3N2 sequences isolated 
between January 1, 2001 and December 1, 2013 using the HA1 domain.  The current 
vaccine recommendation, A/Texas/50/2012), falls in the smaller diminishing portion 
(cluster 3) for the current partition (2013_11).  The cluster that the current vaccine 
was in the last report, accounting for 93% of the sequences, has split into three 




which has the current vaccine recommendation.  Cluster 4, which accounts for only 
2% of the sequences, is composed of H3N2v viruses (Swine Origin Influenza Viruses 
– SOIV). 
 
Figure 42 Proportional Sizes of H3N2 Clusters as Fraction of Total Sequences. 
 
 
Figure 43 Sequence Counts Used for H3N2 Windowed Proportion Tracking. 
 
H3N2 Proportion Tracking without Swine Origin Viruses 
Windowed proportion tracking analysis was performed on all non-swine origin H3N2 
sequences isolated between Jan 1, 2001 and December 1, 2013 using the HA1 




A/Texas/50/2012, falls in the smallest cluster (3) for the current partition (2013_11) 
accounting for only 10.6% of the circulating sequences of the total H3N2 sequences. 
 





Figure 45 Sequence Counts Used for H3N2 Windowed Proportion Tracking (Without Swine Origin 
Viruses). 
 




Analysis of DASH results for both clusters without HI cohorts and candidate 
antigenic coverage prediction produced the following list of antigens that should be 
constructed as vaccine candidates or viruses to fill holes in HI antigen data. 
PTP cluster 1 candidates (Clade 3C-3): 
A/Almaty/2958/2013 (WHO candidate virus) 
A/Estonia/76676/2013 
A/Norway/2255/2013 
PTP cluster 2 candidates (Clade 3C-2): 
A/Estonia/76614/2013 
A/Cameroon/12V-5136/2012 






At an antigenic distance of 2, A/Victoria/361/2012 cell-propagated virus has a 
predicted coverage of circulating viruses of 46.0%.  In our analysis, the 
A/Texas/50/2012 cell-propagated virus is predicted to cover 10.8% of circulating 
viruses.  The Victoria/361 and Texas/50 egg-propagated viruses are predicted to 
cover 45.8% and 16.7% of circulating viruses respectively.  This is a rather poor 
result for both Texas/50 viruses and suggests the WHO recommendation of the 




effectiveness.  It should be noted that the predicted antigenic coverage for all four 
viruses remains rather poor.  Furthermore, the best vaccine candidates available, 
listed above, are only predicted to cover currently circulating viruses at around 70-
85%.  The apparent reason for the poor showing by the current vaccine candidates is 
that they poorly cover viruses from two of the subclades with the highest expansion 
rate; 3C-2 and 3C-3, while maintaining adequate coverage of their own clade 3C-1 as 
well as clade 5, 6, and 3A viruses.  Conversely, A/Estonia/76676/2013 and 
A/Norway/2255/2013, both clade 3C -3 viruses, cover 3C-2 and 3C-3 quite well 
while maintaining adequate predicted coverage of clades 5, 6 and 3A.  Furthermore 
A/Estonia/76614/2013 shows good predicted coverage of 3C-2, and 3C-3, as well as 
clades 3A, 5 and 6, while not covering clade 3C-1 as well.  This lends credence to the 
prospect of a switch from the current clade 3C-1 vaccine candidates to a candidate 
from clade 3C-3 or 3C-2.  Of the recently WHO approved manufacturing seeds, the 
3C-3 viruses perform slightly better with A/Almaty/2958/2013 performing the best.  
We believe a 3C-3 vaccine candidate is possible as the next vaccine selection. 
Table 13 Predicted Antigenic Coverage of Influenza A H3N2 Candidate Viruses in DASH 
Antigen InMedian InLB InUB ObsIn ObsOut ObsUnk DistIn DistOut Seqs 
A/Cameroon/12V-
5136/2012 85.6% 16.4% 100.0% 89.2% 0.4% 10.4% 45 2 1715 
A/Estonia/76676/2013 77.2% 35.4% 100.0% 79.9% 0.4% 19.6% 42 2 1715 
A/Estonia/76614/2013 75.6% 38.4% 89.2% 79.9% 0.4% 19.6% 42 2 1715 
A/Norway/2255/2013 75.6% 35.1% 89.2% 77.1% 3.3% 19.6% 41 3 1715 
A/Hong Kong/1036/2013 74.7% 37.1% 100.0% 76.6% 3.8% 19.6% 39 5 1715 
A/Minsk/1262/2013 70.9% 31.5% 100.0% 77.1% 3.3% 19.6% 41 3 1715 
A/Belgium/G1034/2013 70.6% 21.5% 85.9% 76.6% 3.8% 19.6% 39 5 1715 
A/Cameroon/12V-
5507/2012 70.1% 7.6% 100.0% 89.2% 0.4% 10.4% 45 2 1715 
A/Latvia/1-32593/2013 70.1% 11.1% 85.7% 75.9% 3.0% 21.1% 42 6 1715 
A/Slovenia/709/2013 70.0% 30.3% 94.1% 77.1% 0.6% 22.3% 45 3 1715 
A/Almaty/2958/2013 60.0% 24.0% 75.9% 68.3% 3.8% 27.9% 43 5 1715 
A/Victoria/361/2011 Cell 46.0% 38.7% 54.6% 66.7% 6.6% 26.7% 727 74 1715 
A/Victoria/361/2011* 




A/Texas/50/2012* Egg 16.7% 12.1% 22.1% 18.2% 51.2% 30.6% 398 403 1715 
A/Texas/50/2012 Cell 10.8% 3.4% 94.1% 14.6% 3.5% 81.8% 38 6 1715 
A/Perth/16/2009‡ 5.8% 3.6% 8.7% 3.9% 69.3% 26.8% 134 650 1715 
*Vaccine candidate 
‡Previous vaccine candidate 
Table 14 Analysis of Recent WHO Candidate Viruses. 
Antigen InMedian InLB InUB ObsIn ObsOut ObsUnk DistIn DistOut Seqs 
A/Almaty/2958/2013 60.0% 24.0% 75.9% 68.3% 3.8% 27.9% 43 5 1715 
A/New York/39/2012 
Egg 42.7% 9.9% 85.3% 52.7% 0.5% 46.7% 25 3 1715 
A/Serbia/NS-210/2013 42.0% 3.3% 79.4% 79.6% 3.9% 16.5% 31 6 1715 
A/New York39/2012 Cell 38.0% 8.6% 85.3% 40.0% 3.4% 56.6% 24 4 1715 
A/American 
Samoa/4768/2013 Egg 33.7% 18.2% 77.4% 43.4% 27.9% 28.6% 23 5 1715 
A/American 
Samoa/4768/2013 Cell 25.2% 1.0% 48.9% 25.9% 4.5% 69.5% 18 10 1715 
 
Results of simulations of antigenic coverage of circulating viruses are reported for 
each subtype and lineage in Tables 13 and 14.  The table columns list antigen name 
followed by several performance statistics.  InMedian means from 80 bootstrap 
replicates an average of X% of circulating viruses were predicted to be covered by the 
tested antigen.  InLB and InUB are the lower and upper bounds of the bootstrap 
results for predicted coverage at a 95% confidence cutoff.  ObsIn, ObsOut, and 
ObsUkn are the actual observed coverage predictions for circulating viruses when all 
the HI derived antigenic distance cohort measurements are used.  DistIn and DistOut 
are the number of HI derived antigenic distance cohort measurements that were 
observed to fall in and out with respect to the test antigen at an antigenic distance of 
2.  Seqs is the weight-adjusted number of sequences determined to be circulating 
during the test period.  These results were ordered by InMedian, followed by ObsIn, 





H1N1 proportion tracking 
Windowed proportion tracking analysis was performed on H1N1 sequences isolated 
between Jan 1, 2009 and December 1, 2013 using the HA1 domain.  The analysis was 
conducted on the HA1 domain using a windowed partitioning scheme as described 
above.  The current vaccine strain, A/California/7/2009, falls in the largest cluster of 
the final partition (2013_11), accounting for 59% of the total H1N1pdm sequences.   
 
Figure 46 Proportional Sizes of H1N1 Clusters as Fraction of Total Sequences. 
 
 
Figure 47 Sequence Counts Used for H1N1 Windowed Proportion Tracking. 
 




Analysis of DASH results for clusters without HI cohorts and candidate antigenic 
coverage prediction produced the following list of antigens that should be constructed 
as vaccine candidates or viruses to fill holes in HI antigen data. 
PTP Cluster 2 candidates (Clade 6B): 
A/England/358/2013 
A/Bolivia/559/2013 (WHO candidate virus) 
PTP Cluster 1 candidates (Clade 6C): 
A/Estonia/74816/2013 
A/Dominican Republic/7293/2013 (WHO candidate virus) 







It should be noted that in our analysis A/California/7/2009 is frequently surpassed in 
predicted coverage by a number of other viruses (only the top 4 candidates are shown 
in table 15).  At an antigenic distance of 2, a vaccine containing the current 
recommendation as its H1N1 component is predicted to cover only 71.5% of 
circulating viruses.  In contrast, an A/Estonia/74816/2013 containing vaccine is 
predicted to cover 100% of circulating viruses.  A/England/358/2013 is predicted to 




alone indicates that A/California/7/2009 is still within an antigenic distance of 2 of 
96% of the viruses that it was tested against.  While the performance of 
A/California/7/2009 has dipped in the DASH analysis, there is currently no evidence 
of a new antigenic group emerging to take its place.  A closer look at the 
manufacturing seed A/Christchurch/16/2010, however shows poor performance 
against the currently circulating viruses.  It is our opinion that 
A/Christchurch/16/2010 should be replaced, if it is currently being used in the 
formulation of vaccines, and replaced with a clade 6B virus such as 
A/Bolivia/559/2013 or A/England/358/2013. 
Table 15 Predicted Antigenic Coverage of Influenza A Pandemic H1N1 Candidate Viruses in DASH 
Antigen InMedian InLB InUB ObsIn ObsOut ObsUnk DistIn DistOut Seqs 
A/Estonia/74816/2013 100.0% 60.6% 100.0% 100.0% 0.0% 0.0% 56 0 1341 
A/Luxembourg/80/2013 100.0% 59.4% 100.0% 100.0% 0.0% 0.0% 56 0 1341 
A/England/358/2013 100.0% 31.8% 100.0% 100.0% 0.0% 0.0% 54 1 1341 
A/Luxembourg/13/2013 100.0% 60.5% 100.0% 75.5% 0.1% 24.4% 55 1 1341 
A/California/7/2009* 71.5% 54.7% 79.5% 85.2% 2.5% 12.3% 810 36 1341 
A/Christchurch/16/2010 9.9% 6.7% 16.6% 7.7% 57.1% 35.2% 193 585 1341 
*Vaccine Candidate 
Table 16 Analysis of Recent WHO Candidate Viruses. 
Antigen InMedian InLB InUB ObsIn ObsOut ObsUnk DistIn DistOut Seqs 




70.0% 10.2% 100.0% 83.7% 0.1% 16.2% 16 1 1341 
A/Bolivia/559/2013 
Cell 




68.0% 2.4% 100.0% 83.7% 0.1% 16.2% 16 1 1341 
 
Influenza B/Yamagata Analyses 




Proportion tracking analysis was conducted on all Influenza B/Yamagata lineage 
sequences isolated from January 1, 2001 until December 1, 2013.  The analysis was 
conducted on the HA1 domain using a windowed partitioning scheme as described 
above.  The current recommended vaccine seed, B/Massachusetts/2/2012 is seen in 
the largest cluster 1 of the current partition (2013_05) accounting for 86% of the total 
Influenza B Yamagata virus. 
 
Figure 48 Proportional Sizes of Influenza B/Yamagata Clusters as Fraction of Total Sequences.  Partition 
2013_05 cluster 1 represents Yamagata Group 2 viruses. 
 
 
Figure 49 Sequence Counts Used for Influenza B/Yamagata Windowed Proportion Tracking. 
 




Analysis of DASH results for candidate antigenic coverage prediction produced the 
following list of antigens that should be constructed as vaccine candidates or viruses 
to fill holes in HI antigen data. 
PTP cluster 1 (Group 2) candidates: 
B/Massachusetts/2/2012* 
PTP cluster 2 (Group 3) candidates: 
B/Lithuania/6942/2013 
DASH gap filling viruses: 
None 
 
It should be noted that group 2 of the Yamagata lineage shows the majority of new 
infections, and the current vaccine seed, B/Massachusetts/ 2/2012, performs quite 
well.  This suggests that a new vaccine seed is probably not needed at this time, 
however the best high performing vaccine seed candidate from group 3 has been 
suggested above.   
Table 17 Predicted Antigenic Coverage of Influenza B Yamagata Candidate Viruses in DASH 
Antigen InMedian InLB InUB ObsIn ObsOut ObsUnk DistIn DistOut Seqs 
B/Massachusetts/2/2012
* 100.0% 8.0% 100.0% 100.0% 0.0% 0.0% 42 11 834 
B/Novosibirsk/13/2013 92.9% 49.7% 100.0% 100.0% 0.0% 0.0% 59 2 834 
B/Poland/8/2013 92.7% 58.3% 100.0% 100.0% 0.0% 0.0% 66 3 834 
B/Omsk/35/2013 89.5% 42.0% 100.0% 100.0% 0.0% 0.0% 59 2 834 
B/Ostrava/59/2013 87.7% 46.6% 100.0% 100.0% 0.0% 0.0% 58 3 834 
B/Lithuania/6942/2013 86.9% 20.0% 100.0% 100.0% 0.0% 0.0% 60 1 834 
B/Wisconsin/1/2010‡ 35.2% 28.0% 40.5% 42.3% 40.4% 17.3% 824 597 834 
*Vaccine candidate 
‡Previous vaccine candidate 




Influenza B/Victoria Proportion Tracking 
Proportion tracking analysis was conducted on all Influenza B/Victoria lineage 
sequences isolated from January 1, 2001 until December 1, 2013.  The analysis was 
conducted on the HA1 domain using a windowed partitioning scheme as described 
above.  The current recommended strain for the quadrivalent vaccine includes an 
additional Victoria lineage B/Brisbane/60/2008-like virus along with the 
recommended Yamagata lineage B/Massachusetts/2/2012-like virus. 
B/Brisbane/60/2008 is seen in the largest cluster 1 in the current partition (2013_05) 
accounting for 67% of the total Influenza B Yamagata virus circulating. 
 






Figure 51 Sequence Counts Used for Influenza B/Victoria Windowed Proportion Tracking. 
 
DASH – MAR candidate selection 
Analysis of DASH results for candidate antigenic coverage prediction produced the 
following list of antigens that should be constructed as vaccine candidates or viruses 
to fill holes in HI antigen data. 
PTP cluster 1 candidates: 
B/Belgium/G886/2012 
PTP cluster 2 candidates: 
B/Texas/2/2013 
PTP cluster 3 candidates: 
B/ Formosa Province/V2367/2012 








It should be noted that the current quadrivalent vaccine candidate for the Victoria 
lineage, B/Brisbane/60/2008, shows rather poor predicted coverage of currently 
circulating viruses.  Better performing vaccine candidates, as listed above, exist for 
this lineage.  Of these, a priority should be given to candidates from the larger PTP 
cluster 1, as the vast majority of new infections are members of this cluster.  In PTP 
cluster 2, the recently announced WHO candidate B/Texas/2/2013 performs better 
than Brisbane/60 and appears to be egg stable.  The overall prediction for Texas/2 
was not great compared to other potential candidates.  B/Texas/2/2013 was tested 
against a limited number of viruses, thus the supporting data for this analysis is not 
abundant.  
Table 18 Predicted Antigenic Coverage of Influenza B Victoria Candidate Viruses in DASH 
*Vaccine candidate 
Combined Influenza B Analyses 
Influenza B Combined Proportion Tracking 
Proportion tracking for combined Influenza B lineages was performed for sequences 
isolated from January 1, 2001 until December 1, 2013.  The analysis was conducted 
on the HA1 domain using a windowed partitioning scheme.  The combined 
proportion tracking for both Influenza B lineages shows that the Yamagata lineage 




61.3% 36.8% 76.7% 70.9% 7.7% 21.5% 220 41 377 
B/Belgium/G886/20
12 
45.2% 12.7% 100.0% 47.3% 1.1% 51.6% 30 5 377 
B/Finland/310/2013 36.7% 12.4% 100.0% 47.3% 1.1% 51.6% 30 5 377 
A/Texas/2/2013 Egg 32.3% 3.7% 72.8% 34.1% 1.3% 64.6% 33 2 377 
B/Texas/2/2013 Cell 31.9% 19.5% 84.1% 32.5% 34.5% 33.0% 30 5 377 
B/Dakar/18/2013 31.6% 2.7% 75.9% 32.5% 34.5% 33.0% 30 5 377 
B/Dakar/10/2013 31.2% 2.1% 84.1% 32.2% 34.7% 33.0% 29 6 377 
B/Brisbane/60/2008
* 




has continued to be the dominant lineage (cluster 1) in this current season accounting 
for 64% of the total Influenza B virus in circulation.  
 
Figure 52 Proportional Sizes of Combined Influenza B Clusters as Fraction of Total Sequences.  Partition 
2013_05 cluster 1 are Yamagata lineage viruses, Partition 2013_05 cluster 2 are Victoria lineage viruses. 
 
	  
Figure 53 Sequence Counts Used for Influenza B Combined Windowed Proportion Tracking. 
 
This provides evidence for continuing with a Yamagata lineage recommendation in 
the trivalent vaccine composition.  However, since the Victoria lineage still accounts 
for 36% of the total virus in circulation, the recommendation to include a virus from 




from the Yamagata lineage in the quadrivalent vaccine should cover both of the 




Appendix B. Glycosylation and dN/dS data supporting the 
RSV Study 
Table 19 N-linked and O-linked Glycosylation Sites on the F Protein for 71 RSV Study Samples.  Colored 
backgrounds reflect clade and/or genotype membership (green = GA5, purple = ON1, light blue = TN1, blue = 
TN2, red = BA.1, orange = BA.2). 
lineage accession strain 244 27 70 116 120 126 clade subclade g_duplication constellation_95
RSVA KJ672479.1 RSVA/Homo_sapiens/USA/LA2_18/2013 NITE NGTD NYTL NNTK NVTL 2 2 0 15
RSVA KJ672483.1 RSVA/Homo_sapiens/USA/LA2_19/2013 NITE NGTD NYTL NNTK NVTL 2 2 0 15
RSVA KJ672474.1 RSVA/Homo_sapiens/USA/LA2_38/2012 NITE NGTD NYTL NNTK NVTL 2 2 0 15
RSVA KJ672447.1 RSVA/Homo_sapiens/USA/LA2_67/2013 NITE NGTD NYTL NNTK NVTL 2 2 0 15
RSVA KJ672462.1 RSVA/Homo_sapiens/USA/LA2_84/2013 NITE NGTD NYTL NNTK NVTL 2 2 0 15
RSVA KJ672464.1 RSVA/Homo_sapiens/USA/LA2_04/2012 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672468.1 RSVA/Homo_sapiens/USA/LA2_07/2012 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672466.1 RSVA/Homo_sapiens/USA/LA2_08/2012 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA 45567-MAIN RSVA/Homo_sapiens/USA/LA2_10/2012 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672457.1 RSVA/Homo_sapiens/USA/LA2_100/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672451.1 RSVA/Homo_sapiens/USA/LA2_103/2012 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672461.1 RSVA/Homo_sapiens/USA/LA2_105/2012 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672424.1 RSVA/Homo_sapiens/USA/LA2_106/2012 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672444.1 RSVA/Homo_sapiens/USA/LA2_11/2012 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672465.1 RSVA/Homo_sapiens/USA/LA2_13/2012 + NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672472.1 RSVA/Homo_sapiens/USA/LA2_15/2012 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672475.1 RSVA/Homo_sapiens/USA/LA2_17/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672440.1 RSVA/Homo_sapiens/USA/LA2_22/2012 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672449.1 RSVA/Homo_sapiens/USA/LA2_28/2012 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672470.1 RSVA/Homo_sapiens/USA/LA2_34/2012 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672469.1 RSVA/Homo_sapiens/USA/LA2_44/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA 45606-MAIN RSVA/Homo_sapiens/USA/LA2_49/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672428.1 RSVA/Homo_sapiens/USA/LA2_55/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA 45613-MAIN RSVA/Homo_sapiens/USA/LA2_56/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672480.1 RSVA/Homo_sapiens/USA/LA2_62/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672429.1 RSVA/Homo_sapiens/USA/LA2_69/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672432.1 RSVA/Homo_sapiens/USA/LA2_72/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672454.1 RSVA/Homo_sapiens/USA/LA2_73/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672448.1 RSVA/Homo_sapiens/USA/LA2_74/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672458.1 RSVA/Homo_sapiens/USA/LA2_77/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA 45640-MAIN RSVA/Homo_sapiens/USA/LA2_83/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672471.1 RSVA/Homo_sapiens/USA/LA2_85/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672441.1 RSVA/Homo_sapiens/USA/LA2_87/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA 45646-MAIN RSVA/Homo_sapiens/USA/LA2_90/2012 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672452.1 RSVA/Homo_sapiens/USA/LA2_91/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA 45650-MAIN RSVA/Homo_sapiens/USA/LA2_94/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672433.1 RSVA/Homo_sapiens/USA/LA2_95/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672467.1 RSVA/Homo_sapiens/USA/LA2_97/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA 45654-MAIN RSVA/Homo_sapiens/USA/LA2_98/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672437.1 RSVA/Homo_sapiens/USA/LA2_99/2013 NITE NGTD NYTL NNTK NVTL 1 1a 1 1
RSVA KJ672484.1 RSVA/Homo_sapiens/USA/LA2_01/2012 NITE NGTD NYTL NNTK NVTL 1 1b 0 3
RSVA KJ672439.1 RSVA/Homo_sapiens/USA/LA2_02/2012 NITE NGTD NYTL NNTK NVTL 1 1b 0 3
RSVA KJ672455.1 RSVA/Homo_sapiens/USA/LA2_05/2012 NITE NGTD NYTL NNTK NVTL 1 1b 0 3
RSVA KJ672427.1 RSVA/Homo_sapiens/USA/LA2_09/2012 + NITE NGTD NYTL NNTK 1 1b 0 3
RSVA KJ672431.1 RSVA/Homo_sapiens/USA/LA2_14/2012 NITE NGTD NYTL NNTK NVTL 1 1b 0 3
RSVA KJ672443.1 RSVA/Homo_sapiens/USA/LA2_21/2013 NITE NGTD NYTL NNTK NVTL 1 1b 0 3





lineage accession strain 244 27 70 116 120 126 clade subclade g_duplication constellation_95
RSVA KJ672478.1 RSVA/Homo_sapiens/USA/LA2_29/2013 + NITE NGTD NYTL NVTL 1 1b 0 3
RSVA KJ672463.1 RSVA/Homo_sapiens/USA/LA2_31/2013 NITE NGTD NYTL NNTK NVTL 1 1b 0 3
RSVA KJ672477.1 RSVA/Homo_sapiens/USA/LA2_33/2012 NITE NGTD NYTL NNTK NVTL 1 1b 0 3
RSVA KJ672426.1 RSVA/Homo_sapiens/USA/LA2_36/2013 NITE NGTD NYTL NNTK NVTL 1 1b 0 3
RSVA KJ672435.1 RSVA/Homo_sapiens/USA/LA2_37/2012 NITE NGTD NYTL NNTK NVTL 1 1b 0 3
RSVA KJ672460.1 RSVA/Homo_sapiens/USA/LA2_40/2013 NITE NGTD NYTL NNTK NVTL 1 1b 0 3
RSVA KJ672482.1 RSVA/Homo_sapiens/USA/LA2_41/2012 NITE NGTD NYTL NNTK NVTL 1 1b 0 3
RSVA KJ672450.1 RSVA/Homo_sapiens/USA/LA2_46/2013 NITE NGTD NYTL NNTK NVTL 1 1b 0 3
RSVA KJ672453.1 RSVA/Homo_sapiens/USA/LA2_48/2013 NITE NGTD NYTL NNTK NVTL 1 1b 0 3
RSVA KJ672434.1 RSVA/Homo_sapiens/USA/LA2_53/2013 NITE NGTD NYTL NNTK NVTL 1 1b 0 3
RSVA 45648-MAIN RSVA/Homo_sapiens/USA/LA2_92/2013 NITE NGTD NYTL NNTK NVTL 1 1b 0 3
RSVA KJ672446.1 RSVA/Homo_sapiens/USA/LA2_27/2012 NITE NGTD NYTL NNTK NVTL 1 1b 1 1
RSVA 45596-MAIN RSVA/Homo_sapiens/USA/LA2_39/2013 NITE NGTD NYTL NNTK NVTL 1 1b 1 1
RSVA KJ672442.1 RSVA/Homo_sapiens/USA/LA2_45/2013 NITE NGTD NYTL NNTK NVTL 1 1b 1 1
RSVA 45635-MAIN RSVA/Homo_sapiens/USA/LA2_78/2013 NITE NGTD NYTL NNTK NVTL 1 1b 1 1
RSVA KJ672436.1 RSVA/Homo_sapiens/USA/LA2_30/2012 NITE NGTD NYTL NNTK NVTL 1 1c 0 3
RSVA KJ672459.1 RSVA/Homo_sapiens/USA/LA2_60/2013 NITE NGTD NYTL NNTK NVTL 1 1c 0 3
RSVB KJ672476.1 RSVB/Homo_sapiens/USA/LA2_42/2013 NITE NGTD NYTI NTTK NVSI 3 3a 1 22
RSVB 45573-MAIN RSVB/Homo_sapiens/USA/LA2_16/2012 NITE NGTD NYTI NTTK NVSI 3 3b 1 19
RSVB KJ672473.1 RSVB/Homo_sapiens/USA/LA2_24/2012 NITE NGTD NYTI NTTK NVSI 3 3b 1 19
RSVB KJ672425.1 RSVB/Homo_sapiens/USA/LA2_25/2013 NITE NGTD NYTI NVSI 3 3b 1 19
RSVB KJ672438.1 RSVB/Homo_sapiens/USA/LA2_50/2013 NITE NGTD NYTI NTTK NVSI 3 3b 1 19
RSVB KJ672430.1 RSVB/Homo_sapiens/USA/LA2_51/2013 NITE NGTD NYTI NTTK NVSI 3 3b 1 19





Table 20 N-linked and O-linked Glycosylation Sites on the G Protein for 71 RSV Study Samples.  Colored 
backgrounds reflect clade and/or genotype membership (green = GA5, purple = ON1, light blue = TN1, blue = 
TN2, red = BA.1, orange = BA.2). 












RSVA KJ672479.1 RSVA/Homo_sapiens/USA/LA2_18/2013 + + + + + + + + + + + + +
RSVA KJ672483.1 RSVA/Homo_sapiens/USA/LA2_19/2013 + + + + + + + + + + + +
RSVA KJ672474.1 RSVA/Homo_sapiens/USA/LA2_38/2012 + + + + + + + + + + + + +
RSVA KJ672447.1 RSVA/Homo_sapiens/USA/LA2_67/2013 + + + + + + + + + + + + +
RSVA KJ672462.1 RSVA/Homo_sapiens/USA/LA2_84/2013 + + + + + + + + + + + + +
RSVA KJ672464.1 RSVA/Homo_sapiens/USA/LA2_04/2012 + + + + + + + + + + + +
RSVA KJ672468.1 RSVA/Homo_sapiens/USA/LA2_07/2012 + + + + + + + + + + + + +
RSVA KJ672466.1 RSVA/Homo_sapiens/USA/LA2_08/2012 + + + + + + + + + + + +
RSVA 45567-MAIN RSVA/Homo_sapiens/USA/LA2_10/2012 + + + + + + + + + + + + +
RSVA KJ672457.1 RSVA/Homo_sapiens/USA/LA2_100/2013 + + + + + + + + + + + +
RSVA KJ672451.1 RSVA/Homo_sapiens/USA/LA2_103/2012 + + + + + + + + + + + +
RSVA KJ672461.1 RSVA/Homo_sapiens/USA/LA2_105/2012 + + + + + + + + + + + +
RSVA KJ672424.1 RSVA/Homo_sapiens/USA/LA2_106/2012 + + + + + + + + + + + +
RSVA KJ672444.1 RSVA/Homo_sapiens/USA/LA2_11/2012 + + + + + + + + + + + + +
RSVA KJ672465.1 RSVA/Homo_sapiens/USA/LA2_13/2012 + + + + + + + + + + + +
RSVA KJ672472.1 RSVA/Homo_sapiens/USA/LA2_15/2012 + + + + + + + + + + + + +
RSVA KJ672475.1 RSVA/Homo_sapiens/USA/LA2_17/2013 + + + + + + + + + + + + +
RSVA KJ672440.1 RSVA/Homo_sapiens/USA/LA2_22/2012 + + + + + + + + + + + + +
RSVA KJ672449.1 RSVA/Homo_sapiens/USA/LA2_28/2012 + + + + + + + + + + + + +
RSVA KJ672470.1 RSVA/Homo_sapiens/USA/LA2_34/2012 + + + + + + + + + + + +
RSVA KJ672469.1 RSVA/Homo_sapiens/USA/LA2_44/2013 + + + + + + + + + + + + +
RSVA 45606-MAIN RSVA/Homo_sapiens/USA/LA2_49/2013 + + + + + + + + + + + + +
RSVA KJ672428.1 RSVA/Homo_sapiens/USA/LA2_55/2013 + + + + + + + + + + + +
RSVA 45613-MAIN RSVA/Homo_sapiens/USA/LA2_56/2013 + + + + + + + + + + + + +
RSVA KJ672480.1 RSVA/Homo_sapiens/USA/LA2_62/2013 + + + + + + + + + + + + +
RSVA KJ672429.1 RSVA/Homo_sapiens/USA/LA2_69/2013 + + + + + + + + + + + + +
RSVA KJ672432.1 RSVA/Homo_sapiens/USA/LA2_72/2013 + + + + + + + + + + + + +
RSVA KJ672454.1 RSVA/Homo_sapiens/USA/LA2_73/2013 + + + + + + + + + + + + +
RSVA KJ672448.1 RSVA/Homo_sapiens/USA/LA2_74/2013 + + + + + + + + + + + + +
RSVA KJ672458.1 RSVA/Homo_sapiens/USA/LA2_77/2013 + + + + + + + + + + + + +
RSVA 45640-MAIN RSVA/Homo_sapiens/USA/LA2_83/2013 + + + + + + + + + + + +
RSVA KJ672471.1 RSVA/Homo_sapiens/USA/LA2_85/2013 + + + + + + + + + + + + +
RSVA KJ672441.1 RSVA/Homo_sapiens/USA/LA2_87/2013 + + + + + + + + + + + + +
RSVA 45646-MAIN RSVA/Homo_sapiens/USA/LA2_90/2012 + + + + + + + + + + + +
RSVA KJ672452.1 RSVA/Homo_sapiens/USA/LA2_91/2013 + + + + + + + + + + + +
RSVA 45650-MAIN RSVA/Homo_sapiens/USA/LA2_94/2013 + + + + + + + + + + + + +
RSVA KJ672433.1 RSVA/Homo_sapiens/USA/LA2_95/2013 + + + + + + + + + + + + + +
RSVA KJ672467.1 RSVA/Homo_sapiens/USA/LA2_97/2013 + + + + + + + + + + + + +
RSVA 45654-MAIN RSVA/Homo_sapiens/USA/LA2_98/2013 + + + + + + + + + + + + +
RSVA KJ672437.1 RSVA/Homo_sapiens/USA/LA2_99/2013 + + + + + + + + + + + +
RSVA KJ672484.1 RSVA/Homo_sapiens/USA/LA2_01/2012 + + + + + + + + + + + +
RSVA KJ672439.1 RSVA/Homo_sapiens/USA/LA2_02/2012 + + + + + + + + + + + +
RSVA KJ672455.1 RSVA/Homo_sapiens/USA/LA2_05/2012 + + + + + + + + + + + +
RSVA KJ672427.1 RSVA/Homo_sapiens/USA/LA2_09/2012 + + + + + + + + + + + +
RSVA KJ672431.1 RSVA/Homo_sapiens/USA/LA2_14/2012 + + + + + + + + + + + +
RSVA KJ672443.1 RSVA/Homo_sapiens/USA/LA2_21/2013 + + + + + + + + + + + +


















RSVA KJ672478.1 RSVA/Homo_sapiens/USA/LA2_29/2013 + + + + + + + + + + + +
RSVA KJ672463.1 RSVA/Homo_sapiens/USA/LA2_31/2013 + + + + + + + + + + +
RSVA KJ672477.1 RSVA/Homo_sapiens/USA/LA2_33/2012 + + + + + + + + + + + +
RSVA KJ672426.1 RSVA/Homo_sapiens/USA/LA2_36/2013 + + + + + + + + + + + +
RSVA KJ672435.1 RSVA/Homo_sapiens/USA/LA2_37/2012 + + + + + + + + + + + +
RSVA KJ672460.1 RSVA/Homo_sapiens/USA/LA2_40/2013 + + + + + + + + + + + +
RSVA KJ672482.1 RSVA/Homo_sapiens/USA/LA2_41/2012 + + + + + + + + + + + +
RSVA KJ672450.1 RSVA/Homo_sapiens/USA/LA2_46/2013 + + + + + + + + + + + +
RSVA KJ672453.1 RSVA/Homo_sapiens/USA/LA2_48/2013 + + + + + + + + + + + +
RSVA KJ672434.1 RSVA/Homo_sapiens/USA/LA2_53/2013 + + + + + + + + + + + +
RSVA 45648-MAIN RSVA/Homo_sapiens/USA/LA2_92/2013 + + + + + + + + + + + +
RSVA KJ672446.1 RSVA/Homo_sapiens/USA/LA2_27/2012 + + + + + + + + + + + +
RSVA 45596-MAIN RSVA/Homo_sapiens/USA/LA2_39/2013 + + + + + + + + + + + +
RSVA KJ672442.1 RSVA/Homo_sapiens/USA/LA2_45/2013 + + + + + + + + + + + +
RSVA 45635-MAIN RSVA/Homo_sapiens/USA/LA2_78/2013 + + + + + + + + + + + +
RSVA KJ672436.1 RSVA/Homo_sapiens/USA/LA2_30/2012 + + + + + + + + + + + +
RSVA KJ672459.1 RSVA/Homo_sapiens/USA/LA2_60/2013 + + + + + + + + + + + +
RSVB KJ672476.1 RSVB/Homo_sapiens/USA/LA2_42/2013 + + + + + + + + + + + + + + + +
RSVB 45573-MAIN RSVB/Homo_sapiens/USA/LA2_16/2012 + + + + + + + + + + + + + + +
RSVB KJ672473.1 RSVB/Homo_sapiens/USA/LA2_24/2012 + + + + + + + + + + + + + +
RSVB KJ672425.1 RSVB/Homo_sapiens/USA/LA2_25/2013 + + + + + + + + + + + + + + +
RSVB KJ672438.1 RSVB/Homo_sapiens/USA/LA2_50/2013 + + + + + + + + + + + + + + +
RSVB KJ672430.1 RSVB/Homo_sapiens/USA/LA2_51/2013 + + + + + + + + + + + + + + +
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Table 21 dN/dS Results for Positive or Diversifying Selection Sites Across All RSV Genes Categorized by 

































































23 10.64 0.059 3.942 0.027 >100 0.072 0.619 0.937 
117 6.071 0.233 4.39 0.04 >100 0.098 0.499 0.874 
518 7.6 0.132 3.038 0.054 >100 0.119 0.317 0.859 
560 -12.241 0.986 -4.579 0.154 >100 0.01 -1.091 0.03 
563 4.151 0.467 2.928 0.345 >100 0.004 0.071 0.606 
574 3.596 0.447 3.979 0.098 2.668 0.326 0.565 0.854 
F RSV-B 
12 4.279 0.342 4.372 0.063 >100 0.093 0.232 0.79 
15 -0.011 0.742 0.372 0.906 29.882 0.091 -0.064 0.381 
45 6.132 0.183 7.358 0.065 >100 0.088 0.516 0.848 
292 2.277 0.768 3.377 0.429 >100 0.096 -0.013 0.545 
516 2.991 0.445 3.106 0.305 >100 0.017 0.054 0.585 
G RSV-A 
15 2.258 0.252 1.161 0.052 >100 0.075 0.188 0.855 
71 4.335 0.035 0.947 0.067 >100 0.07 0.172 0.862 
94 3.131 0.229 1.929 0.005 >100 0.019 0.436 0.961 
101 5.909 0.046 1.463 0.053 >100 0.022 0.266 0.905 
117 5.929 0.057 2.115 0.089 >100 0.025 0.569 0.933 
126 5.224 0.048 1.311 0.116 5.904 0.062 0.292 0.874 
132 2.212 0.3 1.401 0.041 >100 0.02 0.237 0.873 
142 -0.156 0.764 -0.276 0.838 >100 0.035 -0.087 0.409 
161 1.252 0.554 0.682 0.087 >100 0.161 0.135 0.81 
196 2.957 0.199 1.961 0.016 >100 0.022 0.399 0.929 
206 2.147 0.303 0.786 0.248 >100 0.068 0.068 0.668 
215 4.196 0.088 1.307 0.054 >100 0.069 0.197 0.868 
231 -0.699 0.889 -0.706 0.412 >100 0.008 -0.162 0.231 
241 4.912 0.057 2.124 0.055 >100 0.049 0.511 0.931 
244 6.76 0.041 3.218 0.046 >100 0.065 0.824 0.976 
250 1.788 0.426 0.629 0.618 >100 0.041 0.236 0.697 
255 1.879 0.413 1.168 0.028 >100 0.069 0.21 0.89 
256 5.836 0.019 1.826 0.031 >100 0.029 0.39 0.931 
258 4.576 0.095 2.101 0.027 >100 0.057 0.45 0.932 
284 27.952 0 -0.274 0.343 0 0.67 -0.094 0.211 
286 5.094 0.127 2.393 0.043 14.108 0.044 0.763 0.983 
293 -2.099 0.855 -1.181 0.335 >100 0.019 -0.401 0.155 
298 7.731 0.014 2.424 0.088 24.998 0.053 0.758 0.969 




310 10.06 0 2.192 0.005 >100 0.005 0.701 0.99 
314 7.833 0.006 2.619 0.014 >100 0.011 0.77 0.988 
321 4.579 0.183 2.661 0.142 33.497 0.047 0.83 0.937 
322 8.797 0.206 7.919 0.01 49.085 0.001 3.288 0.997 
G RSV-B 
121 -0.346 0.801 2.167 0.502 23.176 0.082 0.116 0.594 
133 2.984 0.198 6.951 0.048 >100 0.074 0.398 0.84 
138 -1.492 0.889 -1.283 0.706 >100 0.002 -0.146 0.33 
154 1.393 0.51 3.998 0.076 >100 0.12 0.235 0.791 
159 11.482 0.006 0 1 0 0.67 -0.085 0.343 
207 2.984 0.198 5.871 0.064 >100 0.088 0.501 0.888 
219 3.735 0.08 5.317 0.121 >100 0.137 0.403 0.856 
223 1.348 0.472 4.418 0.245 26.301 0.041 -0.089 0.336 
236 14.023 0 0 1 0 0.67 1.808 0.959 
272 6.114 0.241 13.155 0.101 >100 0.078 0.413 0.847 
275 5.409 0.299 5.827 0.077 >100 0.111 0.429 0.796 
283 2.719 0.324 8.765 0.194 >100 0.029 1.394 0.976 
292 4.343 0.128 10.214 0.026 >100 0.053 0.052 0.592 
302 2.965 0.203 4.593 0.094 >100 0.122 0.385 0.862 
323 8.764 0.345 14.761 0.081 >100 0.116 1.478 0.856 
L RSV-A 
171 -5.405 0.963 -4.598 0.115 >100 0.035 -0.828 0.06 
218 5.187 0.335 3.83 0.036 >100 0.1 0.313 0.8 
400 -9.989 0.975 -8.375 0.247 >100 0.085 -1.027 0.181 
746 1.425 0.631 1.958 0.395 >100 0 0.067 0.546 
1049 3.458 0.483 2.218 0.104 >100 0.034 0.154 0.679 
1161 3.109 0.442 3.659 0.289 >100 0.008 -0.014 0.468 
1168 3.603 0.444 1.798 0.281 >100 0.012 0.023 0.535 
1313 -3.308 0.938 -5.002 0.253 >100 0.049 -0.686 0.126 
1490 -10.399 0.992 -9.509 0.056 >100 0.033 -1.847 0.021 
1592 3.603 0.47 2.908 0.074 >100 0 0.207 0.716 
1724 3.468 0.547 2.956 0.356 >100 0.004 0.008 0.539 
1725 13.929 0.056 8.718 0.035 >100 0.105 1.499 0.957 
1874 -0.871 0.8 -3.307 0.49 >100 0.08 -0.508 0.24 
1948 -6.352 0.974 -5.264 0.133 >100 0.089 -0.962 0.058 
1967 -1.802 0.889 -1.605 0.508 >100 0.088 -0.385 0.165 
2039 3.595 0.446 2.524 0.082 >100 0.136 0.19 0.712 
L RSV-B 
102 7.131 0.41 35.665 0.256 >100 0.001 1.115 0.718 
376 4.577 0.483 18.206 0.08 >100 0.182 0.411 0.72 
1733 85.758 0 -20.487 0.706 0 0.67 -0.76 0.053 
M RSV-A NONE                 
M RSV-B NONE 





170 2 0.501 2.718 0.1 >100 0.258 0.114 0.747 
M2-1 
RSV-B 
120 3.844 0.444 9.803 0.147 >100 0.092 0.117 0.723 
142 3.729 0.472 22.741 0.055 >100 0.223 0.498 0.826 
M2-2 
RSV-A 69 4.196 0.137 6.029 0.067 >100 0.08 0.411 0.92 
M2-2 
RSV-B 52 8.421 0.255 25.323 0.211 >100 0.214 0.629 0.905 
N RSV-A 216 7.614 0.107 6.968 0.018 >100 0.069 0.804 0.966 
N RSV-B NONE                 
NS1 RSV-
A NONE                 
NS1 RSV-
B NONE       
 
        
NS2 RSV-
A 6 2.459 0.274 6.483 0.047 >100 0.07 0.442 0.9 
NS2 RSV-
B NONE                 
P RSV-A 73 4.562 0.027 6.157 0.107 >100 0.082 0.713 0.965 
P RSV-B NONE                 
SH RSV-
A 49 8.459 0.136 4.427 0.18 >100 0.091 0.196 0.848 
SH RSV-
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